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Stroke can impair cough function. Respiratory muscle training (RMT) was investigated as an 
intervention for improving cough function in acute stroke; and as a potential strategy for 
preventing aspiration-related post-stroke pneumonia.  
Measures of cough function (volitional tests of cough flow and respiratory muscle strength, 
automated cough frequency measurement) required validation in the acute stroke population. 
Test-retest reliability was equally high in eleven healthy volunteers and six stroke survivors 
(ICCs >0.90). Minimal detectable difference was ≈7%. A calibrated pneumotachograph was 
found most appropriate for cough flow assessments, due to inaccuracy of portable flow meters 
(Bland-Altman 95% limits of agreement spanning ≈150 L/min). Automated cough frequency 
measurements (Leicester Cough Monitor) showed high accuracy (ICC >0.99).  
The effectiveness of RMT was investigated in a single-blind randomised placebo-controlled trial 
of 82 acute stroke survivors in three parallel groups (inspiratory, expiratory, and sham training). 
Mean group changes from baseline (SEM), respectively, were: 91 (42), 49 (27) and 84 (34) 
L/min for peak voluntary cough flow (p=0.46); -4 (28), 17 (19) and 32 (18) L/min for peak reflex 
cough flow (p=0.41); 20 (4), 12 (3) and 12 (4) cmH2O for maximal expiratory mouth pressure 
(p=0.35); and 18 (4), 10 (3) and 14 (3) cmH2O for maximal inspiratory mouth pressure (p=0.40). 
Pneumonia occurred in 13 (16%) participants with no difference between groups (p=0.65). 
Higher voluntary cough flow at baseline predicted lower pneumonia risk in patients with unsafe 
swallow (OR 0.73, 95%CI 0.51-0.95, p=0.012), but not in patients with safe swallow. In a sub-
group of 21 patients, 24-hour cough frequency was abnormally high at baseline (median (range) 
118 (4, 375)) and decreased to 56 (1, 186) at four weeks and 34 (6, 108) at twelve weeks 
(p=0.0003).  
RMT did not improve cough flow or respiratory muscle strength beyond natural recovery. 
Stronger cough was protective from aspiration-related post-stroke pneumonia.  
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Chapter 1 Introduction 
 
The present studies were conducted to investigate respiratory muscle training (RMT) as a 
means of improving cough effectiveness in adults after acute stroke, with the aim of reducing 
the risk of pneumonia posed by swallowing difficulty and aspiration in this patient group.  
 
In this introduction, the scene shall be set by first giving an overview of the impact and burden 
of stroke in today’s society in the United Kingdom (UK) (section 1.1). Then follows a narrative 
review of two key topics, which form the basis of the argument for investigating RMT in acute 
stroke: pneumonia in stroke (section 1.2) and the impairment of cough in stroke (section 1.3). A 
description of RMT as a training technique is then given (section 1.4). This introduction is 
concluded by a systematic review of previous studies of RMT in stroke (section 1.5).  
 
The argument underlying the present research is that pneumonia is a relevant medical 
complication after stroke, and that the risk of post-stroke pneumonia (PSP) is increased due to 
swallowing difficulty and aspiration after stroke. Recent studies have shown that cough, the 
most immediate mechanism protecting the lungs from inhaled foreign materials, can be 
impaired in stroke survivors; and that the likely cause for this impairment is central weakness of 
the respiratory musculature. Thus, respiratory muscle training as a treatment intervention in 
acute stroke may be useful in the recovery of respiratory muscle and cough function, and may 
reduce the risk of pneumonia.  
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1.1 Stroke in the United Kingdom today 
 
Stroke, or cerebrovascular accident, is defined as the sudden onset of a focal neurological 
deficit, due to a local disturbance of blood supply to the brain and the subsequent destruction of 
brain cells (World Health Organisation 1971). Most commonly, stroke occurs due to lack of 
blood supply to the brain, caused by narrowing or blockage of cerebral blood vessels (Great 
Britain. Department of Health 2007). This is termed ischemic stroke and accounts for 
approximately 85% of all strokes (Intercollegiate Stroke Working Party 2012). The second-most 
common mechanism of stroke is through bleeding originating in the brain parenchyma (Great 
Britain. Department of Health 2007). This is termed haemorrhagic stroke and causes 
approximately 10% of all strokes (Intercollegiate Stroke Working Party 2012).  
 
Stroke is a leading cause of death. In the UK in 2010, stroke caused approximately 7% of all 
deaths in men and 10% of deaths in women (Townsend et al. 2012). Overall, stroke caused 
almost 50,000 deaths in the UK in 2010, the fourth largest cause of death after cancer, heart 
disease and respiratory disease (Townsend et al. 2012). Data from 2006 show that 17% to 25% 
of those suffering a stroke die within 60 days of the event (Townsend et al. 2012).  
 
Estimates from 2007 and 2009 put the annual incidence of stroke in the UK at approximately 
152,000 (Townsend et al. 2012). In England in 2007, the annual incidence rate of stroke per 
100,000 was 139 for women and 178 for men (Townsend et al. 2012). The prevalence of stroke 
in the UK in 2010 and 2011 is estimated at 1.1 million or 1.8% of the population (Townsend et 
al. 2012). Time-trend studies suggest that in the UK incidence and mortality rates for stroke 
have decreased over the past decade, while the prevalence of stroke has risen (Lee et al. 2011, 
Bhatnagar et al. 2010).  
 
Stroke is a major cause of adult disability (Adamson et al. 2004). Audit data for England, Wales 
and Northern Ireland from 2010 show that at the time of discharge from hospital approximately 
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42% of stroke survivors have returned to independence, whereas 36% have mild to moderate 
disability, and 22% have severe or very severe disability (Intercollegiate Stroke Working Party 
2011). Stroke has a greater disability impact than other chronic diseases; it causes a greater 
range of disabilities than any other condition; and it is the largest cause of complex disability in 
adults in the UK (Adamson et al. 2004).  
 
Stroke generates considerable costs to the UK health and social care system and to society in 
general. Based on data from 2008 and 2009, it is estimated that the annual costs of stroke to 
services within the health and social care system amount to at least £3 billion. The wider 
economic costs to society, including benefit payments and lost economic productivity, are 
estimated at about £8 billion (National Audit Office 2010).  
 
In the past decade, remarkable advancements in health care have led to decreased stroke 
incidence and mortality rates and improved outcomes after stroke rehabilitation. Major 
advances in stroke care have been: the introduction of specialised stroke units; thrombolysis 
within three hours of acute ischemic stroke; aspirin within 48 hours of acute ischemic stroke; 
and a number of primary and secondary prevention strategies (Donnan et al. 2008). 
Nevertheless, there are many opportunities for further improvement in stroke treatment, 
prevention and rehabilitation, one of which concerns pneumonia after stroke (Kalra 2010, 
Donnan et al. 2008).  
 - 24 - 
1.2 Post-stroke pneumonia 
 
1.2.1 Incidence of post-stroke pneumonia 
 
Pneumonia is frequently described as a relevant medical complication after stroke. However, an 
estimation of its incidence and clinical impact is complicated by variations between studies. 
Studies differ in the criteria for the diagnosis of pneumonia; study settings; characteristics and 
size of study samples; and time periods of observation for the incidence of pneumonia. Forty-
two studies reporting the incidence of pneumonia after stroke were reviewed and are 
summarised in Appendix 1. These publications span from 1987 to 2012 and present data from 
intensive care, acute, and rehabilitation settings. Most studies are prospective or retrospective 
longitudinal observational studies with samples of consecutively admitted stroke patients, 
thereby providing a picture of the ‘naturally’ occurring incidence of post-stroke pneumonia 
(PSP). In some studies additional selection criteria were applied, such as presence of 
swallowing difficulty, and these are likely to have influenced the observed incidence rates.  
 
The incidence of PSP across all studies ranges from 2% to 57%, with a median incidence rate 
of 10% and an inter-quartile range from 6.4% to 16.2%. The highest incidence of PSP is 
reported in intensive care settings, where it ranges from 21% to 57% (Yeh et al. 2011, Walter et 
al. 2007, Upadya et al. 2004, Hilker et al. 2003), reflecting the general vulnerability to respiratory 
infection of patients requiring intensive care management and mechanical ventilation (Hoffmann 
et al. 2012). The most current PSP rates for the UK are derived from the Royal College of 
Physicians bi-annual stroke audit for England, Wales and Northern Ireland. The audit captures 
consecutive admissions to acute stroke services for the period from April to June. In 2008, 16% 
of acute stroke patients included in the audit developed pneumonia during their hospital stay, 
compared with 13% in 2010 (Royal College of Physicians 2011, 2009).  
 
While most studies focus on pneumonia during the first weeks after stroke, mainly for the 
duration of the patient’s acute hospital admission or rehabilitation stay, some studies have 
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observed PSP incidence over longer time periods. Sellars et al. (2007) reported confirmed 
pneumonia during the first three months after stroke in 18.9% and suspected pneumonia in 
19.9% of patients. Masiero et al. (2008) reported an incidence of pneumonia within the first six 
months after stroke of 13.4%. In the study by Mann et al. (1999), 9% of patients developed 
pneumonia in the first week after stroke, 12% within the first month, and 20% within six month of 
stroke. Langhorne et al. (2000) observed the incidence of pneumonia for 30 months following 
stroke and reported an incidence rate of 22% from hospital admission to two months; 13% from 
discharge from hospital to six months; 23% from six to 18 months; and 29% from 18 to 30 
months. These limited long-term data indicate that PSP may be as relevant in chronic stroke as 
in the acute phase of stroke.  
 
In summary, while incidence rates for PSP are widely reported in the international literature, 
these figures should be appreciated taking into account varying definitions of pneumonia and 
other differences between studies. As a general estimate, the incidence of pneumonia between 
stroke onset and hospital discharge lies between approximately 6% and 16% internationally. 
Rates are likely to be most valid for the particular setting and time period, and it may not be 
appropriate to compare directly between studies. The most current and valid data for the UK is 
probably from the national stroke audit for England, Wales and Northern Ireland, which showed 
incidence rates of 16% in 2008 and 13% in 2010.  
 
1.2.2 Post-stroke pneumonia and stroke outcomes 
 
Several studies investigated the association of PSP with mortality, disability, length of hospital 
stay and cost of care after stroke. Authors generally describe that PSP is associated with 
increased risk of death, poorer rehabilitation outcomes, increased length of hospital stay and 
increased healthcare costs, although the reported magnitude of these risks and negative 
implications varies. As with incidence rates of PSP, it may be most appropriate to appreciate 
reported figures in the context of the individual studies’ sample characteristics, health care 
settings, time periods, and data collection and analysis methods.  
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Several studies analysed the association between pneumonia and mortality after stroke (Wilson 
2012, Finlayson et al. 2011, Koennecke et al. 2011, Tong et al. 2010, Saposnik et al. 2008, 
Sellars et al. 2007, Ovbiagele et al. 2006, Hinchey et al. 2005, Aslanyan et al. 2004, 
Heuschmann et al. 2004, Katzan et al. 2003, Vernino et al. 2003), reporting adjusted odds ratios 
in the range from 1.9 (Saposnik et al. 2008) to 6.6 (Heuschmann et al. 2004). Studies reporting 
the causes of death after acute stroke (Hong et al. 2008, Vernino et al. 2003, Henon et al. 1995, 
Derouesne et al. 1993, Oppenheimer & Hatchinski 1992, Viitanen et al. 1987) further link PSP 
with increased mortality, with the cause of death being attributed to pneumonia in up to 35% of 
stroke deaths (Oppenheimer & Hatchinski 1992). These studies also show that within the first 
week after stroke, death is most frequently attributed to neurological causes, mostly increased 
intracranial pressure. Whereas in the following weeks, medical complications, including 
pneumonia, become more pertinent (Derouesne et al. 1993, Oppenheimer & Hachinski 1992, 
Viitanen et al. 1987, Silver et al. 1984, Brown 1973). One study reported a relative risk of death 
of 4.9 for patients who developed PSP over a ten-year period compared with those who did not 
(Vernino et al. 2003).  
 
Several studies demonstrate that post stroke pneumonia is associated with poorer rehabilitation 
outcomes, increased level of disability and increased use and cost of acute health care 
resources. Ovbiagele et al. (2006) reported that patients with PSP were less likely to walk 
without assistance at the time of discharge compared with those without pneumonia, while other 
studies reported that pneumonia was associated with worse National Institutes of Health Stroke 
Scale (NIHSS) score, worse Barthel Index, and worse Rankin Scale score (Finlayson et al. 
2011, Koennecke et al. 2011, Hong et al. 2008, Aslanyan et al. 2004). Increased length of 
hospital stay for stroke patients with pneumonia was reported by Finlayson et al. (2011), Tong 
et al. (2010), Ovbiagele et al. (2006) and Hinchey et al. (2005). In the study by Katzan et al. 
(2007), patients who developed pneumonia were more likely to require extended care after 
discharge from the acute hospital, and were more likely to be re-admitted to the acute hospital 
within 30 days of discharge. In the United States of America (USA), the additional 
hospitalisation cost related to PSP was estimated at USD 15,000 (Katzan et al. 2007) and USD 
27,366 (Wilson 2012).  
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In summary, patients who develop pneumonia after stroke are more likely to die than those who 
do not, with an estimated two- to six-fold increase in risk of death. This estimate is derived 
mainly from data pertaining to the first weeks and months after stroke, although one long-term 
study matches this estimate with a suggested five-fold increase in risk of death over ten years. 
Some evidence is available to show that patients with post-stroke pneumonia have worse 
rehabilitation outcomes within the first weeks and months after stroke, as they are more likely to 
have poor scores on various rehabilitation indicators compared with those who did not develop 
pneumonia. Some studies indicate the potential additional cost of PSP to health care providers, 
as on average patients with pneumonia stay in the acute hospital for longer than those without 
pneumonia, and also require higher levels of care after hospital discharge.  
 
1.2.3 Risk factors for post-stroke pneumonia 
 
A number of studies have described risk factors for pneumonia after stroke and are listed in 
Table 1. Studies conducted in intensive care settings have been omitted here, since ventilator-
associated pneumonia may be regarded as a separate clinical presentation (Hoffmann et al. 
2012). To identify risk factors for PSP, most authors applied multivariate regression methods 
and adjusted for participant characteristics, whereby the number of variables accounted for 
differs between studies. Most commonly, risk factor analyses were adjusted for patients’ age, 
sex, stroke severity at admission and presence of dysphagia. The studies differ with respect to 
sample characteristics, sample size, clinical setting and details of statistical analysis methods. 
An appreciation of the results in the particular context of individual studies is therefore 
advisable. The identification of risk factors in these studies is also influenced by the a priori 
selection of potential candidate variables and the availability of data.  
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Table 1. Risk factors for post-stroke pneumonia reported in the literature 
Risk factor Studies Range of adjusted odds ratios 
(95% CI) 
Higher level of 
stroke impairment 
Hoffmann et al. 2012 
Shaheen et al. 2012 
Finlayson et al. 2011 
Chumbler et al. 2010 
Royal College of Physicians 2009 
Indredavik et al. 2008 
Sellars et al. 2007 
Hinchey et al. 2005 
Aslanyan et al. 2004 
Roth et al. 2001 
 
1.1 (1.0, 1.1) (Aslanyan et al. 
2004) 





Hoffmann et al. 2012 
Shaheen et al. 2012 
Finlayson et al. 2011 
Chumbler et al. 2010 
Lakshminarayan et al. 2010 
Royal College of Physicians 2009 
Sellars et al. 2007 
Martino et al. 2005 
Mann et al. 1999 
Smithard et al. 1996 
 
1.9 (1.5, 2.4) (Finlayson et al. 
2011) 
to 11.6 (3.4, 39.8) (Martino et al. 
2005) 
Older age Aslanyan et al. 2004 
Royal College of Physicians 2009 
Chumbler et al. 2010 
Hoffmann et al. 2012 
Finlayson et al. 2011 
Ovbiagele et al. 2006 
Sellars et al. 2007 
 
1.1 (1.0, 1.1) (Aslanyan et al. 
2004) 
to 3.9 (2.0, 7.5) (Sellars 2007) 
Male sex Aslanyan et al. 2004 
Finlayson et al. 2011 
Hoffmann et al. 2012 
Katzan et al. 2003 
 
1.7 (1.4, 2.0) (Hoffmann et al. 
2012) 
to 1.9 (1.6, 2.3) (Finlayson et al. 
2011) 
Reduced level of 
consciousness 
Dziewas et al. 2004 
Katzan et al. 2003 
Masiero et al. 2008 
Royal College of Physicians 2009 
5.6 (2.2, 16.0) (Masiero et al. 
2008) 
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The most frequently reported risk factors for PSP are increasing stroke severity, older age, the 
presence of swallowing difficulty, male sex and reduced level of consciousness. In the context 
of the present research, the interaction between aspiration, cough and PSP is of particular 
interest. Synthesising the evidence on dysphagia as a risk factor for PSP, Martino et al. (2005) 
conducted a systematic review and meta-analysis, which included nine studies (Lim et al. 2001, 
Mann et al. 1999, Sala et al. 1998, Chua & Kong 1996, Gottlieb et al. 1996, Smithard et al. 
1996, Kidd et al. 1995, Holas et al. 1994, Gordon et al. 1987). Using broad criteria for the 
detection of dysphagia, from ‘soft’ clinical signs to findings from instrumental swallow 
assessments, these studies combined gave a sample of 400 dysphagic patients, out of whom 
87 developed PSP, and 491 non-dysphagic patients, out of whom 29 developed PSP. The 
combined relative risk (95% CI) for developing pneumonia in the dysphagic group was 3.2 (2.1, 
4.9). A meta-analysis of studies reporting the incidence of aspiration and pneumonia after 
stroke included 51 patients who aspirated, out of whom 22 developed PSP, and 59 non-
aspirators, out of whom 2 developed PSP. The combined relative risk (95% CI) for developing 
pneumonia for those with aspiration was 11.6 (3.4, 39.8) (Martino et al. 2005).  
 
Further aspects of dysphagia and aspiration in relation to the risk of PSP have been reported. In 
the study by Holas et al. (1994), the risk of developing pneumonia was higher for those who 
aspirated silently (i.e. aspirated without eliciting a protective cough) compared with those who 
coughed on aspiration or did not aspirate (RR 5.6, 95% CI 1.4, 21.3); and higher for those who 
aspirated 10% or more of the swallowed material compared with those who aspirated less than 
10% or did not aspirate (RR 8.4, 95% CI 2.7, 25.5). In the study by Johnson et al. (1993), longer 
pharyngeal transit time (time for the bolus to pass through the pharynx, and for the epiglottis to 
return to its original position) was associated with an increased risk of PSP. Vallecular pooling, 
piriform pooling and penetration to or through the true vocal cords were also associated with an 
increased incidence of PSP, although this did not reach statistical significance (Johnson et al. 
1993). In the study by Masiero et al. (2008), the lack of reflex cough after swallow (indicating 
silent aspiration) was associated with an increased risk of pneumonia (adjusted OR 7.6, 95% CI 
1.8, 30.0). The studies by Addington et al. (1999a, 2005) showed that a reduced or absent 
cough reflex was associated with increased PSP incidence, highlighting the risk posed by silent 
aspiration and the protective function of cough from aspiration pneumonia. Overall, these 
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studies demonstrate that dysphagia in general is associated with an approximately two- to 
three-fold increase in risk of pneumonia after stroke. This risk increases to five- to eleven-fold 
with increasing severity of swallowing difficulty, the presence of aspiration, and increasing 
severity of aspiration.  
 
In summary, studies have identified a variety of risk factors for PSP. The most consistently 
reported predictors are increasing stroke severity, older age, the presence of swallowing 
difficulty, male sex and reduced level of consciousness. The reported magnitude of these risks 
can vary considerably, and it may be advisable to appreciate figures in the context of the 
particular study characteristics. A number of studies demonstrate the link between aspiration, 
impaired cough and PSP. This evidence lends support to the rationale for the present research, 
which aimed to reduce pneumonia by increasing cough effectiveness and improving airway 
protection from aspiration.  
 
1.2.4 Strategies for the prevention of post-stroke pneumonia 
 
To date, the most widely used strategy for the prevention of PSP is the routine screening of 
stroke patients for swallowing difficulty coupled with the implementation of dysphagia 
management strategies. This approach is based on the established association between 
dysphagia and pneumonia incidence. Accordingly, national clinical guidelines for stroke 
recommend screening for dysphagia prior to allowing the patient to eat and drink (Intercollegiate 
Stroke Working Party 2012, National Collaborating Centre for Chronic Conditions 2008, Great 
Britain. Department of Health 2007). The studies by Ickenstein et al. (2010), Lakshminarayan et 
al. (2010) and Hinchey et al. (2005) provide evidence for the effectiveness of formalised routine 
dysphagia screens for the prevention of PSP. Hinchey et al. (2005) compared stroke units 
which operated with either a formal or informal swallow screen. Units with a formal swallow 
screen had higher adherence to swallow screening (78% compared with 56%) and lower 
incidence of PSP (2.4% compared with 5.3%). In the study by Lakshminarayan et al. (2010) the 
adjusted odds ratio for developing pneumonia for those who failed dysphagia screening, 
compared with those who passed dysphagia screening, was 3.6 (95% CI 3.0, 4.3). In addition, 
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those patients who did not undergo a swallow screen also had an increased risk of pneumonia 
compared with those who passed swallow screening, with an adjusted odds ratio of 2.2 (95% CI 
1.7, 2.7). In the study by Ickenstein et al. (2010), the annual incidence of pneumonia for patients 
admitted to one stroke unit dropped from 7.4% to 2.8% after the introduction of a structured 
swallowing screen.  
 
There is some evidence to indicate that the introduction of specialised stroke units also reduces 
the incidence of PSP. In the study by Kalra et al. (1995), patients who required further hospital 
care two weeks after stroke were randomised to a general ward or a stroke unit setting. The 
incidence of pneumonia was 8% for stroke unit patients, compared with 16% for general ward 
patients. In the study by Ickenstein et al. (2010) the in-house incidence rate for PSP dropped 
from 12.4% to 7.4% following the introduction of a dedicated stroke unit. The mechanism for this 
is unclear and may be related to heightened alertness of staff towards the possibility of 
dysphagia and aspiration pneumonia in acute stroke patients. Also, a concerted 
multidisciplinary patient management approach may contribute to reducing the risk of PSP. 
Optimised patient positioning and early mobilisation may positively affect respiratory function 
(Lee et al. 2012), and adequate positioning, assistance and supervision provided during meal 
times may facilitate swallowing function and reduce the risk of aspiration.  
 
When investigating an intervention to reduce PSP risk it may seem intuitive to focus on those 
stroke patients who are identified as having swallowing difficulty, due to the evidence for 
dysphagia and aspiration as risk factors for PSP. However, while swallowing difficulty and 
aspiration increase the risk of PSP, it is the case that not all stroke patients with swallowing 
problems develop pneumonia; and that stroke patients who are not identified clinically as having 
swallowing problems may also develop pneumonia. The picture of predictors and circumstances 
of PSP is multi-factorial. While clinically detected dysphagia plays a key part in this picture, it 
has to be considered that patients who have passed a cursory swallow screen and are deemed 
to have a ‘safe’ swallow may still have swallowing difficulty. Some evidence for this is provided 
by the reported frequency of dysphagia after stroke, which is generally lowest according to 
results of swallow screening, higher with specialist clinical bedside assessment, and highest 
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with instrumental swallow assessment (Martino et al. 2005). This indicates that more detailed 
assessments of swallow are likely to identify more instances of swallowing difficulty. It is 
therefore possible that a portion of those stroke patients who pass a cursory swallow screen 
have some degree of undetected dysphagia or aspirate silently. Furthermore, several authors 
suggest that aspiration pneumonia should be considered as a possibility without any 
relationship to the swallowing of food and drink (Teramoto 2009). It is suggested that the 
aspiration of nasal, throat and periodontal secretions, which mainly occurs overnight, should be 
regarded as a separate form of silent aspiration, with its own association to PSP (Teramoto 
2009). For these reasons, the present studies recruited stroke patients with and without 
clinically detected swallowing difficulty.  
 
Despite the success of screening for swallowing difficulty and dysphagia management 
strategies in preventing PSP, there remains scope for further developments to reduce 
pneumonia rates after stroke. Various avenues have been suggested and researched, based on 
different patho-physiological and clinical justifications. Pharmacological approaches include the 
preventive administration of antibiotics to reduce fever and infection (Westendorp et al. 2012), 
the use of angiotensin-converting enzyme (ACE) inhibitors to improve reflex cough sensitivity 
(Shinohara & Origasa 2012), selective decontamination of the digestive tract to minimise 
exposure to pathogens (Gosney et al. 2006), and pharmacological agents targeting stroke-
induced immuno-suppression (Braun et al. 2007, Prass et al. 2003). Non-pharmacological 
strategies include elevated positioning to prevent aspiration (Teramoto 2009), passive 
mobilisation and re-positioning regimes to improve lung ventilation and airway clearance (Cuesy 
et al. 2010), and intensive oral hygiene and dental treatment to reduce oro-pharyngeal 
colonisation with pathogens (Teramoto 2009).  
 
The present research took a novel and original approach in investigating RMT as a non-
pharmacological intervention, with the aim to improve cough effectiveness and increase airway 
protection in acute stroke patients. The following section shall discuss human cough; its 
impairment after acute stroke; and the rationale for RMT as a method for improving cough 
effectiveness in this patient group.  
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1.3 Impairment of cough in stroke 
 
1.3.1 Normal respiratory function 
 
The movement of air in and out of the lungs is termed ventilation. Ventilation is achieved 
through respiratory muscle action. Respiratory muscles are distinguished into inspiratory and 
expiratory muscles. Inspiratory muscle contraction causes air to be drawn into the lungs; 
expiratory muscle action causes air to be forced out of the lungs. The main inspiratory muscle is 
the diaphragm, which spans across the lower thorax and separates the thoracic and abdominal 
compartments. The external intercostal muscles also act as inspiratory muscles. The main 
expiratory muscles are the abdominal muscles and the internal intercostal muscles. In addition, 
a number of other skeletal muscles can contribute to inspiration or expiration (scaleni, 
sternocleido-mastoid, descending trapezius, pectoralis major and minor, latissimus dorsi, and 
other muscles contributing to movement or stability of the chest wall and the thoraco-abdominal 
unit); these are termed accessory respiratory muscles (Sieck & Gransee 2012, Petersen 2007).  
 
Respiratory mechanics can be likened to a bellows-type system. Contraction of the diaphragm 
creates negative pressure in the respiratory tract, which results in inspiratory airflow. When the 
diaphragm relaxes, passive recoil of the lungs and chest wall generates expiratory airflow. 
Thus, at rest inspiration is an active process, while expiration is passive. At higher respiratory 
demands, expiratory muscle contraction causes forced expiration, thereby shortening expiration 
time and contributing to an increased rate of breathing. Accessory respiratory muscles are 
usually only activated at high respiratory demands, for example during exercise or in respiratory 
disease (Sieck & Gransee 2012, Petersen 2007).  
 
The total volume of air occupying the lungs after a maximal inspiratory effort (approximately 6 L) 
is termed total lung capacity (TLC). The lungs cannot be entirely emptied, and after a maximal 
expiration there remains the residual volume (RV) of approximately 1.2 L. The volume of air that 
can actively be shifted in and out of the lungs is termed vital capacity (VC), and is in effect TLC 
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less RV. The volume of air moved in and out of the lungs during relaxed breathing is termed 
tidal volume (VT). In healthy adults, the tidal volume is about 500 mL at rest. The volume that 
remains in the lungs at the end of a relaxed expiration is the functional residual capacity (FRC). 
FRC is approximately 2.5 L. With each breath, it is replenished with O2 and CO2 is removed. 
The volume that can be inspired with a maximal inspiratory effort after a relaxed expiration is 
termed the inspiratory capacity (IC). The volume that can be expired with a prolonged expiratory 
effort after a relaxed expiration is termed the expiratory reserve volume (ERV). The volume that 
can be inspired with a prolonged inspiratory effort after a relaxed breath in is termed inspiratory 
reserve volume (IRV) (Petersen 2007, Despopoulos & Silbernagel 2003).  
 
The neural control of respiration is arranged in a complex network involving the brainstem 
(medulla oblongata and pons), as well as higher brain centres (hypothalamus, limbic system, 
and cerebral cortex). The continuous rhythm of breathing is generated in the brainstem centres 
and modulated through sensory afferents according to metabolic demands. Higher centres 
influence breathing through stimuli such as pain, temperature or emotion; and through voluntary 
control, for example in breath-holding or other voluntary respiratory manoeuvres (Petersen 
2007, Despopoulos & Silbernagel 2003).  
 
The brainstem network has pontine and medullary components. The pontine respiratory group 
(PRG) includes expiratory neurons in the nucleus parabrachialis medialis, and inspiratory 
neurons in the nucleus parabrachialis lateralis and Kölliker-Fuse nucleus. The medullary areas 
are the dorsal respiratory group (DRG), ventral respiratory group (VRG) and Bötzinger complex. 
The DRG, part of the nucleus of the tractus solitarius, consists mainly of inspiratory upper motor 
neurons, which project ipsilaterally to the lower motor neurons of mainly the phrenic nerve. They 
also show inhibitory action on the expiratory motor neurons of the VRG. The VRG is located 
rostrally in the nucleus ambiguous and caudally in the nucleus retroambigualis. The nucleus 
ambiguous contains inspiratory upper motor neurons as well as motor neurons to the laryngeal 
muscles and parasympathetic neurons to the bronchioles and heart. The rostral nucleus 
retroambigualis contains inspiratory upper motor neurons. The inspiratory neurons in the VRG 
mainly supply the external intercostals and the accessory muscles, as opposed to the 
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diaphragm. The caudal nucleus retroambigualis contains expiratory upper motor neurons 
supplying the internal intercostals and abdominals. During relaxed breathing, these expiratory 
neurons do not cause discharge of the corresponding lower motor neurons. They inhibit 
inspiratory motor neurons in the late inspiration, and contribute to the termination of inspiration. 
The Bötzinger complex is located rostral to the nucleus ambiguous and contains expiratory 
neurons, which inhibit inspiratory neurons in the DRG and VRG and excite expiratory neurons in 
the VRG. The exact mechanism of respiratory rhythm generation is not clear. The neurons in 
the pre-Bötzinger complex, located rostral to the Bötzinger complex, display a cyclical firing 
pattern, which may act as a respiratory pacemaker. An alternative hypothesis considers a 
neural network of local re-excitation with reciprocal inhibition of inspiratory and expiratory neural 
pools (Petersen 2007).  
 
The higher brain centres influence respiration via various pathways. The DRG receives input 
from the cerebral cortex, limbic system, hypothalamus and cerebellum in response to 
temperature, pain, emotional stimuli and exercise. In contrast, all voluntary control of respiration 
(taking deep breaths, performing forced expirations, hyperventilating deliberately, holding one’s 
breath, etc) are initiated from the cerebral cortex, bypassing the brainstem centres of respiration 
and traveling through the pyramidal system directly to the lower motor neurons (Petersen 2007).  
 
Respiration is modulated by afferent input from chemoreceptors and mechanoreceptors via the 
nucleus of the tractus solitarius in the medulla oblongata. The principal control of ventilation 
occurs through the monitoring of arterial pO2, pCO2 and pH in the peripheral and central 
chemoreceptors. The peripheral chemoreceptors are the carotid bodies, located at the 
bifurcations of the internal and external carotid arteries and connecting to sensory fibres of the 
glossopharyngeal nerve; and the aortic bodies, which are scattered over the aortic arch and the 
main arteries in that area, and which connect to afferent fibres of the vagus nerve. The central 
chemoreceptors are located at the ventrolateral surface of the medulla oblongata. The pattern 
of breathing (respiratory rate and depth of breathing) is adjusted in order to maintain the blood 
acid-base balance through the carbonic-acid bicarbonate buffer system. Through this buffer 
system, excess hydrogen ions are removed from the blood as they are bound in H2O, while CO2 
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is removed from the blood through the lungs. Breathing is more sensitive to stimulation by 
increased pCO2 (hypercapnia) than decreased pO2 (hypoxia). Thereby, ventilation is matched to 
metabolism through the CO2 produced rather than the O2 consumed (Petersen 2007).  
 
Several mechanoreceptors influence the pattern of breathing. Lung-stretch receptors are 
situated in the smooth muscle of the trachea and lower airways and connect to afferent fibres of 
the vagus nerve. Lung-irritant receptors are vagal nerve endings situated in the epithelia of the 
trachea and lower airways. Lung-stretch receptors inhibit inspiratory neurons of the DRG while 
inspiration is in progress, thereby shortening inspiratory time and reducing the inspiratory tidal 
volume. Lung-irritant receptors give excitatory input to the DRG, thereby shortening the 
expiration phase. Together, these vagal afferents produce the typical relatively shallow and 
rapid breathing pattern that is normal for humans. Removal of these afferents results in a slow 
and deep breathing pattern (Petersen 2007). Other mechanoreceptors influencing the pattern of 
breathing are the proprioceptors (joint receptors, Golgi tendon organs and muscle spindles) in 
the chest wall and diaphragm. These provide information about thoracic inflation and are 
integrated within the spinal cord, but also relay to the sensory cortex and the respiratory centres 
(Petersen 2007).  
 
The respiratory system exhibits a number of protective reflexes. One of these is cough, which 
shall be described in detail in the following section. Other protective reflexes are: sneeze; 
aspiration reflex; Hering-Breuer reflex; sigh; and the responses to stimulation of bronchial and 
pulmonary C-receptors. A sneeze is characterized by a number of superimposed inspirations, 
followed by a strong rapid expiration and then a short pause in the expiratory position, in 
combination with broncholaryngeal constriction. It is triggered by stimulation of trigeminal nerve 
endings in the nasal mucosa through chemical or mechanical irritants. The aspiration reflex is a 
powerful inspiration combined with bronchodilation. It is triggered by mechanical irritation of 
glossopharyngeal nerve ending in the epithelium of the epipharynx, for example due to a 
blockage. This response attempts to pull the blockage into the pharynx and thereby re-establish 
a patent airway. The Hering-Breuer reflex is a response to the degree of lung inflation and is 
mediated by the lung-stretch receptors. At high levels of inflation, the response is a cessation of 
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diaphragmatic activity, while at sustained deflation the response is a promotion of strong and 
frequent inspiratory efforts. A sigh is an augmented breath, which is thought to serve the re-
inflation of alveoli that have collapsed during periods of quiet breathing. Sigh is mediated by 
lung-irritant receptors. Bronchial C-receptors and pulmonary C-receptors (the latter also termed 
J-receptors) are vagal nerve endings of unmyelinated fibres, situated in the bronchial or alveolar 
interstitium, respectively. These receptors do not have a role in normal breathing. They are 
stimulated by mechanical distortion or increases in interstitial fluid pressure, for example 
through large inflation or lung oedema. The response is broncholaryngeal constriction and 
apnoea followed by rapid shallow breathing. If the stimulus is severe, the response is the J-
reflex, which is an inhibition of the spinal motor neurons. This causes a relaxation of skeletal 
muscles in response to severe lung damage (Petersen 2007).  
 
1.3.2 Normal cough function 
 
Cough is the most pronounced defensive respiratory manoeuvre. Its function is to generate high 
expiratory airflow, in order to achieve removal of mucus or other material from the lower airways 
into the oropharynx. Cough is a reflex function, but can also be initiated voluntarily. Four phases 
of cough have been described. Cough begins with an inspiratory phase, characterised by an 
emphasised preparatory inspiration with laryngeal abduction. Then follows the compressive 
phase, during which the glottis is occluded through laryngeal adductor activity as intra-
abdominal and intra-thoracic pressure are built up through expiratory muscle contraction. The 
third phase of cough, termed expulsive phase, results from a rapid opening of the glottis, 
achieved by active laryngeal abduction, while expiratory muscles continue to contract. This 
forceful contraction of expiratory muscles is accompanied by broncholaryngeal constriction, 
overall resulting in expiratory air flow at high flow rates. It is during this phase that the 
expectorating effect of cough is exerted. A fourth and final phase is sometimes described as the 
cessation phase, characterised by a momentary suspension of breathing activity and laryngeal 
abduction (Widdicombe et al. 2011, Petersen 2007, Fontana & Lavorini 2006).  
 
 - 38 - 
A separate defensive respiratory manoeuvre similar to cough has been described as the 
(laryngeal) expiration reflex. This is a response to stimulation at the level of the vocal folds or 
upper trachea. It lacks a distinct inspiratory phase and consists of an immediate glottis 
compression phase followed by an expulsive phase (Widdicombe et al. 2011, Fontana & 
Lavorini 2006, Widdicombe & Fontana 2006).  
 
Current knowledge about the neural pathways for reflex and voluntary cough in humans is 
limited. Most evidence is derived from animal models (Brooks 2011, Mazzone 2005). The main 
reflexogenic zones for cough are the larynx and the tracheobronchial tree. A substantial body of 
literature describes reflex cough afferents, and various approaches to grouping these have 
been applied (Canning 2006, Canning et al. 2006, Fontana & Lavorini 2006, Singh 2006, 
Widdicombe 2001, Widdicombe 1998). There is some indication that cough afferents can be 
distinguished according to function, into mechanosensory and chemosensory. The former 
consist of myelinated Aβ and Aδ fibres and respond to mechanical stimulation, i.e. inhaled 
foreign materials, and gastric acid; the latter are conveyed partly through Aδ and partly through 
unmyelinated C-fibres and respond to chemical irritants, such as capsaicin, citric acid and 
hypertonic saline, and inflammatory processes (Brooks 2011, Mazzone 2005). Sensory 
afferents from laryngeal receptors are conveyed via the superior laryngeal nerve and terminate 
in the nucleus tractus solitarii, from where they project further to the pontine and medullary 
respiratory areas. Similarly, vagal afferents from the lower airways and afferent C-fibres 
terminate at the nucleus of the tractus solitarius, in a part termed the commissural subnucleus. 
From there, second-order neurons project extensively to the pontine and medullary respiratory 
centres. The efferent pathway of reflex cough leads from the medullary respiratory centres 
(DRG and VRG) via upper motor neurons to the spinal motor neurons supplying the inspiratory 
and expiratory muscles, effecting the inspiratory and expiratory muscle action; via cranial motor 
neurons to the intrinsic laryngeal muscles, effecting the co-ordinated laryngeal abduction and 
adduction; and via sympathetic and parasympathetic efferents to the smooth airway muscles, 
effecting the bronchoconstriction (Brooks 2011, Bianchi & Gestreau 2009, Fontana & Lavorini 
2006). While further details of the neuro-physiology of reflex cough remain to be described, it is 
suggested that a functional distinction can be made into cough which is triggered mainly 
through extrapulmonary mechanosensory stimulation and serves as the primary airway 
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defensive mechanism from aspiration; and cough that is elicited in the context of airway 
inflammation and disease and is stimulated through intrapulmonary chemosensory afferents 
(Canning et al. 2006, Mazzone 2005).  
 
Current understanding of the neural control of voluntary cough in humans, including the 
voluntary suppression of reflex cough, is limited. The cortical manifestation of cough sensation 
is described as “urge to cough” (Brooks 2011). It is thought that areas identified through 
functional magnetic resonance imaging during volitional inspiration are likely involved in the 
motor patterns of voluntary cough. These areas include the superior motor cortex, the premotor 
cortex, the supplementary motor area, the inferolateral sensorimotor cortex, the prefrontal 
cortex, and the striatum (Fontana & Lavorini 2006). Also, functional magnetic resonance 
imaging has shown that areas involved in respiratory-related oro-facial tasks (i.e. speaking or 
singing) and areas involved in non-respiratory related oral-facial and tongue movements appear 
to be involved during volitional coughing (Brooks 2011).  
 
1.3.3 Objective assessment of cough 
 
Cough function can be evaluated in various ways. In clinical situations, cough is mostly 
evaluated through clinicians’ subjective observation. The presence, frequency and strength of 
cough may be observed. The quality of the cough sound may be described, and the 
effectiveness of cough in clearing retained lung secretions may be judged (Jenkins & Tucker 
2002).  
 
Objective assessments of cough are mainly conducted in research contexts, whereby various 
aspects of cough may be evaluated. Methods of measuring reflex cough sensitivity, cough 
frequency, and cough-related quality of life have attracted increasing interest over the past 
decade, as the suppression of chronic cough has become a focus for pharmaceutical research 
(Chung 2006, Irwin et al. 2006). In this context, coughing is excessive and disproportionate to 
the functional benefit of coughing. Cough becomes an irritant and impacts on personal 
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wellbeing, social interactions and quality of life. Pharmaceutical research of cough-suppressing 
agents makes use of measures of reflex cough sensitivity, cough frequency, and cough-related 
quality of life as outcome parameters. These methods are relatively well developed and 
standardised (Morice et al. 2007, Chung 2006). Reflex cough sensitivity is assessed by 
inhalation cough challenge. The subject is exposed to inhaled chemical irritants, usually citric 
acid, tartaric acid or capsaicin. The irritant is delivered in increasing concentrations, and the 
threshold at which reflex coughs are elicited is noted. Cough frequency is measured by counting 
the number of coughs over a certain period of time. Automated cough monitoring systems have 
been developed, which greatly reduce the time and effort required to capture cough frequency, 
particularly over long periods of time. Most systems are based on sound recordings and 
software packages for the automated detection of cough sounds on such recordings. These 
systems allow convenient measurement of cough frequency over 24 or 48 hours (Morice et al. 
2007, Chung 2006). Cough-related quality of life may be assessed using self-reported 
questionnaires. Several cough-specific measures are available, although generic health-related 
quality of life questionnaires have also been used (Morice et al. 2007, Chung 2006).  
 
Methods of objectively assessing cough intensity or cough strength are of interest in contexts of 
effective airway clearance or effective protection from aspiration, especially in clinical 
populations with acquired or degenerative neuromuscular conditions. Here, the focus is on 
quantifying ineffective cough, for example with the aim of predicting the risk of pneumonia, or to 
identify the need for assisted airway clearance treatment (Jones et al. 2012, Boitano 2006). The 
loudness of cough sound recordings (sound pressure level) has been used as an indicator for 
cough strength by some researchers (Smith Hammond et al. 2001, 2009). Oesophageal and 
gastric pressures during a cough manoeuvre can be measured as parameters of cough strength 
with close relation to respiratory muscle strength, in particular abdominal muscle strength 
(American Thoracic Society (ATS) & European Respiratory Society (ERS) 2002). Expiratory 
cough flow is a parameter which most closely relates to the effectiveness of a cough manoeuvre 
in transporting particles from the lower airways towards and into the pharynx (American 
Thoracic Society (ATS) & European Respiratory Society (ERS) 2002). It is thought that the 
sheer forces exerted onto the airway walls through expiratory airflow move mucus and other 
materials along the airways. In a mechanical model, the distance of material moved was 
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proportional to the airflow generated (King et al. 1985). Cough flow is usually measured at the 
mouth, using calibrated pneumotachograph systems. Peak expiratory flow during a cough 
manoeuvre is most frequently taken as the outcome parameter of interest, although various 
other parameters may be derived form a cough flow recording, such as the peak rise time and 
the inspired and expired cough volumes (Singh et al. 1994). In the context of cough as a 
defence mechanism from aspiration, the measurement of reflex cough sensitivity is also of 
interest in neurological conditions such as stroke or traumatic brain injury, where the cough 
reflex may be diminished due to central depression (Lee et al. 2013, Addington et al. 2005).  
 
1.3.4 Impairment of cough in acute stroke 
 
Cough function has been an ongoing research interest in neuromuscular conditions. Aspects of 
cough have been examined in populations with muscular dystrophy (LoMauro et al. 2014, Brito 
et al. 2009, Daftary et al. 2007, Dohna-Schwake et al. 2006, Kang et al. 2006a, Gauld & 
Boynton 2005, Sancho et al. 2004), motor neuron disease (Cleary et al. 2013, Sancho et al. 
2007, Bach et al. 2006, Bach 1995), spinal cord injury (Yoon et al. 2011, Bolser et al. 2009, 
Kang et al. 2006b), traumatic brain injury (Lee et al. 2013), Parkinson’s disease (Silverman et 
al. 2014, Pitts et al. 2009) and stroke (Zhou et al. 2012, Yoon et al. 2011, Ward et al. 2010, 
Smith Hammond et al. 2009, Harraf et al. 2008, Addington et al. 2005, Stephens et al. 2003, 
Smith Hammond et al. 2001, Addington et al. 1999a, 1999b). Studies of cough in stroke can be 
distinguished into those that focus on reflex cough sensitivity, and those investigating cough 
intensity in the sense of cough strength and the generation of cough airflow.  
 
With respect to reflex cough in stroke, there is some evidence indicating that reflex cough 
sensitivity can be reduced following stroke, and that a diminished cough reflex is associated 
with an increased risk of pneumonia. Addington et al. (1999a) assessed the cough reflex in 161 
stroke patients admitted to a rehabilitation hospital within 30 days of stroke. Patients inhaled 
nebulised L-tartaric acid at a concentration that normally triggers a strong reflex cough 
response. Thirty patients showed an abnormal (weak or absent) cough reflex at this level of 
stimulation. Out of these 30 patients, five (17%) developed pneumonia, while none of the 
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patients with normal cough reflex developed pneumonia. In another publication, the same group 
reported that cough reflex assessment showed abnormal responses in 40 (10%) out of 400 
stroke rehabilitation patients when tested with the nebulised irritant; and 81 (20%) out of 400 
patients showed weak or absent voluntary cough as assessed subjectively by the treating 
clinician (Addington et al. 1999b). In their later work, Addington et al. observed a cohort of 818 
stroke rehabilitation patients whose cough reflex was assessed with the above method. Out of 
736 patients with normal cough reflex, 26 (3.5%) developed pneumonia, while out of 82 patients 
with abnormal cough reflex 9 (11.0%) developed pneumonia (Addington et al. 2005). The group 
also conducted a study of the laterality of voluntary and reflex cough in 30 right-handed patients 
with acute middle cerebral artery infarction (Stephens et al. 2003). Cough reflex, as assessed 
through inhalation challenge using L-tartaric acid, and voluntary cough, assessed subjectively 
by a clinician, were both normal in all 16 patients with right hemispheric lesion sites. Out of 14 
patients with left hemispheric stroke lesions, reflex cough was normal, and voluntary cough was 
weak or absent in 11 patients (79%). None of the patients in this study developed pneumonia. 
The authors hypothesised that the neural control of voluntary cough might be closely linked to 
speech and voice-clearing, which might account for the observed impairment of voluntary cough 
in patients with left-sided stroke lesions (Stephens et al. 2003). Overall, these studies provide 
some evidence that reflex cough sensitivity can be considerably reduced in a portion of acute 
and sub-acute stroke survivors; and that an abnormal cough reflex is associated with increased 
incidence of PSP.  
 
Several studies have examined cough intensity in stroke using cough flow measurements. 
Smith Hammond et al. conducted two cross-sectional studies, examining the relationship 
between cough flow parameters and swallowing function in stroke (Smith Hammond et al. 2009, 
2001). Both studies applied similar methods. Voluntary cough flow was recorded using a face 
mask and the Perci-SAR system, a customised speech-aeromechanic measurement system 
that includes a pneumotachograph (MicroTronics Corp, Chapel Hill, North Carolina). Sound 
pressure levels were recorded using a calibrated microphone. Instrumental swallowing 
assessments (video-fluoroscopy or fibre-optic endoscopic evaluation of swallow) were 
conducted to determine whether patients aspirated or not. In their first study, Smith Hammond 
et al. compared 43 acute and sub-acute stroke patients with 18 age- and sex-matched healthy 
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control subjects. Compared with the control subjects, stroke patients had reduced parameters of 
cough intensity throughout. These parameters were: duration, volume and peak flow of the 
inspiratory phase of cough; duration of the glottis compression phase of cough; peak flow and 
cough volume acceleration during the expulsive phase of cough; and cough sound pressure 
levels. Within the stroke sample, these parameters generally decreased with worsening degree 
of swallowing dysfunction and aspiration (Smith Hammond et al. 2001). In their second study, 
Smith Hammond et al. assessed 96 stroke patients using similar methods and replicated their 
findings of generally worse cough function in patients who aspirated compared with non-
aspirators. In both studies, the authors also analysed the diagnostic value of voluntary cough 
flow measurement for the identification of aspiration risk in stroke patients. Their findings 
support the association between reduced cough flow parameters and aspiration, and they 
suggest that further research could be conducted to validate the use of objective measures of 
voluntary cough for the assessment of aspiration in stroke (Smith Hammond et al. 2009).  
 
Further evidence of the impairment of cough flow in stroke was provided by Yoon et al. (2011). 
In their study, 31 chronic stroke patients were compared with 30 healthy elderly subjects. Peak 
expiratory flow rate of voluntary cough was found to be reduced by approximately one third in 
the stroke group. Similarly, Zhou et al. (2012) found that in a group of 32 acute stroke patients 
voluntary peak cough flow rate was reduced by approximately one third when compared with 
the normative range for peak expiratory flow (during forced expiration).  
 
The studies by Ward et al. (2010) and Harraf et al. (2008) provide the most detailed and 
physiologically sophisticated examinations of cough and respiratory muscle function in stroke to 
date. Ward et al. studied 18 patients with acute middle cerebral artery infarcts in comparison 
with 20 age-matched healthy control subjects. Subjects did not have any respiratory conditions 
or neuromuscular conditions affecting the respiratory pump, other than stroke. Investigations 
included assessments of lung function (forced spirometry), respiratory muscle strength (gastric 
and oesophageal pressures, inspiratory and expiratory mouth pressures, and sniff pressures), 
and cough flow for voluntary and reflex cough measured with a pneumotachograph at the 
mouth. Reflex cough was triggered through nebulised L-tartaric acid solutions of escalating 
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concentrations. Stroke patients had significantly reduced respiratory muscle strength and cough 
flow, for both voluntary and reflex cough, with parameters reduced by one third to half in 
comparison with the control group.  
 
Several aspects of the study by Ward et al. are noteworthy. Firstly, the observation that in 
addition to voluntary cough, reflex cough intensity was also reduced in this group of hemispheric 
stroke patients may seem unexpected. Intuitively, it could be assumed that reflex cough 
function, which is primarily controlled at the level of the brainstem, would not be affected in 
hemispheric stroke; however, these findings suggest otherwise, and on this basis hypotheses of 
the central neural mechanisms involved in reflex cough may be reconsidered. Secondly, the 
authors were able to exclude any undetected obstructive airway disease in their subjects, by 
conducting forced spirometry. Airway obstruction limits forced expiratory airflow, and therefore 
also cough expiratory airflow. The subjects studied by Ward et al. all had parameters of airway 
obstruction (FEV1/FVC ratio) within the normal to mildly obstructive range, and there was no 
significant difference between the stroke patients and control subjects. It can therefore be 
asserted with confidence that the cough flow limitations in the stroke group observed by Ward et 
al. were not related to airway obstruction, but to other aspects of cough generation. Thirdly, the 
study gives a good indication as to which physiological impairments result in the observed 
cough dysfunction. From the point of view of cough mechanics, the volume inspired at the 
beginning of cough, the driving pressure generated by expiratory muscle contraction, and the 
quality of glottis control (adequate glottis closure during the compression phase of cough and 
rapid glottis opening to initiate the expulsive phase) all contribute to effective cough generation. 
Stroke patients showed adequate cough compression phases as visualised on cough flow-time 
traces, and no significant difference in glottis closure times compared with control subjects, 
indicating adequate glottis function during cough. However, stroke patients showed a reduction 
in inspiratory lung volumes (FVC, inspiratory cough volume) and in both in- and expiratory 
muscle strength (maximum inspiratory and expiratory mouth pressures, sniff pressures, gastric 
and oesophageal cough pressures). It can therefore be surmised that the following two factors 
are the likely causes of reduced cough intensity in acute stroke: 1) reduced cough inspiratory 
volume, related to reduced inspiratory muscle strength; and 2) reduced cough driving 
pressures, related to reduced expiratory muscle strength.  
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The study by Harraf et al. (2008) provided evidence to identify the site of neuro-muscular 
impairment causing reduced cough in stroke. Comparing 15 patients with acute hemispheric 
infarct and 16 age- and sex-matched controls, Harraf et al. studied voluntary cough flow, 
respiratory muscle strength (maximum expiratory mouth pressure, gastric and oesophageal 
cough pressures), and in- and expiratory muscle activation by transcutaneous magnetic 
stimulation (TMS). As in the study by Ward et al., expiratory muscle strength and expiratory 
cough flow were reduced by one third to half in the stroke group compared to healthy control 
subjects. Harraf et al. then measured gastric and oesophageal pressures when respiratory 
muscles were stimulated involuntarily through magnetic stimulation. The diaphragm was 
activated through peripheral phrenic nerve stimulation from the anterior neck. The abdominal 
musculature was activated through stimulation of the spinal nerve root at the tenth thoracic 
level. These stimulations resulted in equivalent gastric and oesophageal pressures in the stroke 
and control group. However, when the abdominal musculature was activated through TMS over 
the vertex, the stroke group showed lower pressures than the control group. This indicates that 
the function of the peripheral portion of the motor unit (neural transmission along the lower 
motor neuron and trigger of muscle contraction) in stroke is equivalent to neurologically normal 
controls; and that the breakdown in respiratory muscle force generation observed in stroke is 
likely related to the central portion of the motor unit, i.e. the cerebral lesion.  
 
In summary, there is good evidence to demonstrate that there is a significant impairment of 
cough and respiratory muscle function in acute stroke; that the impairment in cough function is 
likely related to respiratory muscle weakness, as opposed to dysfunction at the level of the 
glottis; and that the respiratory muscle weakness is related to the central component of the 
motor pathway, i.e. the stroke lesion. This provides the physiological rationale for the novel 
treatment approach taken in the present studies, which is to target stroke-induced central 
respiratory muscle weakness to improve cough effectiveness.  
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1.4 Respiratory muscle training 
 
Approaches to training the respiratory muscles follow the general principles of skeletal muscle 
training, which is founded on exercise physiology, although adapted to the functional 
requirements of the respiratory system (McConnell 2013, pp. 135-147, Syabbalo 1998, Polkey 
et al. 1995, Reid & Dechman 1995). These principles are overload, specificity and reversibility 
(McConnell 2013, pp. 135-147, 2011, pp. 80-85). Overload refers to imposing a training 
challenge that exceeds the usual level of muscle performance. Implicit within this principle is the 
concept of training duration, intensity and frequency. Accordingly, an overload can be applied to 
a muscle by increasing the duration, intensity or frequency the muscle is required to contract at, 
whereby most training regimens combine these factors (McConnell 2011, p. 80). Specificity 
refers to the principle that the nature of the training response depends on the type of stimulus 
delivered. Here, the general distinction between strength and endurance training is made. High 
intensity and short duration training stimuli lead to an improvement in strength, whereas low 
intensity and long duration stimuli lead to an improvement in endurance (McConnell 2011, p. 
82). The reversibility principle refers to the phenomenon of detraining. Training gains need to be 
maintained through ongoing use, or else they will be reversed (‘use it or lose it’). Generally, a 
maintenance programme with stimuli at a lower level than for the training programme is 
sufficient to prevent the loss of training gains (McConnell 2011, p. 84).  
 
Approaches to training the respiratory muscles can be divided according to the desired training 
response into resistance training (aimed at improving strength) and endurance training. Another 
distinction can be made into functional training of the respiratory muscles, i.e. training the 
respiratory muscles through breathing-based training activities, and traditional skeletal muscle 
training, i.e. training respiratory muscles through traditional weight-lifting type exercises, which 
is possible for the abdominal muscles and some of the accessory respiratory muscles. 
Functional RMT can be divided according to the ‘direction’ of training, i.e. inspiratory or 
expiratory training. A further distinction into RMT and other respiratory-type exercises and novel 
interventions can be made, mainly based on what historically has been understood and 
described as RMT in the literature, and there may be some overlap with respect to the proposed 
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mechanisms of effect and aims of training. Other respiratory-type exercises and novel 
interventions include diaphragmatic breathing (Sutbeyaz et al. 2010), pursed lip breathing 
(Sutbeyaz et al. 2010), directed breathing with biofeedback (Kim et al. 2011) and electrical 
stimulation of respiratory muscles (Jung et al. 2014).  
 
The following sections describe techniques that historically have been described as RMT in the 
literature. Most robust evidence is derived from research in healthy and athletic populations 
(McConnell & Romer 2004) and a limited but growing body of evidence is available for several 
clinical populations (McConnell 2013, pp. 161-162). Historically, most work has focussed on 
training of the inspiratory muscles, as opposed to the expiratory muscles (McConnell 2013, p. 
140).  
 
1.4.1 Voluntary isocapnic hyperventilation training 
 
Voluntary isocapnic hyperpnoea is an endurance training method that involves maintaining 
voluntary hyperventilation at 60% to 90% of maximum voluntary ventilation for up to 40 minutes. 
Sustained hyperventilation in healthy subjects leads to hypocapnia with tingling sensations in 
hands, feet and lips, dizziness and eventual loss of consciousness (Martini 2004, p. 1036). In 
voluntary isocapnic hyperventilation, hypocapnia is avoided by the use of a rebreathing circuit, 
which allows the subject to maintain hyperventilation over an extended period of time. This 
requires an elaborate equipment setup. Voluntary isocapnic ventilation leads to improvement in 
respiratory muscle endurance but not strength (McConnell 2013, pp. 140-141, 2011, pp. 85-92, 
Verges et al. 2008).  
 
1.4.2 Static resistive load training 
 
In early studies of respiratory muscle strength training, training stimuli were applied through 
‘quasi-isometric’ static contractions of the inspiratory or expiratory muscles, whereby subjects 
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exerted an inspiratory or expiratory effort against a closed lumen (Reid & Dechman 1995, Leith 
& Bradley 1976). Although this training method was shown to increase respiratory muscle 
strength (Leith & Bradley 1976), alternative methods that require subjects to shift lung volume 
were regarded as more functional and have been favoured training methods in recent years 
(Reid & Dechman 1995).  
 
1.4.3 Flow resistive load training 
 
In flow resistive load training, the training stimulus is achieved by breathing through a device 
with a narrowed lumen, whereby the size of the lumen can be selected to adjust the training 
intensity. As airway resistance is dependent on both the diameter of the airway and airflow, 
resistance increases with both decreasing airway diameter and increasing airflow. In theory, 
training resistance to the respiratory muscles can conveniently be applied by reducing the 
lumen of the airway while maintaining airflow constant. The principle underlying this method is 
simple; however, effective training requires monitoring of the airflow (i.e. the speed of 
breathing), as slower breaths result in reduced resistance and therefore lower training intensity 
(McConnell 2013, p. 139, 2011, p. 86, Reid & Samrai 1995).  
 
1.4.4 Pressure threshold loading  
 
In the pressure threshold loading method, the training stimulus is delivered through a device 
containing a spring-loaded valve, which opens at a pre-set pressure. For inspiratory training, the 
subject breathes in against the threshold load and has to generate sufficient inspiratory 
pressure to open the valve, from which point on the inspiration can be completed. The breath 
out is unimpeded. For expiratory training, the direction of the spring-loaded valve is reversed 
(McConnell 2013, pp.139-140, 2011, pp. 86-87, Reid & Samrai 1995). The load can be adjusted 
conveniently by tightening or releasing the spring. This training method has become 
increasingly popular, due to the relatively simple and inexpensive training devices that are 
nowadays available. A further advantage of this method is that the training load is not influenced 
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by airflow (i.e. the same threshold load is delivered, regardless whether the subjects breathes 
through the valve at higher or lower airflow); and that the function of the device is not dependent 
on gravity (i.e. the device can be tilted in any direction, making it convenient for use with 
patients who are in bed, as opposed to other respiratory training devices which require upright 
positioning for the device to function adequately) (McConnell 2011, pp. 86-87, Reid & Samrai 
1995).  
 
1.4.5 Physiological responses to pressure threshold loading 
 
The physiological responses to RMT using pressure threshold loading have been researched 
extensively in healthy and athletic populations. Inspiratory muscle training has been shown to 
lead to inspiratory muscle hypertrophy and improvement in strength (McConnell 2013, pp. 97-
131, 2011, p.52-56, McConnell & Romer 2004). In general, respiratory muscles respond to high-
load low-frequency loading by increase in strength. Taking into account both the resistance load 
and the airflow generated during a training manoeuvre, it has been shown that training with high 
loads at low airflow leads to improvement in maximal strength but not maximal flow. Training 
with low loads at high flow leads to improvement in maximal flow but not strength. However, 
training stimuli at intermediate loads and flow elicit improvements in both maximal strength and 
flow (Romer & McConnell 2003). Accordingly, the recommended training load in healthy 
subjects is at 50% to 70% of maximal respiratory muscle strength, and with a frequency of 30 
breaths at least twice daily (McDonnell 2011, pp. 93-111). In addition to the training effects on 
the respiratory system, transient increase in heart rate and arterial blood pressure has been 
observed in healthy athletes in response to inspiratory threshold training at a moderate 
resistance load (60% of maximal inspiratory mouth pressure; PImax) (McConnell & Griffiths 
2010).  
 
In clinical populations, RMT has been researched most in patients with primary cardio-
respiratory conditions and in surgical patients, and some studies have been conducted in 
patients with neuromuscular conditions (McConnell 2013, pp. 135-173, Pollock et al. 2013, 
Hulzebos et al. 2012, Lin et al. 2012, Gosselink et al. 2011). Most consistently, studies have 
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demonstrated that inspiratory muscle training leads to improvements in maximal inspiratory 
mouth pressure, inspiratory muscle endurance and subjective perception of dyspnoea. Some 
studies have also demonstrated improvements in lung function (spirometry) and exercise 
tolerance (McConnell 2013, pp. 135-173).  
 
1.5 Systematic literature review of respiratory muscle training in 
stroke 
 
A systematic literature review was conducted to evaluate the evidence base for RMT in stroke; 
and to use previous research in the field to inform the subsequent clinical studies.  
 
1.5.1 Search strategy 
 
Fourteen databases were searched between September and November 2012, using the search 
terms ‘stroke’ in combination with ‘respiratory training’ and ‘respiratory exercise’. Details of the 
search strategy and search history are given in Table 2 and Figure 1. Included were research 
articles or conference abstracts of studies investigating RMT in stroke patients, which were 
published in indexed, peer-reviewed scientific journals. To maximise the pool of potential 
results, no limitations were set with respect to time of publication, language or study design. The 
search yielded 2,928 results. Where the title of the search result appeared relevant, the abstract 
was read. Where the abstract appeared relevant, the citation was obtained in full text. 
Reference lists of citations obtained in full text were reviewed for further relevant publications. 
Eight citations were obtained in full text, of which three were excluded: one conference abstract 
(Teixeira-Salmela et al. 2010), which describes the study published in full by Britto et al. (2011); 
and two reports of clinical studies, which investigated respiratory exercise other than RMT 
(Kang et al. 2012; Kim et al. 2011). Of the remaining five publications, three are reports of 
original research (Britto et al. 2011, Sutbeyaz et al. 2010, Fernandes et al. 2007), and two are 
systematic reviews of RMT in stroke (Pollock et al. 2012; Xiao et al. 2012), each of which 
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included two of the three original research articles identified (Britto et al. 2011, Sutbeyaz et al. 
2010). Monthly automated search alerts were set up to identify newly published articles, and 
one further study was added for review in May 2014 (Jung et al. 2014). The literature search is 
up to date as of 31st December 2014.  
 
Due to the paucity of available publications, the value of statistically combining the reported 
results is limited. Rather, detailed appraisals of individual studies are warranted, which are 
given in the following sections.  
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Table 2. Search strategy for the systematic literature search 
Database (search portal) Date Search terms Database fields Results 
MEDLINE (PubMed) 17/09/2012 stroke AND respiratory training Title, abstract 1 
17/09/2012 stroke AND respiratory training All fields 181 
     
BIOSIS, SciELO, Web of Science Core Collection 
(Web of Knowledge v. 5.7) 
18/09/2012 stroke AND *piratory AND (train* OR 
exercise*) NOT swim* NOT cardio* 
Topic 373 
     
CINAHL (EBSCO Host) 12/11/2012 stroke AND resp* AND (train* OR exercise*) All fields 962 
     
Embase, PsychINFO (OvidSP) 12/11/2012 stroke AND respir* AND (train* OR exercise*) All fields 804 
     
AMED, BNI (NHS Evidence) 13/11/2012 stroke AND respir* AND (train* OR exercise*) Title, abstract 20 
13/11/2012 stroke AND respiratory Title, abstract 51 
     
PEDro, OTSeeker, PsycBITE, SpeechBITE 
(Allied Health Evidence) 
13/11/2012 stroke respiratory All fields 29 
13/11/2012 stroke breathing All fields 10 
13/11/2012 stroke AND resp* AND (train* OR exercise*) All fields 0 
13/11/2012 stroke respiratory train* All fields 6 
     
metaRegister of Controlled Trials (www.controlled-
trials.com) 
13/11/2012 stroke AND respiratory All fields 491 
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Figure 1. Flow diagram of the systematic literature search 
 
 
1.5.2 Critical appraisal of individual studies 
  
1.5.2.1 Inspiratory Muscular Training in Chronic Stroke Survivors: A Randomized 
Controlled Trial (Britto et al. 2011) 
 
Britto et al. (2011) conducted a randomised controlled trial of RMT in 21 chronic stroke 
survivors. The study recruited community-dwelling adults in a large Brazilian city. Criteria for 
recruitment were: a history of stroke more than nine months prior to enrolment; presence of a 
residual hemiparesis; maximal inspiratory mouth pressure (PImax) of less than 90% of that 
predicted for age and gender; and lack of pre-existing respiratory or cardiac conditions. 
Participants were randomised to receive either pressure threshold training RMT with a 
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commercially available inspiratory muscle training (IMT) device (Threshold IMT, Philips 
Respironics, Andover, MA) or sham respiratory training.  
 
RMT was conducted over a period of eight weeks. Participants trained independently and 
completed a training diary. The training resistance for the intervention group was set at 30% of 
PImax, and adjusted in biweekly sessions with a researcher. The control group followed the 
same procedures as the intervention group, but used training devices without valves, thereby 
breathing through the device without added resistance. Participants and assessors were 
blinded. The primary outcome was PImax. Further outcomes were inspiratory muscle 
endurance, cardiovascular fitness, daily functioning and quality of life. The data was examined 
for normality and repeated-measures analysis of variance (ANOVA) was used for the inferential 
statistical analysis.  
 
After eight weeks of training, both groups showed an increase in mean PImax (Table 3). This 
improvement was three times higher in the intervention group, with a statistically significant 
between-group difference (p=0.033). The intervention group also demonstrated a statistically 
significant increase in inspiratory muscle endurance (p=0.04), while there was a minimal and 
statistically insignificant increase only in the control group. In the remaining three outcomes, 
there was no treatment effect in both groups.  
 
Table 3. Values for outcome maximal inspiratory mouth pressure (PImax, cmH2O) in the study 
by Britto et al. (2011) 
Group n Baseline Post intervention Change score 95% CI for 
change score a 
IMT 9 67.8 (14.6) 102.2 (26.0) 34.4 (27.1) 13.6, 55.2 
Control 9 45.6 (13.8) 56.7 (8.7) 11.1 (2.9) 8.9, 13. 3 
Figures are mean (SD) 
IMT, inspiratory muscle training.  
a 95% confidence intervals for change scores are not given in the paper and were calculated 
from the given mean (SD) 
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As a double-blind randomised controlled trial, the study of Britto et al. had a low risk of bias. The 
inclusion of a sham intervention and transparent statistical methods further strengthened the 
design, and a relatively high level of confidence can be placed in the reported results. The study 
benefited from an explicit hypothesis statement and a clear primary outcome of interest, PImax. 
A sample size calculation was conducted to detect an effect size of 12.3 cmH2O in PImax. In 
spite of three participants who did not complete the study, the sample of nine participants per 
group met the requirements of the sample size calculation to give 80% power at a significance 
level of 5%.  
 
One negative criticism relates to the group characteristics at baseline. Clinical characteristics 
relating to stroke were not reported, such as the type of stroke, the time from the onset of 
stroke, or the severity of hemiparesis. These data would add to the reader’s understanding of 
the sample and the potential transferability of findings. Although the authors were satisfied that 
the two groups were sufficiently similar at baseline, several group differences are evident from 
the reported baseline characteristics: body mass index, PImax, inspiratory muscle endurance, 
and cardiovascular fitness were considerably higher in the intervention group. While it is 
uncertain whether these differences would confound the study findings, these differences are 
obvious and should have been acknowledged by the authors.  
 
The authors present summary data for all five outcomes at baseline and post-training. Also 
presented are within-group differences (change scores) and between-group differences 
(differences in change scores) for all outcomes. The 95% confidence interval for the between-
group difference in PImax change score was 0.9 to 45.8 cmH2O. Accordingly, the true 
difference in treatment effect of IMT on PImax compared to sham IMT could be as large as 45.8 
cmH2O or as little as 0.9 cmH2O. While at the upper end of the confidence interval this 
represents a highly relevant effect size, at the lower end of the confidence interval the value 
approaches the effect size observed in the control group. It is advisable to bear this wide 
confidence interval in mind when judging the clinical relevance of the findings. No long-term 
follow-up was carried out, and therefore no data is available on whether the training effect was 
maintained after RMT was discontinued.  
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In summary, the study by Britto et al. warrants confidence in the reported findings. Although 
there were some group differences at baseline, it is uncertain whether these could have 
confounded the results, and it is reasonable to attribute the change in outcome measures to the 
intervention. The study recruited a sufficiently large sample to reach the statistical power aimed 
for; however, the confidence intervals remain wide and at the lower margin the difference 
between intervention and control group is minimal. Accordingly, it can be concluded that IMT in 
chronic stroke survivors appears a promising intervention to increase inspiratory muscle 
strength and endurance. However, these findings are preliminary and warrant further research 
to improve the statistical confidence in the findings, which will be achieved through larger 
samples.  
 
1.5.2.2 Respiratory muscle training improves cardiopulmonary function and exercise 
tolerance in subjects with subacute stroke: a randomized controlled trial (Sutbeyaz et al. 
2010) 
 
Sutbeyaz et al. (2010) conducted a randomised controlled trial in 45 subacute stroke patients. 
Adults with a first ever hemiparetic stroke were recruited from a Turkish inpatient rehabilitation 
unit on average five months after onset of stroke. Patients with pre-existing respiratory or 
cardiovascular conditions were excluded. Participants were randomised into three groups. The 
first experimental group carried out ‘breathing retraining exercises’ (BRT), a combination of 
diaphragmatic breathing, pursed lip breathing, air-shifting techniques, and voluntary isocapnic 
hyperpnoea; the second experimental group carried out IMT using pressure threshold loading 
with a commercially available device (Threshold IMT, Philips Respironics, Andover, MA); the 
control group received no specific respiratory exercise.  
 
Interventions were delivered over a period of six weeks, during which all participants underwent 
the usual post-stroke rehabilitation programme. A number of outcome measures were 
assessed: lung function testing, cardiovascular fitness testing, activities of daily living, perceived 
dyspnoea on exertion, and health-related quality of life. Overall, the authors analysed 18 
different outcome parameters. Following testing for normality of the data, the authors used one-
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way ANOVA for inferential statistical analysis. The most sizeable treatment effect was observed 
in the IMT group, which showed statistically significant improvements in lung function, including 
a mean increase in PImax of 7.9 cmH2O (p<0.001), and cardiovascular fitness, including a 
mean increase in power output of 9.0 W during an incremental arm crank ergometer test 
(p=0.01). The BRT group also showed some treatment effect, with a statistically significant 
mean increase in PImax of 7.1 cmH2O (p<0.001), in maximal expiratory mouth pressure 
(PEmax) of 5.4 cmH2O (p<0.001), and in peak expiratory flow (PEF) of 0.6 L/s (p=0.01). There 
was insignificant or no improvement in other parameters in the BRT group. The mean increase 
in ergometer power output in the BRT group was 1.8 W. The control group showed statistically 
insignificant improvements in PImax, maximal expiratory mouth pressure (PEmax) and 
ergometer power output, and no change in the remaining parameters. Table 4 summarises 
maximal mouth pressure values for the study sample.  
 
Table 4. Values for outcomes maximal inspiratory and expiratory mouth pressure (PImax, 
PEmax) in the study by Sutbeyaz et al. (2010) 








BRT 15 50.3 (6.7) 57.3 (7.9) 7.1 (4.8) 4.4, 9.7 
IMT 15 49.5 (5.9) 57.3 (8.6) 7.9 (6.6) 4.2, 11.5 
Control 15 51.0 (6.3) 53.9 (6.3) 2.9 (1.9) 1.8, 4.0 
       
PEmax 
(cmH2O) 
BRT 15 60.8 (7.1) 66.2 (8.2) 5.4 (2.9) 3.8, 7.0 
IMT 15 60.7 (9.2) 62.8 (9.9) 2.1 (2.0) 1.0, 3.2 
Control 15 62.9 (6.4) 65.9 (5.7) 3.0 (1.6) 2.1, 3.9 
Figures are mean (SD) 
BRT, breathing retraining; IMT, inspiratory muscle training.  
a 95% confidence intervals for change scores are not given in the paper and were calculated 
from the given mean (SD) 
 
 
The study by Sutbeyaz et al. holds several strengths, but also has a number of limitations. As a 
randomised controlled trial, it provides high level evidence regarding the effect of the 
investigated interventions, although only the assessors were blinded. Blinding participants, for 
example using a sham intervention for the control group, would have further strengthened the 
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design. The randomisation procedure was carried out appropriately, and the three groups 
showed comparable baseline characteristics.  
 
The authors state that a sample size calculation was conducted to detect a 20% difference in 
improvement between groups with a power of 80% and a significance level of 5%. However, the 
outcome parameter used in the power calculation is not made explicit. The study would have 
benefited from a clearly stated hypothesis defining the primary outcome of interest. Accordingly, 
the statistical analysis method appears unfocused, with between-group comparisons of change 
scores and within-group comparisons of pre- and post-intervention values conducted for each of 
the 18 outcome parameters. Although it is reported that adjustment for multiple testing was 
carried out, this is not made evident in the presented results.  
 
Confidence intervals are not presented, but can be calculated from the data provided in order to 
estimate the precision of the results. For example, the 95% confidence interval for the mean 
increase in PImax in the IMT group was 4.5 to 11.3 cmH2O. The mean difference in PImax 
change score between the IMT group and the control group was 5.0 cmH2O, with the 95% 
confidence interval ranging from 4.5 to 5.4 cmH2O. This is a narrow confidence interval 
indicating that in subacute stroke survivors undergoing IMT, with 95% probability the mean 
increase in PImax is between 4.5 and 5.4 cmH2O higher than in stroke patients who do not 
carry out any respiratory exercise. The study did not include long-term follow up and therefore 
no data is available on whether the positive treatment effects were maintained after the 
intervention was discontinued.  
 
Two aspects stand out amongst the results. Firstly, both experimental treatments resulted in a 
similar increase in PImax compared to the control group. In addition, the BRT group also 
showed an increase in PEmax and PEF, while the IMT group had PEmax and PEF changes 
similar to the control group. It therefore seems that the combination of breathing exercises 
delivered to the BRT group had an effect on lung function parameters that was similar, if not 
more beneficial, to the IMT group. The lack of improvement in PEmax and PEF in the IMT group 
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may be explained through the mechanics of the training device, which delivers resistance during 
the inspiration phase only, while components of BRT created increased expiratory resistance 
(pursed lip breathing and isocapnic hyperpnoea), which could act as a training stimulus for the 
expiratory muscles and impact on expiratory function. Secondly, only the IMT group showed 
improvements in those parameters that relate to respiratory muscle endurance (maximum 
voluntary ventilation, MVV), and cardiovascular fitness (peak oxygen consumption, VO2peak; 
power output during incremental arm crank ergometer test; perceived dyspnoea on exertion). 
This may indicate that, while both interventions are effective in increasing PImax, an indicator of 
inspiratory muscle strength, IMT also has an effect on respiratory muscle endurance and overall 
cardiovascular fitness. This finding is consistent with trials of IMT in other clinical populations.  
 
In summary, the study by Sutbeyaz et al. merits confidence in the presented results due to a 
strong study design. However, lack of clarity in the inferential data analysis method and overall 
modest positive effect sizes warrant caution with respect to the statistical significance and 
clinical relevance of these findings.  
 
1.5.2.3 Efeito do Treinamento Muscular Respiratorio por Meio do Manovacuometro e do 
Threshold Pep em Pacientes Hemipareticos Hospitalizados [Effect of Respiratory Muscle 
Training through Vacuum-Manometer and Threshold PEP in Hospitalised Hemiparetic 
Patients] (Fernandes et al. 2007) 
 
Fernandes et al. (2007) conducted a clinical study of 36 adult inpatients with a diagnosis of 
stroke and hemiparesis. Patients were recruited from a hospital in a large Brazilian city. 
Participants were divided into two groups of 18. The intervention group received daily expiratory 
muscle training using pressure threshold loading with a commercially available device 
(Threshold PEP, Philips Respironics, Andover, MA) at a resistance level of 40% of PEmax over 
five days. The control group did not receive any respiratory training. Both groups underwent 
respiratory testing of PImax, PEmax and PEF at baseline and after five days.  
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The authors present summary data for each of the three outcomes at baseline and at day five, 
but no change scores or differences in change scores (Table 5). The data were analysed using 
ANOVA and with the level of significance set at p=0.05. Overall, the intervention group showed 
statistically significant improvement in PEmax (p<0.001), PImax (p=0.003) and PEF (p=0.021). 
The control group showed deterioration in all three outcomes.  
 
Table 5. Values for outcomes maximal inspiratory and expiratory mouth pressure (PImax, 
PEmax) in the study by Fernandes et al. (2007) 




EMT 18 39 (14) 56 (20) 17 
Control 18 45 (14) 37 (11) -8 
      
PEmax 
(cmH2O) 
EMT 18 43 (16) 70 (19) 27 
Control 18 56 (17) 46 (15) -10 
Figures are mean (SD) 
EMT, expiratory muscle training 
a Mean change scores are not given by the authors and were calculated as mean score post 
intervention minus mean score at baseline; the standard deviations of mean change scores 
cannot be derived from the data reported in the paper, and therefore 95% confidence intervals 
for change scores cannot be calculated.  
 
 
In the publication by Fernandes et al. some aspects of the study methodology were described in 
sufficient detail to support the validity of the findings. For example, the respiratory testing 
methods were described in detail and comply with the international standards set out by the 
American and European respiratory societies. However, the authors did not state key aspects of 
their methodology, most importantly how participants were assigned to the intervention and 
control group and the degree of blinding of assessors, participants and health care staff. Also 
lacking are descriptions of a power calculation; detailed inclusion and exclusion criteria; 
participants’ baseline characteristics, including demographic and stroke-related clinical data; the 
participant flow through the study and participant attrition; the study setting; the level of 
additional contact with health care or research staff for the two groups as a result of involvement 
in the study; and whether an adjustment for multiple testing was incorporated in the statistical 
analysis. Providing change scores and differences in change scores with 95% confidence 
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intervals would have aided the interpretation of results, in particular with respect to estimating 
the potential effect size and its clinical relevance. From the data given, confidence intervals 
cannot be calculated. The authors were contacted with a request for further information, 
however no reply was received.  
 
In summary, due to the lack of detail in the research paper by Fernandes et al., it is not possible 
to determine the risk of bias in the study. Subsequently, no judgement can be made on the 
internal validity of the reported findings. While, in view of the paucity of research on RMT in 
stroke, it is relevant to include the study by Fernandes et al. in this review, these findings should 
not be used towards the cumulated evidence.  
 
1.5.2.4 Effects of abdominal stimulation during inspiratory muscle training on 
respiratory function of chronic stroke patients (Jung et al. 2014) 
 
This South Korean study compared IMT using pressure threshold loading with IMT augmented 
with concurrent electrical stimulation of the abdominal muscles. The aim was to determine the 
effect of abdominal stimulation in addition to IMT on forced expiratory function. Eighteen chronic 
stroke survivors with hemiplegia were recruited and the average time from stroke onset was four 
years. Participants were randomised to the two training conditions, which were delivered for 20 
minutes per day, three times per week over four weeks. IMT resistance was set at 30% of 
PImax. Outcome measures were diaphragm thickness ratio and forced spirometry, which were 
assessed before and after the intervention.  
 
The authors observed improved diaphragm thickness ratios at the post-training time point in 
both groups, with no between-group difference. With respect to forced expiratory function 
(forced vital capacity (FVC), forced expiratory volume in one second (FEV1), PEF, and forced 
expiratory flow between 25% and 75% of the expired volume (FEF25-75)), the IMT plus 
abdominal stimulation group showed improvement throughout, whereas the IMT group 
remained stable, with statistically significant between-group differences for FEV1 and PEF. The 
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authors conclude that, while IMT benefits inspiratory lung function, abdominal stimulation in 
addition to IMT has the potential to improve lung function parameters relating to forced 
expiration, such as forced expiratory flow.  
 
The study by Jung et al. is interesting in its original and novel approach; however, it is of limited 
relevance to the present research. Firstly, the experimental component of the intervention was 
electrical stimulation of the abdominal muscles to augment RMT, as opposed to RMT alone. 
Electrical stimulation techniques of respiratory muscles have mainly been researched in clinical 
populations with spinal cord injuries (Golle et al. 2008), with the aim to improve tidal volume, 
forced expiratory function and cough function. While electrical stimulation may merit further 
investigation in the stroke population, also in the context of improving cough function, the focus 
of the present studies is RMT alone. Secondly, several methodological aspects of the study by 
Jung et al. could not be assessed due to lack of reporting. Participant baseline characteristics 
were not reported according to study group, and there was no indication of the severity of stroke 
impairment or the presence of pulmonary disease. The authors did not state the concealment of 
group allocation or the level of blinding. While from the data presented it can be assumed that 
all participants remained in the study until the post-test time point, treatment fidelity was not 
described. Of note, the outcome parameters relating to forced spirometry (FVC, FEV1, PEF, 
FEF25-75) were reported as percentage of the predicted value, rather than in the original unit of 
measurement. This is unusual and raises the question whether this statistic may have been 
selected in order to present the findings more favourably.  
 
In summary, the study by Jung et al. investigated a novel treatment approach in combining 
electrical stimulation with RMT. However, this intervention has little relevance in the context of 
the present studies. Also, several methodological aspects of the study have not been reported, 
and a judgement on risk of bias and internal validity is not possible. The study should therefore 
not be included towards the cumulative evidence of RMT in stroke.  
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1.5.2.5 Respiratory muscle strength and training in stroke and neurology: a systematic 
review (Pollock et al. 2012) and Inspiratory muscle training for the recovery of function 
after stroke (Xiao et al. 2012) 
 
Two systematic reviews of RMT in stroke have been published. The review by Xiao et al. 
(2012), published in the Cochrane Database of Systematic Reviews, included randomised 
controlled trials of inspiratory RMT in stroke. The review by Pollock et al. (2012) included 
randomised controlled trials of in- and/or expiratory RMT in stroke. Due to the paucity of 
published studies, Pollock et al. extended their review to include populations with various 
neurological conditions, including Parkinson’s disease, multiple sclerosis, amyotrophic lateral 
sclerosis, and myasthenia gravis, and conducted a meta-analysis of RMT in neurological 
populations. This approach is possible on the basis that common outcome measures (maximal 
mouth pressures) were applied in all included studies; although the clinical populations differ in 
that stroke represents a one-off insult to the brain with remarkable potential for recovery, and 
the other included conditions are generally of the progressive degenerative-type.  
 
In both reviews only two randomised controlled trials of RMT in stroke could be identified (Britto 
et al. 2011, Sutbeyaz et al. 2010). No studies of RMT in stroke using different research designs 
were identified. The combined effect size of IMT on PImax in the meta-analysis by Pollock et al. 
was a mean (95% CI) group difference of 6.9 (1.8, 12.1) cmH2O for the two studies in stroke 
patients, and 6.9 (2.8, 11.0) cmH2O for all nine studies including different neurological 
conditions. In relation to absolute values of PImax in healthy and clinical populations, this can 
be considered a modest effect size.  
 
A note on different statistical analysis methods between the original research studies and the 
systematic reviews of these studies shall be made at this point. The authors of the original 
studies analysed the mean differences (change scores) in outcome parameters from pre- to 
post-intervention. In contrast, the reviews by Xiao et al. and Pollock et al. present the data 
comparing the mean post-test scores between groups. The latter approach is less sensitive to 
individual treatment effect, as it does not incorporate the baseline level of the outcome 
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parameter. For example, in the study by Sutbeyaz et al. the mean (SD) PImax measurements 
post-intervention for the IMT and the control group were 57.3 (8.6) cmH2O and 53.9 (6.3) 
cmH2O, respectively. The mean difference between the two groups was 3.4 cmH2O, with a 95% 
confidence interval of –2.0 to 8.8 cmH2O. While the mean difference favours the intervention, 
the confidence interval includes the value of indifference (zero), indicating that the difference did 
not reach statistical significance. If, however, the change scores or the difference in change 
scores between groups are assessed, this takes account of group differences at baseline and 
arguably more adequately reflects individual treatment effect. In the same example, the mean 
PImax at baseline was slightly lower in the IMT group (49.5 cmH2O) than in the control group 
(51.0 cmH2O), which means that the IMT group improved to a greater extent (by 7.9 cmH2O 
compared to 2.9 cmH2O in the control group) than is reflected by comparing group means post-
treatment. The analysis of change scores in this instance does give a statistically significant 
result in favour of the intervention (mean difference 5.0 cmH2O, 95% CI 1.2, 8.7).  
 
In summary, the systematic reviews by Xiao et al. and Pollock et al. provide some high-level 
evidence that IMT in stroke leads to improvement in inspiratory muscle strength as measured by 
PImax, although the overall effect size can be considered modest. The reviews illustrate the 
paucity of evidence in the field, thus corroborating the search strategy and the findings of the 




In the literature search conducted for this review, only four published studies of RMT in stroke 
were found. The paucity of published studies is corroborated by two systematic reviews of the 
topic. The four original research studies included in this review differ considerably in several 
aspects, from sample characteristics to specifics of the investigated RMT interventions. The 
studies also differ with respect to methodological quality. The studies by Britto et al. and 
Sutbeyaz et al. were randomised controlled trials with relatively high methodological quality, and 
a high level of confidence can be placed in their internal validity and reported results. The 
methodological quality of the studies by Fernandes et al. and Jung et al. could not be 
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adequately assessed due to lack of detail given in the publications. Table 6 gives an overview of 
the methodological quality of the four studies using the quality assessment criteria for 
randomised controlled trials suggested by Verhagen et al. (1998).  
 
Despite differences between these studies, several practical aspects of research conduct 
specific to the intervention and the clinical population were thought to be relevant and 
transferable to the present studies: mode of administration of RMT; duration, frequency and 
intensity of training; adverse effects of training; adherence to treatment and participant 
retention; methods of assessing the effects of training; and reported magnitude of training 
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Table 6. Assessment of methodological quality of research studies included in this review, using the quality criteria from Verhagen et al. (1998).  
  Britto et al. 2011 Sutbeyaz et al. 2010 Fernandes et al. 2007 Jung et al. 2014 
1.  Treatment allocation     
 a) Was a method of randomisation performed? Yes Yes Not stated Yes 
 b) Was the treatment allocation concealed? Yes Yes Not stated Not stated 
2.  Were the groups similar at baseline regarding the 
most important prognostic indicators? 
No Yes Not stated Not stated 
3.  Were the eligibility criteria specified? Yes Yes Not stated Yes 
4.  Was the outcome assessor blinded? Yes Yes Not stated Not stated 
5.  Was the care provider blinded? Not stated Not stated Not stated Not stated 
6.  Was the patient blinded? Yes No Not stated Not stated 
7.  Were point estimates and measures of variability 
presented for the primary outcome measures? 
Yes Yes Yes Yes 
8.  Did the analysis include an intention-to-treat 
analysis?  
Not stated Yes Not stated Not stated 
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Table 7. Details of administration of respiratory muscle training (RMT) and outcome assessment in the four original studies of RMT in stroke.  
Study Mode of delivery of 
RMT 
Duration, frequency 





Adherence to treatment Participant retention Methods of assessing training effects / 
outcome measurements 
Britto et al. 






supervised by a 
researcher 
Eight weeks, daily for 
five days per week, 
30 minutes per 
session (6x5 minutes 
of breathing with 
intermittent rests of 
one minute duration); 
resistance set at 
30% of PImax and 






diary; of a maximum of 
1200 prescribed 
training minutes, the 
intervention group 
trained on average 
1,141 minutes (range 
780 to 1,560) and the 
control group 1,160 
minutes (range 600 to 
1,860) 
Out of 21 
participants two 
dropped out due to 
lack of time 
(intervention group) 
and one due to 
hypertension 
(control group); 18 
participants 
completed the study 
Maximal inspiratory mouth pressure (PImax) 
Inspiratory muscle endurance (incremental 
threshold loading method) 
Functional performance (incremental cycle 
ergometer test, maximum activity score of the 
Human Activity Profile) 
Health-related quality of life (Nottingham 
Health Profile) 
Sutbeyaz 




of supervision or 
assistance 
provided by health 
staff not stated 
Six weeks, twice 
daily for six days per 
week, 15 minutes per 
session; resistance 
adjusted to 40% of 
PImax initially, then 
gradually increased 
to 60% of PImax; 
number of breaths 




Not stated 45 out of 45 
participants 
completed the study 
Lung function testing (VC, FVC, FEV1, FEF25-
75, PEF, MVV) 
Maximal mouth pressures (PImax, PEmax) 
Incremental hand crank ergometer test 
(VO2peak, HRpeak, VEpeak, SaO2, 
VD/VTpeak, power output, perceived 
dyspnoea) 
Functional status (Barthel Index, Functional 
Ambulation Categories) 
Health-related quality of life (SF-36) 
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Table 7. continued 
Fernandes 




of supervision or 
assistance 
provided by health 
staff not stated 
Five days; daily 5x10 
breaths with 
intermittent rests of 
one minute duration; 
resistance set at 
40% of PEmax 
Not 
stated 
Not stated Not stated Maximal mouth pressures (PImax, PEmax) 
Peak expiratory flow (PEF) 





of supervision or 
assistance 
provided by health 
staff not stated 
Four weeks, 20 
minutes per day 
three times per 
week; resistance set 
at 30% of PImax 
Not 
stated 
Not stated Not stated Forced spirometry (FVC, FEV1, FEF25-75, 
PEF) 
Diaphragm thickening ratio 
FEF25-75, forced expiratory flow between 25% and 75% of the expired volume; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HRpeak, 
peak heart rate; IMT, inspiratory muscle training; MVV, maximum voluntary ventilation; PEF, peak expiratory flow; PEmax, maximal expiratory mouth pressure; PEP, 
positive expiratory pressure; PImax, maximal inspiratory mouth pressure; RMT, respiratory muscle training; SaO2, arterial oxygen saturation; SF-36, short form 36; 
VC, vital capacity; VD/VTpeak, peak dead space – tidal volume ratio; VEpeak, peak minute ventilation; VO2peak, peak oxygen consumption 
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1.5.3.1 Mode of administration of respiratory muscle training 
 
In all four studies by Britto et al., Sutbeyaz et al., Fernandes et al. and Jung et al., the threshold 
loading technique was used to administer RMT. Commercially available devices (Threshold IMT 
and Threshold PEP, Philips Respironics, Andover, MA) were used for inspiratory and expiratory 
training, respectively. No rationale was given for the choice of RMT technique. However, 
threshold loading is generally described as a more practical and controllable training method 
compared with alternative techniques (Reid & Samrai, 1995).  
 
Only Britto et al. described the level of training supervision provided in their study. Participants 
trained independently at their homes, and biweekly sessions with a researcher were held to 
observe training technique and adjust threshold pressures. The level of training supervision or 
assistance given is not described in the papers by Sutbeyaz et al., Fernandes et al. and Jung et 
al., although it may be assumed that training sessions were overseen by research or health 
care staff where participants were admitted as inpatients (i.e. studies by Sutbeyaz et al. and 
Fernandes et al.). The provision of supervision for training interventions in research requires 
careful consideration. On the one hand, a high level of supervision and personal coaching are 
likely to increase training fidelity and quality, and thereby increase confidence in the internal 
validity of the research. On the other hand, the level of staff resources utilised to provide training 
supervision in a research context also impacts on the external validity and transferability of the 
research. In particular, a problem may arise if it is not possible to match the level of supervision 
that was provided during the conduct of a research study when attempting to implement a 
training intervention in real-life clinical practice. In this respect, a pragmatic research design, in 
which staffing resources from real-life clinical practice are replicated, holds greater external 
validity.  
 
 - 70 - 
1.5.3.2 Duration, frequency and intensity of training 
 
Participants in the study by Britto et al. trained for a period of eight weeks for five days per 
week. Each training session lasted for 30 minutes, whereby participants breathed through the 
threshold resistance device for 6x5 minutes with intermittent rests of one minute duration. 
Sutbeyaz et al. delivered training over a period of six weeks, twice daily for six days per week. 
Participants trained for 15 minutes per session. In the study by Fernandes et al. participants 
trained daily for five days and took 5x10 breaths with intermittent rests of one minute duration. 
In the study by Jung et al., training was delivered in three weekly sessions of 20 minutes 
duration. Threshold resistance was set at 30% of PImax in the studies by Britto et al. and Jung 
et al. Participants in the study by Sutbeyaz et al. started training at 40% of PImax, and 
resistance was gradually increased over the duration of the intervention to 60% of PImax. In the 
study by Fernandes et al. threshold resistance was set at 40% of PEmax.  
 
In the seven randomised controlled trials of RMT in neurological populations other than stroke, 
which were included in the systematic review by Pollock et al., the following range of training 
parameters was applied: duration of training from eight to 12 weeks; frequency of training from 
three times per week to three times per day; session duration from 10 minutes to 30 minutes 
per session, or sets of 3x10 to 3x15 breaths per session; and resistance at 20% to 60% of 
PImax or PEmax. In one study resistance was set at the highest level that could be maintained 
throughout the session. These RMT parameters lie within the wider range of training protocols 
used in research in cardio-respiratory populations (Geddes et al. 2008, Weiner & McConnell 
2005, Reid & Samrai 1995). Overall, while there is some variability in the delivery of RMT 
across clinical studies, these training protocols provide a general framework for future study 
designs. Due to the differences in study populations, study settings, and differences in the 
clinical rationales for providing RMT, an attempt to relate specific training protocols to optimum 
treatment effect may be of limited value.  
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1.5.3.3 Adverse effects of training 
 
Adverse effects relating to RMT are not commented on in the publications by Britto et al., 
Sutbeyaz et al., Fernandes et al. and Jung et al. The safety and potential adverse effects of 
RMT find little discussion in the wider literature. For example, the recent guidelines for the 
physiotherapy management of the adult, medical, spontaneously breathing patient (Bott et al. 
2009) give evidence-based recommendations on the use of RMT in different clinical groups 
without raising any safety concerns. The lack of reported adverse effects of RMT may be taken 
as evidence of the relative safety of the intervention, in particular IMT, which has been 
researched more extensively than expiratory muscle training (EMT) and in a range of clinical 
groups. EMT has been investigated less, and Weiner and McConnell (2005) discuss potential 
safety concerns of expiratory muscle training, suggesting that increased intra-thoracic pressure 
may have a negative impact on cardio-vascular function. However, no adverse events were 
reported in two studies of EMT by their group, which included a total of 58 patients with chronic 
obstructive pulmonary disease (COPD). Also, other clinical studies of EMT have not reported 
any safety concerns (Kim & Sapienza, 2005, Pitts et al. 2005, Gosselink et al. 2000, Smeltzer et 
al. 1996).  
 
1.5.3.4 Participant retention and adherence to treatment 
 
Britto et al. and Sutbeyaz et al. give a detailed description of the participant flow through their 
study. Of 21 participants who entered the trial by Britto et al., two discontinued in the 
intervention group due to insufficient time, and one dropped out of the control group due to 
hypertension. In the study by Sutbeyaz et al., all 45 participants (15 per group) completed the 
trial. Fernandes et al. and Jung et al. do not comment on participant retention in their studies, 
although it may be inferred from their paper that all participants completed the study.  
 
Sutbeyaz et al., Fernandes et al. and Jung et al. do not comment on adherence to treatment or 
treatment acceptability to participants. It may be assumed that in these studies participants 
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were supervised by health staff when carrying out the intervention and that therefore adherence 
to treatment was unproblematic. In the study by Britto et al., participants completed training 
diaries, which were used to assess treatment adherence. The prescribed amount of respiratory 
training was a total of 1,200 minutes over eight weeks. Mean adherence was 1,141 minutes 
(range 780 to 1,560) in the intervention group and 1,159 minutes (range 600 to 1,860) in the 
control group. While the average training time approximates the prescribed intensity of training, 
the spread ranges from half to about 50% more than the prescribed training time.  
 
1.5.3.5 Methods of assessing the effects of training 
 
The studies included in this review differed with respect to research hypotheses, clinical 
rationales and methods of assessing the effects of RMT. The studies by Britto et al. and 
Sutbeyaz et al. investigated RMT in stroke with respect to its impact on general cardiovascular 
fitness and the further implications on daily functioning and quality of life. The study by 
Fernandes et al. and Jung et al. focussed solely on the effect of RMT on physiological 
respiratory parameters. An overview of the outcome measurements undertaken in these studies 
is given in Table 7. The most commonly used measure was maximal mouth pressure (PImax, 
PEmax). Other tests included: various physiological cardio-respiratory tests such as forced 
spirometry; functional measures such as the Barthel Index; and measures of health-related 
quality of life such as the Nottingham Health Profile. None of the studies examined cough or 
clinical respiratory outcomes.  
 
1.5.3.6 Reported magnitude of training effects and clinically relevant improvement 
 
The four studies by Britto et al., Sutbeyaz et al., Fernandes et al. and Jung et al. all reported 
positive effects of RMT. Insufficient information is presented in the papers by Fernandes et al. 
and Jung et al. to ascertain the internal validity of their study, and their results should therefore 
be interpreted with caution. Britto et al. and Sutbeyaz et al. were able to establish several 
statistically significant training effects of RMT; however, the authors offer little discussion of the 
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clinical relevance of these findings. Notably, all positive effects were found in physiological 
measures, as opposed to measures of functional performance or wellbeing. It may be argued 
that the value of physiological improvement is uncertain, unless it can be linked to concrete 
benefit for the individual’s wellbeing and their ability to function in everyday life. This link can be 
demonstrated through according outcome measures. In the studies by Britto et al. and Sutbeyaz 
et al. those outcome measures that relate directly to improvement in everyday life and general 
wellbeing, i.e. measures of function and quality of life, did not show any changes.  
 
Alternatively, the benefit of improvement in physiological outcomes may be established by 
comparison with norm values for healthy subjects, as these may represent a desired treatment 
goal. The effect size for PImax, for example, in the study by Britto et al. amounted to a mean 
(95% CI) increase of 34.4 (13.6, 55.2) cmH2O from a mean PImax at baseline of 67.8 cmH2O. In 
the study by Sutbeyaz et al. the mean (95% CI) improvement was 7.9 (4.2, 11.5) cmH2O from a 
mean PImax at baseline of 49.5 cmH2O. In both studies, groups consisted of equal numbers of 
male and female participants. Comparing these values with PImax norm values in healthy 
subjects (105-129 cmH2O in men; 70-98 cmH2O in women) (American Thoracic Society (ATS) & 
European Respiratory Society (ERS), 2002, p. 532), it could be suggested that in the study by 
Britto et al. RMT potentially restored PImax to near normal levels (taking into consideration the 
wide 95% confidence interval). In contrast, in the study by Sutbeyaz et al. RMT lead to a small 
improvement towards healthy norm values.  
 
1.5.3.7 Considerations informing the present research design 
 
To summarise, from the considerations discussed in sections 1.5.3.1 through 1.5.3.6, the 
following decisions were made with respect to the design and conduct of the present research:  
 
Regarding the level of supervision and assistance provided during the training implementation, 
a pragmatic design, replicating staffing resources from real-life clinical practice, was selected to 
maximise generalisability to UK National Health Service (NHS) clinical settings.  
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The RMT protocol chosen for the present study (training duration of four weeks; daily sessions 
of 5x10 breaths with intermittent one minute rests; resistance set at 50% of PImax or PEmax, 
respectively) had one of the shortest durations, and frequency and intensity parameters within 
the higher range compared to other protocols described in the literature. Judging from previous 
research, this training protocol could reasonably be expected to induce a training effect; while 
time afforded to training, and therefore participant burden, was kept to a minimum. Also, these 
training parameters mirrored the physiological purpose of the intervention, i.e. improving cough, 
which occurs in short bursts of high intensity, as opposed to e.g. endurance-related 
performance, which may require lower intensity training over longer periods of time.  
 
Regarding adverse effects of RMT, the present research was the first to investigate both in- and 
expiratory training early after acute stroke, as participants were recruited within two weeks of 
stroke onset. While from published research there is no indication that RMT may cause harm in 
this population, the introduction of a new intervention in the acute stage of a clinical condition 
warrants careful monitoring of the safety of training. Accordingly, the present research included 
monitoring of vital parameters (blood pressure, heart rate, blood oxygen saturation) and 
subjective adverse clinical signs before and after training at baseline and in subsequent weekly 
sessions with the investigator.  
 
With respect to study outcomes, in contrast to previous studies, the present research focused 
on peak cough flow as the primary physiological outcome measure, and also included maximal 
mouth pressures and incidence of pneumonia as secondary endpoints. The present research 
was likely the first to investigate the effect of RMT on cough flow in stroke survivors. A small 
number of RMT studies in clinical populations other than stroke have included cough 
parameters as outcomes. Gosselink et al. (2000) conducted a randomised controlled trial 
comparing EMT with unsupervised unspecific breathing exercises in severely impaired patients 
with multiple sclerosis. Cough was assessed using the Pulmonary Index (PI), a clinical measure 
using a combination of objective and subjective criteria to quantify cough efficacy. Their study 
showed statistically significant improvement in the PI in the EMT group. A study by Salem et al. 
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(2004, cited in Kim & Sapienza, 2005) showed improved expiratory flow in voluntary cough after 
EMT in patients with Parkinson’s disease, while a cohort study by Chiara et al. (2006) failed to 
demonstrate improvements in cough flow after EMT in multiple sclerosis patients. More recently, 
Kim et al. (2009) conducted a cohort study of healthy sedentary older adults, which showed a 
statistically significant increase in expiratory flow during capsaicin-induced reflex cough after 
EMT. In contrast, in a cohort study of individuals with Parkinson’s disease by Pitts et al. (2009) 
voluntary expiratory cough flow remained unchanged after EMT. The hypothesis that RMT may 
improve cough effectiveness is discussed frequently in relevant publications. However, little 




In summary, this introduction described the context for the present research and gave a 
justification for its clinical relevance. From a narrative review of the literature, it was established 
that pneumonia after stroke remains a current clinical concern, with in-hospital incidence rates 
between 6% and 16% internationally. Patients who develop pneumonia after stroke have a two- 
to six-fold increase in risk of death, are more likely to have poor rehabilitation outcomes and on 
average require higher levels of hospital and community care.  
 
It was shown that one of the most consistently reported risk factors for pneumonia after stroke is 
the presence of swallowing difficulty; and that the most widely applied prevention strategy is the 
routine screening of stroke patients for swallowing difficulty coupled with the implementation of 
dysphagia management strategies. Different novel strategies for reducing pneumonia incidence 
after stroke have been and are currently being researched. The present research took an 
original approach in investigating respiratory muscle strengthening as a non-pharmacological 
intervention, with the aim to improve cough effectiveness and increase airway protection in 
acute stroke.  
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The rationale for this novel approach was provided, first, by clinical evidence, which 
demonstrates that increased pneumonia risk after stroke is associated with aspiration and 
cough impairment; and second, by physiological evidence, which shows that there is significant 
impairment of cough in acute stroke, and that this impairment can be linked to respiratory 
muscle weakness. Thus, a respiratory muscle strengthening intervention may prove useful in 
improving cough effectiveness, increasing airway protection, and ultimately reducing pneumonia 
risk in acute stroke.  
 
RMT using the pressure threshold loading technique was identified as the most appropriate 
intervention. This intervention is supported by an extensive evidence base derived from healthy 
and athletic populations and a fair evidence base from primarily cardio-respiratory clinical 
populations. A systematic review of the literature was conducted to establish the evidence base 
for RMT in stroke, and it was found that little research is available. Two randomised controlled 
trials of good methodological quality have demonstrated that RMT in chronic and subacute 
stroke survivors leads to improvements in physiological parameters of respiratory muscle 
strength, lung function and endurance. A meta-analysis of randomised controlled trials in 
different neurological conditions showed a modest strengthening effect of RMT on inspiratory 
muscles. No previous studies of RMT in stroke have included patients in the acute phase of 
stroke; investigated RMT with the aim to improve cough effectiveness; or investigated RMT for 
the prevention of pneumonia. Based on the findings of this literature search, the present 
research was the first of its kind and provided valuable evidence in a little researched field. 
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Chapter 2 Aims and objectives 
 
The overarching aim of the present studies was to investigate the merit of respiratory muscle 
training as an intervention for the reduction of pneumonia risk during the first weeks after stroke. 
The specific aims and objectives relating to each thesis chapter are as follows:  
 
Chapter 3 describes a series of validation experiments of three respiratory assessment 
methods: forced spirometry, measurement of maximal mouth pressures, and cough flow 
measurement. The aim was to evaluate measurement variability when applying these 
assessment procedures in novel patient groups and settings different from those in which they 
have previously been validated. The purpose was to allow an interpretation of clinical findings 
against the estimated magnitude of measurement error that may be expected with respect to 
the particular equipment and testing procedures and in this clinical population. The specific 
objectives were:  
 To describe instrument repeatability 
 To describe test-retest reliability in the absence of clinical change, both in healthy subjects 
and in acute stroke patients 
 To describe instrument performance properties with specific relevance to the cough flow 
measurement system (linearity and dynamic response) 
 To determine the minimal detectable difference for the main outcome parameters of interest 
(maximal expiratory and inspiratory mouth pressure, peak expiratory cough flow of voluntary 
and reflex cough) 
 
Chapter 4 summarises a series of validation experiments with the aim to compare the accuracy 
in measuring peak cough flow between portable flow measuring devices and the flow 
measurement system used in the present research. The purpose was to investigate whether the 
flow measurement system used in the present studies, which provided physiologically detailed 
measurements but consisted of an elaborate and expensive equipment setup, could potentially 
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be substituted with convenient and less expensive hand-held clinical flow measurement 
devices. The specific objectives were:  
 To describe the accuracy of devices when measuring peak expiratory cough flow 
 To explore potential sources of the observed inaccuracy.  
 
Chapter 5 gives an account of the main clinical study of this thesis. The aim of this pilot study 
was to investigate a respiratory muscle strengthening programme in the first weeks after stroke, 
providing estimates on its magnitude of effect, safety, acceptability and feasibility, and informing 
about the value and design of a large clinical trial. The specific objectives were:  
 To determine the magnitude of effect of respiratory muscle training on cough generation, 
respiratory muscle strength, and incidence of pneumonia 
 To explore the training duration, frequency and intensity required to achieve improvement in 
cough flow rate and inspiratory and expiratory muscle strength 
 To evaluate patient participation, acceptability of study procedures to participants, and 
concordance with training protocol 
 To describe safety parameters and potential adverse effects of respiratory muscle training 
in this patient group 
 To describe characteristics of those patients most likely to gain from the intervention 
 To determine the relevance and feasibility of delivering respiratory muscle training to acute 
stroke patients in UK National Health Service (NHS) settings.  
 
Chapter 6 describes a secondary exploratory analysis of data from the main clinical study. The 
aim was to use these data to describe the relevance of cough as a mediating parameter in the 
relationship between swallowing impairment and pneumonia in acute stroke. Little published 
data is available about this particular interaction. The specific objectives were:  
 To explore pneumonia risk according to parameters of respiratory function, respiratory 
muscle strength and cough function 
 To quantify the interaction between peak cough flow, aspiration risk and pneumonia risk.  
 
 - 79 - 
Chapter 7 presents data from cough frequency measurements using an automated cough 
counting device (Leicester Cough Monitor) in a subgroup of participants. The aim was to 
validate the device and to explore longitudinal measurements of cough frequency in a cohort of 
acute stroke patients. The specific objectives were:  
 To validate the Leicester Cough Monitor as a method of cough frequency measurement in 
acute stroke 
 To describe cough frequency over 24-hour periods at baseline, and at one week, four 
weeks and twelve weeks after baseline 
 To compare the observed cough frequency in stroke survivors with normative values 
 To explore relationships between cough frequency and other relevant patient 
characteristics, including the severity of stroke impairment, presence of swallowing 
impairment, lung function and cough intensity.  
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This chapter describes a series of experiments for the validation of three respiratory 
assessment methods applied in subsequent studies: forced spirometry, measurement of 
maximal mouth pressures and cough flow measurement. Equipment and testing procedures for 
these assessments are described. These validation experiments include laboratory bench tests 
and tests with healthy volunteers and stroke patients. The primary purpose of these validation 
studies was to evaluate the level of measurement error inherent in the assessment procedures, 
which subsequently informed the analysis and interpretation of clinical data.  
 
Measurement error, uncertainty or variability relates to the fact that repeated measurements of 
the same quantity may yield different results. The magnitude of the discrepancy between these 
results indicates the precision or reliability of the measurement. The wider the discrepancy, the 
less precise is the measurement, and vice versa (Taylor 1997, pp. 3-11). Variability in 
measurements of physiological parameters in human subjects can generally be related to four 
aspects of the measurement process: the measurement instrument; a single observer (intra-
rater); different observers (inter-rater); and the subject (intra-subject) (Domholdt 2005, pp. 243-
274).  
 
One important consideration with respect to the assessments evaluated here is that these are 
measurements of volitional respiratory manoeuvres, for which the test subject is asked to 
produce maximal efforts. The aspect of subjective motivation and effort therefore needs to be 
considered as a relevant source of measurement error (unlike when measuring a quantity that 
does not require active engagement from the test subject). A second consideration is that in 
order to increase the assessor’s confidence that a maximal effort has been exerted, it is 
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convention to ask the test subject to repeat the manoeuvre several times. The principle is that 
consecutive efforts can be compared against each other, judging the relative influence of 
familiarisation with the task (improving performances with increasing number of repetitions) and 
fatigue (worsening performances with increasing number of repetitions). In practice this means 
that in a single sitting, the volitional test manoeuvre should be repeated several times to allow 
the subject familiarisation with the technique; but that the maximal number of repetitions should 
be limited to prevent fatigue and overexertion. A strategy that is commonly applied in practice is 
to observe whether a number of measurements within a certain range of the maximum can be 
achieved, which is taken as an indication that the subject’s maximal volitional effort has been 
reached. As an example, the international guidelines for the standardisation of forced 
spirometry (Miller et al. 2005, p. 326) state that three manoeuvres within a certain margin of the 
best effort (largest forced vital capacity and forced expiratory volume in one second) need to be 
achieved, but that no more than eight attempts should be performed altogether in one sitting.  
 
3.2 Aims and objectives 
 
The aim of this study was to evaluate the measurement variability for forced spirometry, 
measurement of maximal mouth pressures and cough flow measurement when applying the 
same assessment procedures as in subsequent clinical studies.  
 
The objectives were to:  
- Describe instrument repeatability 
- Describe test-retest reliability in the absence of clinical change, both in healthy subjects 
and in acute stroke patients  
- Describe instrument performance properties with specific relevance to the cough flow 
measurement system (linearity and dynamic response) 
- Determine the minimal detectable difference for the outcome parameters of interest 
(maximal expiratory and inspiratory mouth pressure, peak expiratory cough flow of 
voluntary and reflex cough) 
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3.3 Methods 
 
3.3.1 Study design 
 
To examine instrument repeatability, a series of bench tests were conducted at the respiratory 
physiology laboratory at the Department of Respiratory Medicine and Allergy, School of 
Medicine, King’s College London. Relevant inputs (volume, pressure, flow) of a known and 
consistent quantity were repeatedly delivered and measured with the instruments under test, 
allowing an assessment of the consistency of repeated measurements.  
 
To examine test-retest reliability, healthy subjects and stroke patients performed the tests 
following the same sequence and procedures as in the subsequent clinical studies. One 
investigator conducted all assessments. All tests were repeated within the time period of two 
hours. It was assumed that no physiological change had occurred in test subjects within this 
time window and that the variability observed could be interpreted as measurement variability in 
the absence of change.  
 
While the evaluation of instrument repeatability informs about the extent of measurement error 
that can be ascribed to the performance of the measurement instrument alone, test-retest 
reliability gives an estimate of measurement variability in the absence of change, incorporating 
all possible sources of measurement error, i.e. instrument repeatability, intra-rater variability and 
intra-subject variability. As in the subsequent clinical studies all measurements were performed 
by one investigator, inter-rater variability was not relevant for the present study.  
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3.3.2 Participants 
 
Eleven healthy volunteers (mean (SD) age 40 (14) years, six men) were recruited from amongst 
staff and students at King’s College London. Excluded were individuals with a medical history of 
respiratory disease or conditions affecting larynx structure and function. Volunteers had to be 
comfortable coughing repeatedly and performing repeated maximal respiratory manoeuvres 
over two hours. Ethical approval for the recruitment of healthy volunteers was granted by the 
Psychiatry, Nursing and Midwifery Research Ethics Committee at King’s College London, UK 
(study reference PNM/12/13-143). All healthy volunteers gave written informed consent.  
 
Six acute stroke patients (mean (SD) age 51 (16) years, four men) took part in eleven testing 
sessions, giving data for eleven test-retest reliability assessment sessions. Patients were 
recruited from the hyper-acute stroke unit at King’s College Hospital, London. Patients were 
included if they had moderate to severe level of stroke impairment (National Institutes of Health 
Stroke Scale (NIHSS; International Electronic Education Network 2010) score 5-25) and were 
able to follow instructions and perform testing procedures. Patients were excluded if they had a 
history of respiratory disease, recent cardiac events, or neurological conditions other than 
stroke. Patients took part in assessment sessions between four and twelve weeks after stroke 
onset. Ethical approval for the recruitment of stroke patients was granted by the UK National 
Research Ethics Service (NRES) (Wandsworth Research Ethics Committee, study reference 
10/H0803/32). All stroke subjects gave written informed consent.  
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3.3.3 Respiratory assessments 
 




A turbine-based hand-held portable spirometer (SpiroUSB, CareFusion, San Diego, California) 
connecting to a laptop with accompanying software was used. For infection control purposes, a 
disposable bacterial filter was used (Spiroguard Standard, Air Safety Medical, Morecambe, 
England). A flanged mouth piece (Rubber Flanged Mouthpiece MTH6400, CareFusion, San 
Diego, California) was used to create an optimal mouth seal in the presence of oro-facial 
weakness. A nose clip (Nose Clip, Air Safety Medical, Morecambe, England) was used to avoid 
loss of airflow through the nostrils.  
 
3.3.3.1.2 Testing procedure 
 
Forced spirometry was conducted according to international guidelines (Miller et al. 2005). Test 
subjects were seated comfortably in a chair or positioned sitting up in the hospital bed. The 
investigator explained the procedure, and demonstrated the correct technique for a forced 
expiratory manoeuvre (without equipment). If required, the investigator assisted participants in 
holding the spirometer and achieving adequate positioning of the mouth piece. Test subjects 
performed at least three and up to eight forced expiratory manoeuvres. The investigator gave 
verbal instructions and enthusiastic encouragement during each manoeuvre, and verbal 
feedback on technique after each manoeuvre. The test was concluded when quality 
requirements were met (three acceptable manoeuvres, with the two largest measurements of 
forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) within 0.15 L, or 
within 0.1 L for FVC<1.0 L) (Miller et al. 2005). From the three acceptable manoeuvres with the 
largest values, the highest FVC, FEV1 and peak expiratory flow (PEF) were recorded and used 
for analysis, whereby individual values could be taken from different manoeuvres. On occasion, 
it was not possible to achieve quality requirements within eight attempts. This was mostly due to 
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inconsistent performance and fatigue in acute stroke patients. In these cases, FVC, FEV1 and 
PEF values were selected from the three manoeuvres with the highest FVC.  
 
3.3.3.1.3 Quality control 
 
Volume accuracy of the spirometer was evaluated on each day of testing with a volume 
calibration check as per manufacturer’s guidelines and as recommended by international 
guidelines (Miller et al. 2005, p. 323). Using a three-litre calibration syringe (Series 5530, Hans 
Rudolph Inc, Kansas City, Minnesota, USA), three litre volumes were delivered through the 
spirometer at three levels of flow (0-54 L/min, 96-270 L/min and 420-720 L/min), to ensure that 
the measured volume was within the acceptable 3.5% error margin.  
 




A portable device (MicroRPM, CareFusion, San Diego, California) was used with a disposable 
bacterial filter (Mouth Pressure Bacterial Filters FIL6050, CareFusion, San Diego, California), a 
flanged mouth piece (Rubber Flanged Mouthpiece MTH6400, CareFusion, San Diego, 
California), and a nose clip (Nose Clip, Air Safety Medical, Morecambe, England).  
 
3.3.3.2.2 Testing procedure 
 
Measurements of maximal respiratory mouth pressures (PImax, PEmax) were conducted 
according to international guidelines (American Thoracic Society (ATS) & European Respiratory 
Society (ERS) 2002, pp. 531-533). Test subjects were seated comfortably in a chair or 
positioned sitting up in the hospital bed. The investigator explained the procedure, and 
demonstrated the correct technique (without equipment). For the assessment of PEmax, the 
subject was asked to breathe in to total lung capacity and maintain a maximal forced expiration 
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into the MicroRPM device for three seconds. For the measurement of PImax, the subject was 
asked to breathe out to residual volume and maintain a maximal forced inspiration through the 
MicroRPM device for three seconds. The investigator gave verbal instructions and enthusiastic 
encouragement during each manoeuvre, and verbal feedback on technique after each 
manoeuvre, paying particular attention to adequate lip seal around the mouth piece. A minimum 
of five and up to ten attempts were performed for PEmax and PImax, respectively, until the 
three highest measurements were within 20% of the maximum. The maximum value of the three 
highest measurements was recorded for analysis. On occasion, it was not possible to achieve 
three highest measurements within 20% of the maximum. This was mostly due to inconsistent 
performance and fatigue in acute stroke patients. In these cases, the highest measurement was 
taken for analysis.  
 
3.3.3.2.3 Quality control 
 
Pressure accuracy of the MicroRPM device was confirmed weekly by comparison against a 
digital manometer. A three-way airtight tubing system was used to connect the MicroRPM 
device with the digital manometer (C9553 Pressure Meter, Comark, Norwich, England) and an 
inflation device (Encore 26 Inflator, Boston Scientific, Marlborough, Massachusetts, USA). 
Positive and negative pressure was applied to 200 and -200 cmH2O, respectively, as measured 
by the digital manometer. The reading given by the MicroRPM device was compared to the 
digital manometer reading, to ensure that the MicroRPM measured pressure within the 
acceptable error margin.  
 




Cough flow measurements were conducted with a calibrated pneumotachograph system (Singh 
et al. 1994). An on-site and an off-site measurement system were used. The on-site system was 
used for measurements at the primary study site, King’s College Hospital, London. The off-site 
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system was used for measurements outside the primary study site, for example at the 
neighbouring stroke rehabilitation unit or at participants’ homes. The following components were 
used for the cough testing equipment when cough testing was conducted on site: face mask 
(Adult Face Mask, 8940 Series, Hans Rudolph Inc, Kansas City, Missouri) with connector, head 
straps and clips; Fleisch-type pneumotachograph (internal diameter (ID) 4.4 cm, length 6.0 cm, 
PK Morgan Ltd, Rainham, England); connecting tubing (ID 3.0 mm, length 155.0 cm); pressure 
transducer (MP45-14-871 Low Range Differential Pressure Transducer, range ± 2 cmH2O, 
Validyne Engineering, Northridge, California); demodulator (CD15 Sine Wave Demodulator, 
CD15-C-1-A-1, Validyne Engineering, Northridge, California); analog-to-digital converter 
(PowerLab/16SP, ADInstruments Ltd, Oxford, England); and laptop running data acquisition 




Figure 2. On-site system for cough flow testing. A, face mask; B, pneumotachograph; C, 
connecting tubing; D, pressure transducer; E, demodulator; F, analog-to-digital converter; G, 
laptop and software.  
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When cough testing was conducted off-site, an alternative setup was used, which had better 
practicality and portability. In the portable setup, a different analog-to-digital converter (NI BNC-
2110, National Instruments, Newbury, England) and laptop with software (LabView 5.1, 










Figure 3. Off-site system for cough flow testing. A, face mask; B, pneumotachograph; C, 
connecting tubing; D, pressure transducer; E, demodulator; F, analog-to-digital converter; G, 
laptop and software 
 
Analog-to-digital sampling rate for both systems was 2,000 Hz. The pneumotachograph 
systems were calibrated before each testing session by two-point flow calibration with a 
rotameter (InFlux OF1”S, 60-600 L/min flow, Techniquip Ltd, Taunton, England) using a 
reference flow of 500 L/min (Figure 4).  
 





Figure 4. Two-point flow calibration at 500 L/min reference flow. D, pneumotachograph; J, 
rotameter (InFlux); K, flow generating device (Outwell Thunder High Performance Pump) 
 
3.3.3.3.2 Testing procedure 
 
Voluntary and reflex coughs were assessed. Test subjects were seated comfortably in a chair or 
positioned sitting up in the hospital bed. For voluntary coughs, participants made up to 15 
maximal cough efforts into a tight-fitting face mask, until five coughs with peak expiratory cough 
flow (PECF) within 5% of the highest reading were recorded. The investigator’s verbal 
instruction was to ‘take a deep breath in and give a strong cough’. The investigator 
demonstrated a strong voluntary cough (without equipment). During recording, the investigator 
evaluated the quality of the subject’s cough sounds and cough flow traces. Inadequate 
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attempts, such as forceful clearing of the throat or forced expiratory manoeuvres without glottis 
closure, were noted.  
 
To elicit reflex coughs, solutions of capsaicin in escalating concentrations (0.49 to 1,000 Mol/L) 
were nebulised with an ultrasonic nebuliser (UltraNeb U3000, DeVilbiss Healthcare Ltd, Tipton, 
England). The nebuliser chamber was connected downstream to the pneumotachograph via a 
non-rebreathing valve (Two-Way T-Shape Non-Rebreathing Valve Series 2700, Hans Rudolph 
Inc, Shawnee, Kansas) and corrugated tubing (Limblite AMCA 1400/1, ID 2.2 cm, length 200.0 
cm, Armstrong Medical Ltd, Coleraine, Northern Ireland). To contain the nebulised capsaicin 
within the system, a filter (Barr-vent S filter 300 400 000, Medisize bv, Hillegom, Netherlands) 
was connected to the exhalation port of the non-rebreathing valve. Escalating concentrations of 
nebulised capsaicin were introduced into the face mask for one minute at a time, until the 
threshold was reached at which at least five bouts of reflex coughing were triggered. Subjects 
were instructed to take deep breaths in and out, and to only cough if stimulated by the irritant. 
Of note, nebulised capsaicin was used for the sole purpose of triggering involuntary coughs, 
and the concentration at which coughs were elicited cannot reliably be taken as a measure of 
subjects’ reflex cough sensitivity, as this method of eliciting reflex coughs does not meet the 
methodological requirements of inhalation cough challenges for assessment of reflex cough 
sensitivity (Morice et al. 2007).  
 
Data was extracted from the five voluntary and five reflex cough flow traces with the highest 
peak expiratory flow values. A sample flow trace is shown in Figure 5. The values for peak 
inspiratory cough flow (PICF) and PECF were obtained from the minimum and maximum on the 
respective portions of the flow trace. Cough volume inspired (CVI) and cough volume expired 
(CVE) were obtained by integrating the area under the curve of the inspiratory and expulsive 
phase portions of the flow curve. Glottis compression time (GCT) was defined as the section 
between inspiratory and expulsive cough phase where the flow trace approximates zero. Rise 
time was defined as the time from the beginning of the expulsive phase to the point of PECF. 
Cough volume acceleration (CVAC) was calculated as PECF/rise time (L/s/s). The highest 
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values for each of these parameters were recorded and used for analysis, whereby values 
could be taken from different cough manoeuvres.  
 
 
Figure 5. Flow time trace of a voluntary cough. A, inspiratory phase; B, peak inspiratory cough 
flow; C, glottis compression phase; D, expulsive phase; E, rise time; F, peak expiratory cough 
flow.  
 
Measurements of gas volume and flow are affected by temperature, pressure and water vapour 
saturation. Within the lungs, air temperature and water vapour saturation increase in 
comparison to ambient conditions. This leads to a discrepancy between inspiratory and 
expiratory volume and flow measurements. Inspiratory measurements are therefore corrected to 
lung conditions, using body temperature, pressure, water vapour saturated (BTPS) correction 
factors. (Miller et al. 2005, pp. 332-333, American Thoracic Society (ATS) 1995, p. 1115). PICF 
and CVI were adjusted by multiplication with BTPS correction factors according to ambient 
temperature (Table 8). Ambient temperature was measured using a digital thermometer (Digital 
Thermo, Russell Scientific Instruments Ltd, Dereham, England).  
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Table 8. Ambient temperature, pressure, water vapour saturated (ATPS) to body temperature, 
















15 1.128  23 1.085  31 1.039 
16 1.123  24 1.08  32 1.032 
17 1.118  25 1.075  33 1.026 
18 1.113  26 1.069  34 1.02 
19 1.108  27 1.063  35 1.014 
20 1.102  28 1.057  36 1.007 
21 1.096  29 1.051  37 1 
22 1.091  30 1.045    
 
 
3.3.3.3.3 Quality control 
 
Key performance characteristics of the measurement systems (linearity and dynamic response) 
were confirmed at the beginning and end of the study period, and remained stable. Details of 
linearity and dynamic response are given below.  
 
3.3.4 Data analysis  
 
The statistical concepts applied were guided by the texts of Streiner and Norman (2008), 
Domholdt (2005, pp. 243-274), Bland and Altman (1999) and Taylor (Taylor 1997).  
 
To quantify instrument repeatability, i.e. the magnitude of measurement error attributable to the 
measurement instruments, the arithmetic mean of repeated measurements was calculated and 
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the error margin was described as mean ± ½ range, expressed both in the unit of measurement 
and as a percentage of the mean. This gives a conservative description, in which the extreme 
measured values are made transparent, as opposed to other options of describing error, such 
as mean ± standard deviation, mean ± standard error of the mean, or mean ± average deviation 
from the mean (Taylor 1997, pp. 13-44).  
 
To quantify test-retest reliability, three methods of analysis were used. First, the discrepancy in 
measurements (first measurement – second measurement) was calculated for the examined 
parameters (FVC, FEV1, PEF, PEmax, PImax, PECF of voluntary cough, and PECF of reflex 
cough). The variability in these parameters from the first to the second testing session was 
summarised using the method of Bland and Altman (1999), describing the mean difference and 
95% limits of agreement.  
 
Second, an intraclass correlation coefficient (ICC) was calculated. The ICC calculated was for 
comparison of absolute agreement (as opposed to consistency of agreement) and for 
comparison of individual measurements (as opposed to group average measurements). A 
mixed-effects model was used, treating the investigator as fixed, as the point of interest was to 
examine test-retest reliability for this particular investigator (as opposed to a population of 
potential investigators) (StataCorp 2013). These two analysis methods were used to 
complement each other. While ICC indicates the magnitude of reliability (greater reliability when 
ICC is closer to one), the method according to Bland and Altman conveys the actual magnitude 
of variability in the unit of measurement. A combination of both approaches allows for an 
evaluation of test-retest reliability against magnitudes of clinically relevant changes in test 
parameters (Rankin & Stokes 1998).  
 
Third, a coefficient of variation was calculated for repeated measurements of PEmax, PImax, 
PECF of voluntary cough and PECF of reflex cough. This fractional statistic was calculated as 
|difference between two measurements|/mean of two measurements (Hankinson et al. 1998) 
and provides an indication of the magnitude of variation across the range of potentially relevant 
 - 94 - 
values. Coefficients of variation were used to inform about the minimal detectable change in 
PEmax, PImax, PECF of voluntary cough and PECF of reflex cough.  
 
Data analyses were conducted using Excel (Microsoft Office Excel 2007, Microsoft Corporation, 




3.4.1 Forced spirometry 
 
3.4.1.1 Instrument repeatability 
 
The arithmetic mean ± ½ range (%) of ten consecutive measurements of three litre volumes 
delivered through the spirometer in the inspiratory direction of flow was: 3.04 ± 0.06 (2.0%) L in 
the flow range 0-54 L/min; 3.02 ± 0.04 (1.0%) L in the flow range 96-270 L/min; and 3.06 ± 0.02 
(<1.0%) L in the flow range 420-720 L/min. In the expiratory direction of flow, it was 3.06 ± 0.06 
(2.0%) L in the flow range 0-54 L/min; 2.97 ± 0.04 (1.0%) L in the flow range 96-270 L/min; and 
3.04 ± 0.02 (<1.0%) L in the flow range 420-720 L/min.  
 
3.4.1.2 Test-retest reliability in healthy subjects 
 
The raw data for test-retest measurements in healthy subjects are presented in Table 9. The 
mean difference (95% limits of agreement) was 0.03 (-0.42, 0.48) L for FVC; 0.03 (-0.40, 0.46) L 
for FEV1; and 24 (-70, 118) L/min for PEF. The ICC (95% confidence interval) was 0.98 (0.94, 
>0.99) for FVC; 0.96 (0.87, 0.99) for FEV1; and 0.84 (0.50, 0.95) for PEF.  
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Table 9. Test-retest measurements for forced spirometry in healthy subjects 
Subject Forced vital capacity (L) Forced expiratory 
volume in one second (L) 
Peak expiratory flow 
(L/min) 
Test 1 Test 2 Test 1 Test 2 Test 1 Test 2 
1 4.77 4.77 3.84 3.94 652 608 
2 4.35 4.49 3.72 3.73 560 572 
3 3.03 3.52 2.69 3.19 410 472 
4 2.90 2.62 2.45 2.16 494 404 
5 5.94 6.14 4.03 4.01 449 475 
6 3.18 3.00 2.44 2.43 398 364 
7 4.67 4.51 3.57 3.43 549 486 
8 2.58 2.37 1.99 2.03 362 344 
9 4.82 4.80 3.85 3.75 442 409 
10 6.09 5.88 4.29 3.97 629 538 
11 4.10 4.01 3.76 3.70 473 481 
 
 
3.4.1.3 Test-retest reliability in stroke patients 
 
The raw data for test-retest measurements in stroke patients are presented in Table 10. The 
measurements are from six patients. All six carried out repeated tests approximately four weeks 
after stroke onset, and five performed repeated tests again approximately twelve weeks after 
stroke. The mean difference (95% limits of agreement) was -0.06 (-0.57, 0.45) L for FVC; -0.01 
(-0.19, 0.17) L for FEV1; and 6 (-49, 61) L/min for PEF. The ICC (95% confidence interval) was 
0.96 (0.85, 0.99) for FVC; 0.99 (0.96, >0.99) for FEV1; and 0.96 (0.85, 0.99) for PEF.  
 
 - 96 - 
Table 10. Test-retest measurements for forced spirometry in stroke patients 
Subject Time post 
stroke 
Forced vital capacity 
(L) 
Forced expiratory 
volume in one second 
(L) 
Peak expiratory flow 
(L/min) 
 Test 1 Test 2 Test 1 Test 2 Test 1 Test 2 
1 4 weeks 1.37 2.12 1.37 1.51 329 339 
2 4 weeks 2.08 2.17 1.71 1.83 294 262 
3 4 weeks 2.48 2.51 2.20 2.16 401 349 
4 4 weeks 3.94 4.00 3.04 3.05 500 473 
5 4 weeks 2.32 2.30 2.00 2.07 287 313 
6 4 weeks 3.88 3.92 3.18 3.26 551 545 
1 12 weeks 2.30 2.37 1.66 1.70 326 356 
2 12 weeks 1.78 1.70 1.42 1.39 260 273 
3 12 weeks 2.57 2.55 2.28 2.23 370 382 
4 12 weeks 4.16 3.83 3.11 2.92 505 463 
5 12 weeks 2.72 2.80 2.36 2.34 382 380 
 
 
3.4.2 Maximal mouth pressure measurements 
 
3.4.2.1 Instrument repeatability 
 
The MicroRPM device was connected via a three-way airtight tubing system with a digital 
manometer (C9553 Pressure Meter, Comark, Norwich, England) and an inflation device (Encore 
26 Inflator, Boston Scientific, Marlborough, Massachusetts, USA). Incremental positive and 
negative pressure was delivered to the system through the inflation device, and the MicroRPM 
measurement was compared against the digital manometer measurement. The arithmetic 
means ± ½ range (%) cmH2O of ten repeated measurements at each pressure level are listed in 
Table 11. Of note, the MicroRPM device displays pressure (cmH2O) in integers, accounting for 
the instances where error margins are zero.  
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Table 11. Instrument repeatability of the MicroRPM calculated from ten repeat measurements at 
each pressure level (cmH2O). Of note, the MicroRPM device displays negative pressure (i.e. 
PImax measurements) in positive values.  
‘Known’ pressure as per 
digital manometer 
MicroRPM measurements 
(mean ± ½ range (%)) 
200 199.6 ± 1.5 (0.8%) 
150 149.8 ± 1.0 (0.7%) 
100 99.9 ± 1.0 (1.0%) 
80 79.9 ± 0.5 (0.6%) 
60 59.9 ± 0.5 (0.8%) 
40 40.0 ± 0 (0%) 
20 20.0 ± 0 (0%) 
10 10.0 ± 0 (0%) 
-10 10.0 ± 0 (0%) 
-20 20.1 ± 0.5 (2.5%) 
-40 40.1 ± 0.5 (1.2%) 
-60 60.0 ± 0.5 (0.8%) 
-80 80.2 ± 0.5 (0.6%) 
-100 100.1 ± 1.0 (1.0%) 
-150 150.3 ± 1.5 (1.0%) 
-200 200.5 ± 1.5 (0.8%) 
 
 
3.4.2.2 Test-retest reliability in healthy subjects 
 
The raw data for test-retest measurements in healthy subjects are presented in Table 12. The 
mean difference (95% limits of agreement) was -2.2 (-19.6, 15.2) cmH2O for PEmax and -5.5 (-
23.7, 12.7) cmH2O for PImax. The ICC (95% confidence interval) was 0.95 (0.84, 0.99) for 
PEmax and 0.95 (0.80, 0.99) for PImax.  
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Table 12. Test-retest measurements for maximal mouth pressures in healthy subjects 
Subject Maximal expiratory mouth 
pressure (cmH2O) 
Maximal inspiratory mouth 
pressure (cmH2O) 
Test 1 Test 2 Test 1 Test 2 
1 129 138 105 112 
2 109 108 118 118 
3 65 77 63 68 
4 104 107 57 48 
5 151 148 84 84 
6 65 69 44 52 
7 133 130 80 75 
8 120 141 95 103 
9 145 144 151 162 
10 125 121 100 128 
11 106 95 98 105 
 
 
3.4.2.3 Test-retest reliability in stroke patients 
 
The raw data for test-retest measurements in stroke patients are presented in Table 13. The 
measurements are from six patients. All six carried out repeated tests approximately four weeks 
after stroke onset, and five performed repeated tests again approximately twelve weeks after 
stroke. The mean difference (95% limits of agreement) was -2.2 (-14.9, 10.5) cmH2O for PEmax 
and 1.1 (-6.9, 9.1) cmH2O for PImax. The ICC (95% confidence interval) was 0.94 (0.79, 0.98) 
for PEmax and 0.96 (0.88, 0.99) for PImax.  
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Table 13. Test-retest measurements for maximal mouth pressures in stroke patients 
Subject Time post 
stroke 
Maximal expiratory mouth 
pressure (cmH2O) 
Maximal inspiratory mouth 
pressure (cmH2O) 
 Test 1 Test 2 Test 1 Test 2 
1 4 weeks 70 80 43 39 
2 4 weeks 53 63 36 37 
3 4 weeks 97 89 43 42 
4 4 weeks 106 109 75 66 
5 4 weeks 69 76 51 55 
6 4 weeks 94 88 74 78 
1 12 weeks 106 107 47 45 
2 12 weeks 64 67 30 32 
3 12 weeks 89 94 47 48 
4 12 weeks 115 108 75 69 
5 12 weeks 72 78 58 56 
 
 
3.4.3 Cough flow measurements 
 
3.4.3.1 Linearity of the measurement system 
 
Linearity of the on-site and the off-site cough measurement systems was assessed in both 
directions of flow through the pneumotachograph. A mechanical flow generating device 
(Numatic NVDQ572, 1700W, Numatic International, Chard, England) and a rotameter 
(Rotameter 2000, TM-47X FM-A, 80-760 L/min flow range, Process Instruments Ltd, Croydon, 
England) were used to deliver steady airflow in increments of 100 L/min. The corresponding 
voltage recorded with the on-site measurement system at each flow level is presented in Figure 
6. The system showed good linearity with an r2 (square of the Pearson correlation coefficient) of 
0.999148. For the off-site measurement system, r2 was 0.999376. Good linearity justified the 
use of two-point calibration.  
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Figure 6. Linearity of the cough flow measurement system, r2 = 0.999148 
 
 
3.4.3.2 Dynamic response of the measurement system 
 
The on-site and the off-site cough measurement systems’ responses to rapid change in air flow 
were assessed. During the expulsive phase of cough, expiratory flow peaks within 0.025 to 
0.050 seconds. The measurement system needs to be sufficiently sensitive to capture this rapid 
increase in signal and not to ‘miss’ the transient flow peak.  
 
Dynamic response was evaluated through rapid cessation of flow (Miller et al. 2003, 2002) 
using the ‘pop-test’ method (Ward 2012, pp. 90-91). An inflated toy balloon was connected to 
the pneumotachograph via a valve and corrugated tubing (ID 20.0 mm, length 40.0 cm). Steady 
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flow was generated from the balloon and rapidly discontinued by bursting the balloon with a 
needle.  
 
For the on-site measurement system, voltage dropped to zero in 0.0101 seconds from when 
flow was discontinued. For the off-site measurement system, the trace reached zero 0.024 
seconds after cessation of flow. For both systems, the response time to sudden cessation of 
flow was adequate to capture the rapid rise in expiratory flow during cough.  
 
3.4.3.3 Instrument repeatability 
 
3.4.3.3.1 Repeatability of flow measurements 
 
Steady flow was delivered through the pneumotachograph in 100 L/min increments from -700 
L/min to 700 L/min, using a mechanical flow generating device (Numatic NVDQ572, 1700W, 
Numatic International, Chard, England) and a rotameter (Rotameter 2000, TM-47X FM-A, 80-
760 L/min flow range, Process Instruments Ltd, Croydon, England). The arithmetic means ± ½ 
range (%) L/min of ten repeated measurements at each flow level are listed in Table 14. Means 
± SD for the off-site measurement system are shown in Figure 7. Systems were calibrated anew 
before each measurement, so that the variability observed here includes error related to the 
flow calibration procedure.  
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Table 14. Repeatability of steady flow measurements calculated from ten repeat measurements 
at each flow level (L/min).  
 ‘Known’ flow as per 
rotameter 
Measurements (mean ± ½ range (%)) 
 On-site measurement system Off-site measurement system 
700 723 ± 28 (3.9%) 737 ± 13 (1.8%) 
600 611 ± 20 (3.3%) 621 ± 7 (1.1%) 
500 500 ± 13 (2.5%) 507 ± 9 (1.8%) 
400 396 ± 8 (2.0%) 403 ± 8 (2.0%) 
300 290 ± 5 (1.7%) 297 ± 8 (2.7%) 
200 191 ± 3 (1.6%) 196 ± 6 (3.1%) 
100 96 ± 2 (2.6%) 99 ± 6 (6.0%) 
-100 -95 ± 3 (2.9%) -100 ± 8 (8.0%) 
-200 -188 ± 8 (4.4%) -192 ± 10 (5.2%) 
-300 -283 ± 15 (5.3%) -288 ± 15 (5.2%) 
-400 -384 ± 26 (6.8%) -390 ± 26 (6.7%) 
-500 -481 ± 36 (7.5%) -490 ± 32 (6.5%) 
-600 -585 ± 49 (8.4%) -606 ± 41 (6.8%) 
-700 -693 ± 65 (9.4%) -711 ± 54 (7.6%) 
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Figure 7. Calibration curve. Error bars represent standard deviation.  
 
 
3.4.3.3.2 Repeatability of volume measurements 
 
Volumes of 0.1 L, 0.5 L, 1.5 L and 3.0 L were delivered through the pneumotachograph in 
inspiratory and expiratory direction of flow at randomly altered flow levels using a three-litre 
calibration syringe. The arithmetic means ± ½ range (%) of ten consecutive measurements for 
each volume and in the respective directions are listed in Table 15.  
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Table 15. Repeatability of volume measurements calculated from ten repeat measurements for 


















0.1 19-180 0.1 ± <0.01 (6.0%) 0.1 ± 0.01 (10.0%) 
0.5 32-305 0.5 ± <0.01 (1.0%) 0.5 ± 0.01 (2.0%) 
1.5 40-680 1.5 ± 0.01 (0.7%) 1.4 ± 0.03 (2.1%) 




0.1 20-146 0.1 ± <0.01 (3.9%) 0.1 ± <0.01 (6.8%) 
0.5 35-363 0.5 ± 0.01 (2.0%) 0.5 ± 0.02 (3.2%) 
1.5 51-728 1.5 ± <0.01 (0.4%) 1.5 ± 0.04(2.4%) 
3.0 64-1086 3.0 ± <0.01 (0.2%) 3.0 ± 0.08 (2.8%) 
 
 
3.4.3.3.3 Peak expiratory flow measurements with and without the nebuliser circuit 
 
The pneumotachograph system had higher airflow resistance when reflex cough flow was 
measured, due to the two-way non-rebreathing valve and filter connected downstream to the 
pneumotachograph. Given consistent driving pressure, higher airflow resistance will result in 
lower flow, and vice versa. Therefore, the influence of the nebuliser circuit on absolute values of 
peak flow measurements was experimentally determined by measuring the peak flow of short 
duration flow bursts. Flow bursts were generated with a 50 L pressure vessel (Medical 
Engineering Department, Royal Brompton Hospital, London, England) connected to a balloon 
occlusion valve (Medical Engineering Department, Royal Brompton Hospital, London, England). 
The vessel was pressurised with compressed air to a predetermined pressure, monitored with a 
digital manometer (C9553 Pressure Meter, Comark, Norwich, England), at which point the 
occlusion valve was opened and a burst of short duration airflow released. The consistency of 
peak flow for these flow bursts was confirmed with five consecutive measurements with the 
pneumotachograph system. Incremental vessel pressures from 25 to 800 mmH2O were used. 
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At each level of pressure, peak flow was measured with the pneumotachograph with and 
without attached nebuliser circuit. Differences in measurements are shown in Table 16 and 
Figure 8. The measurements with nebuliser circuit attached are of a magnitude of between 65% 
and 69% of the corresponding measurements without nebuliser circuit, so that the added 
resistance of the nebuliser circuit caused a systematic reduction of the absolute peak flow 
measurement by between 35% and 31%. This needs to be considered when interpreting 
absolute peak cough flow values for voluntary cough (measured with pneumotachograph 
without attached nebuliser circuit) and reflex cough (measured with pneumotachograph with 
attached nebuliser circuit).  
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Table 16. Peak flow measurements (L/min) of short duration flow bursts, comparing the 
pneumotachograph with and without attached nebuliser circuit 
Driving pressure for 
flow burst generation 
(mmH2O) 
Peak flow measurements (L/min) 
Pneumotachograph Pneumotachograph and attached 
nebuliser circuit (% of measurement 
without attached nebuliser circuit) 
25 72 47 (65%) 
50 131 90 (69%) 
100 243 163 (67%) 
150 336 220 (65%) 
200 427 281 (66%) 
250 490 321 (66%) 
300 553 361 (65%) 
350 607 397 (65%) 
400 662 432 (65%) 
450 708 468 (66%) 
500 746 503 (67%) 
550 793 538 (68%) 
600 840 572 (68%) 
650 884 608 (69%) 
700 934 638 (68%) 
750 971 670 (69%) 
800 1010 697 (69%) 
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Figure 8. Peak flow measurements (L/min) of short duration flow bursts, comparing the 
pneumotachograph with and without attached nebuliser circuit. 
 
 
3.4.3.4 Test-retest reliability in healthy subjects 
 
Test-retest reliability was examined for PECF of voluntary and reflex cough, as these were the 
primary parameters of interest for the subsequent clinical studies. The raw data for test-retest 
measurements in healthy subjects are presented in Table 17. The mean difference (95% limits 
of agreement) was -15 (-199, 169) L/min for PECF of voluntary cough and 4 (-153, 161) L/min 
for PECF of reflex cough. The ICC (95% confidence interval) was 0.94 (0.79, 0.98) for PECF of 
voluntary cough and 0.64 (0.02, 0.90) for PECF of reflex cough.  
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Table 17. Test-retest measurements of peak expiratory cough flow (PECF) in healthy subjects 
Subject PECF of maximal voluntary 
cough (L/min) 
PECF of capsaicin-induced 
reflex cough (L/min) 
Test 1 Test 2 Test 1 Test 2 
1 1221 1129 599 425 
2 1082 1183 350 381 
3 521 578 252 390 
4 800 808 307 267 
5 896 914 - - 
6 625 600 269 309 
7 1211 1094 396 407 
8 540 573 256 200 
9 905 1030 373 405 
10 833 994 276 250 
11 561 458 318 324 
Note: no reflex cough was elicited in subject 5 at the highest available 
concentration of capsaicin 
 
 
3.4.3.5 Test-retest reliability in stroke patients 
 
The raw data for test-retest measurements in stroke patients are presented in Table 18. The 
measurements are from six patients. All six carried out the tests approximately four weeks after 
stroke onset, and five performed the tests again approximately twelve weeks after stroke. The 
mean difference (95% limits of agreement) was 44 (-42, 130) L/min for PECF of voluntary cough 
and 25 (-181, 231) L/min for PECF of reflex cough. The ICC (95% confidence interval) was 0.98 
(0.86, 0.99) for PECF of voluntary cough and 0.68 (0.18, 0.90) for PECF of reflex cough.  
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Table 18. Test-retest measurements of peak expiratory cough flow (PECF) in stroke patients 
Subject Time post 
stroke 
PECF of maximal voluntary 
cough (L/min) 
PECF of capsaicin-induced 
reflex cough (L/min) 
 Test 1 Test 2 Test 1 Test 2 
1 4 weeks 457 467 408 277 
2 4 weeks 332 307 237 182 
3 4 weeks 659 587 362 379 
4 4 weeks 934 958 488 533 
5 4 weeks 851 790 487 379 
6 4 weeks 942 839 305 463 
1 12 weeks 525 512 281 307 
2 12 weeks 313 262 219 112 
3 12 weeks 666 682 388 377 
4 12 weeks 966 959 666 470 
5 12 weeks 853 764 271 360 
 
3.4.3.6 Comparability of the on-site and off-site measurement systems 
 
Linearity, dynamic response and instrument repeatability were examined for both the on-site 
and off-site measurement systems. The two systems had equivalent linearity. The on-site 
system was approximately twice as responsive to rapid change in signal as the off-site system; 
however, both systems met the dynamic response requirements for cough testing. With respect 
to the repeatability of flow and volume measurements the two systems differed in some aspects 
within an overall adequate performance level.  
 
In the evaluation of test-retest reliability in healthy subjects and stroke patients, both the on-site 
and off-site measurement systems were used, depending on the location of the subject. These 
data therefore reflect the actual circumstances of measurement in the subsequent clinical 
studies.  
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3.4.4 Minimal detectable difference for cough flow and maximal mouth pressure 
measurements 
 
To inform the interpretation of change over time, coefficients of variation were calculated using 
the test-retest data from healthy subjects and stroke patients for PEmax, PImax, PECF of 
voluntary cough and PECF of reflex cough. These four parameters were selected, as they were 
primary parameters of interest in subsequent clinical studies. The coefficient of variation 
indicates the difference in two consecutive measurements that can be expected in the absence 
of ‘true’ change. This statistic allows test-retest variability to be described in relation to the 
magnitude of measurements on the scale of potential values (as opposed to Bland-Altman 
statistics, which summarise the mean and spread of differences for the entire range of observed 
values). Coefficients of variation are given in Table 19.  
 
Table 19. Coefficients of variation for maximal mouth pressure and cough flow measurements  
 Mean Min Max 
Healthy subjects    
PECF of voluntary 
cough 
0.09 0.01 0.20 
PECF of reflex cough 0.16 0.02 0.43 
PEmax 0.06 <0.01 0.16 
PImax 0.09 <0.01 0.24 
Stroke patients    
PECF of voluntary 
cough 
0.07 0.01 0.18 
PECF of reflex cough 0.26 0.03 0.65 
PEmax 0.08 0.01 0.17 
PImax 0.06 0.02 0.13 
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The interpretation of these coefficients is that, e.g. for healthy subjects the group mean test-
retest variability for PECF of voluntary cough was 0.09. An observed change over time that 
exceeds this error margin of ± 0.09 or 9% can therefore be interpreted as ‘true’ change, rather 
than variability attributed to test-retest variability in the absence of change. As the most 
conservative estimate of test-retest variability, the highest observed coefficient of variability can 





The series of method validation experiments described in this chapter addresses the issue of 
measurement variability for three respiratory assessment methods: forced spirometry, 
measurement of maximal mouth pressures and cough flow measurement. Forced spirometry 
and maximal mouth pressure measurements are commonly used in clinical practice and 
research, and detailed guidelines on the standardisation of these test procedures are available 
(Miller et al. 2005, American Thoracic Society (ATS) & European Respiratory Society (ERS) 
2002). In contrast, the measurement of cough flow is less commonly applied and there are no 
guidelines for the standardisation of cough flow testing. Measurement error can be reduced by 
standardising test procedures. Table 20 lists potential sources of measurement variability 
relating to the cough flow measurement systems and test procedures applied in the present 
studies. The investigator was conscious of these issues throughout the research process and 
took care to minimise measurement error arising from these sources.  
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Table 20. Sources of measurement error when measuring cough flow in human subjects 
Instrument Comments 
Vertical position of the rotameter when 
calibrating the system 
This consideration was particularly relevant when setting up the measurement system in participants’ homes, where a 
convenient stable horizontal surface was not always readily available.  
Geometry of connecting components  The size and shape of connecting components influence the performance characteristics of the measurement system 
(Jackson & Vinegar 1979, Finucane et al. 1972) and were therefore not altered for the duration of the study.  
Steady reference flow for flow calibration  Negative flow (i.e. vacuum) applied to the rotameter and pneumotachograph shows less oscillation than positive flow, 
and therefore provides a steadier reference point for calibration.  
Direction of flow through the 
pneumotachograph when delivering 
reference flow for calibration and when 
testing 
Linearity of the measurement system was somewhat better in expiratory direction of flow through the 
pneumotachograph. Since expiratory cough flow was more relevant as an outcome for the studies than inspiratory 
cough flow, the reference flow when calibrating was applied to the pneumotachograph in the same direction as the 
subject’s expiratory cough flow. This maximised precision of expiratory flow measurements.  
Fit of the face mask Inadequate fit of the face mask or movement of the mask during testing could lead to air leak and measurement 
variability. Care was taken during testing to monitor the fit of the mask throughout testing.  
Intra-subject Comments 
Location  Room temperature, humidity and atmospheric pressure affect the measurement of air flow. From these, room 
temperature is the most relevant factor and was corrected for using the appropriate correction factor.  
Body position Body position (i.e. supine versus sitting position) influences lung volumes (Dean 2002) and therefore may also 
influence cough flow rates. Testing was always conducted with the test subject in a sitting position, either on a chair, 
armchair or positioned upright in the hospital bed.  
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Table 20. continued 
Changes in mood, motivation, effort, 
alertness, fatigue, pain 
Daily constitution could influence performance of voluntary cough tests. In a population of acute stroke patients, 
alertness, fatigue, mood and pain are particularly relevant factors, which can fluctuate considerably in the acute phase 
of the condition. The investigator took note of subjects’ level of alertness and any indication of fatigue, mood, or pain 
influencing measurements.  
Biological/physiological variation Variability may be due to biological and physiological variation beyond the control or perception of the subject and 
investigator.  
Intra-rater Comments 
Parallax Differing line of sight when reading the calibration reference flow off the rotameter bobbin could introduce variability. 
This consideration was particularly relevant when calibrating at a subject’s home, where the height of surfaces could 
require the operator to crouch, stoop or lean sideways in order to align line of sight with the rotameter scale.  
Consistency of verbal instructions to the 
subject 
The quality of the operator’s verbal instructions could influence the consistency of measurements. More assertive and 
enthusiastic instructions usually result in a more motivated volitional effort by the test subject. Including the instruction 
to take in a deep breath prior to coughing likely results in higher expiratory cough flow, as expiratory cough flow in part 
depends on inspired volume. Care was taken to give consistent instructions to subjects throughout the study period.  
Extracting data from software Variability in marking points of measurement by hand was reduced by using automated functions when possible (e.g. 
maximum and minimum value of a selected portion). However, some parameters had to be extracted from cough flow 
traces by positioning markers by hand. Care was taken to apply consistent procedures when extracting data from 
cough flow traces, e.g. using the same level of screen magnification when positioning markers.  
Inter-rater Comments 
Inter-rater variability was not relevant to the 
present study, as all measurements were 
performed by one investigator.  
In principle, all points relating to intra-rater variability also apply to inter-rater variability, and are likely to affect variability 
to an even greater extent. 
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The measurement error attributable to the performance of measurement instruments was 
evaluated through instrument repeatability bench tests. Instrument repeatability was excellent 
for the spirometer (volume accuracy) and the MicroRPM device (pressure accuracy), with error 
margins below 2% across the range of measurements. The flow measurement systems were 
shown to have adequate linearity and dynamic response. Flow accuracy of the cough flow 
measurement systems was good in the expiratory direction of flow from 200 L/min upwards, 
with conservative error margins estimates of below 4%. In the 100 L/min flow range in the 
expiratory direction error margins were below 6%, and in the inspiratory direction of flow error 
margins were 5% to 9% across the range. Volume accuracy of the cough flow measurement 
system was good for volumes from 0.5 to 3.0 L, with error margins of up to 2% for inspiratory 
volumes and up to 3% for expiratory volumes. For small volumes of 0.1 L, error margins were 
up to 6% and 10% for inspiratory and expiratory volumes, respectively. The salient point from 
these data is that for the parameters that were most relevant in subsequent clinical studies 
(peak expiratory flow of cough and maximal mouth pressures) the instruments showed a good 
level of precision. The MicroRPM was able to measure maximal mouth pressure accurately to 
within ± 2%, and the cough flow measurement system was able to measure expiratory flow 
accurately to within ± 4%.  
 
As to be expected, test-retest reliability data from human subjects showed a greater level of 
variability than instrument repeatability. Variability as quantified through ICCs, Bland-Altman 
statistics and coefficients of variation was of approximately equivalent magnitude in healthy 
subjects and in stroke patients, which demonstrates that these respiratory assessments can be 
performed as reliably in the clinical population of interest for the present studies as in healthy 
subjects.  
 
ICCs were high throughout with values >0.90 for most parameters, except for PEF in healthy 
subjects, where the ICC was 0.84, and PECF of reflex cough in healthy and stroke subjects, 
where ICCs were 0.64 and 0.68, respectively. Bland-Altman statistics and coefficients of 
variation informed about the magnitude of variability (in the unit of measurement) in the absence 
of ‘true’ change. For example, for the test-retest measurements of PECF of voluntary cough in 
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stroke patients, the mean difference (first measurement – second measurement) was 44 L/min, 
indicating that there was a trend towards lower cough flow measurements at the second time of 
testing, which may be interpreted as an element of fatigue. In 95% of observations, the 
difference was between -42 and 130 L/min (95% limits of agreement). This variability may seem 
high, considering that measurements in the flow range of 200, 300 and 400 L/min can be 
expected in stroke patients with impaired cough function. However, 95% limits of agreement 
summarise the discrepancy between measurements across the entire scale of possible 
measurements. The coefficient of variation statistic shows that measurement variability was 
smaller in absolute terms at the lower end of the scale and higher in absolute terms at the 
higher end of the scale. For example, for PECF of voluntary cough in stroke patients, the mean 
coefficient of variability was 0.07, which corresponds to error margins of ± 14 L/min, ± 28 L/min, 
± 42 L/min and ± 56 L/min at 200, 400, 600 and 800 L/min flow, respectively. Using the highest 
observed coefficient of variability for PECF of voluntary cough in the stroke group (0.18) for the 
most conservative estimate of test-retest variability, error margins were ± 36 L/min, ± 72 L/min, 
± 108 L/min and ± 144 L/min at 200, 400, 600 and 800 L/min flow, respectively. The 
interpretation of these statistics is that, e.g. for measurements in the flow range of 200 L/min an 
observed difference of >36 L/min can be attributed to ‘true’ change beyond the level of expected 
test-retest variability, whereas in the flow range of 800 L/min the difference observed needs to 
exceed 144 L/min to be interpreted as ‘true’ change, etc. These data correspond with the 
variability for PECF measurements observed by Singh et al. (1994), who reported coefficients of 
variability ranging from 0.09 to 0.23 (derived from 15 PECF measurements made over a four-
week period in twelve healthy volunteers).  
 
For maximal expiratory and inspiratory mouth pressure measurements in stroke patients, the 
mean coefficients of variation were 0.08 and 0.06, respectively. The highest coefficients of 
variation were 0.17 for PEmax and 0.13 for PImax. As the most conservative estimates 
therefore, expected error margins for PEmax in stroke patients are ± 3 cmH2O, ± 7 cmH2O, ± 10 
cmH2O and ± 14 cmH2O at 20, 40, 60 and 80 cmH2O, respectively; and expected error margins 
for PImax are ± 3 cmH2O, ± 5 cmH2O, ± 8 cmH2O and ± 10 cmH2O at 20, 40, 60 and 80 cmH2O, 
respectively. Of note, these figures indicate the minimal detectable difference based on 
 - 116 - 
measurement variability, but not the minimally important difference (i.e. the smallest change in 
the respective parameters that is considered clinically relevant).  
 
Measurements of PECF of reflex cough showed the highest degree of test-retest variability, with 
ICCs of 0.068 and 0.064 in healthy volunteers and stroke patients, respectively. 95% limits of 
agreement in the stroke group were -181 L/min to 231 L/min. The mean coefficient of variation 
in the stroke group was 0.26, and the highest coefficient of variation in the stroke group was 
0.65. This high test-retest variability for reflex cough flow measurements can be explained by 
the nature of the test. Factors contributing to limited reproducibility of inhalation cough challenge 
tests have been described (Morice et al. 2007, pp. 1258-1261). Variability in subjects’ readiness 
to allow or suppress the urge to cough may contribute to measurement variability. Some 
subjects may respond with hesitation when asked to inhale the irritant. This contributes to 
variability in respiratory flow and volumes, which in turn influence the actual dose of the irritant 
delivered to the target receptor sites in the laryngeal and tracheal region. In addition, receptor 
sensitivity to capsaicin can adapt over the short term, which may lead to variability in the force 
of elicited reflex responses. The moment at which a reflex cough is triggered during the 
breathing cycle is unpredictable. This means that coughs can be elicited at different points 
during inspiration and expiration, when the volume of air within the lungs is greater or lesser. 
This influences the peak cough flow achieved, since expiratory cough flow is dependent on both 




In conclusion, the series of validation experiments described in this chapter addressed issues of 
measurement variability for three respiratory assessment procedures: forced spirometry, 
measurement of maximal mouth pressures and cough flow measurement. Instrument 
repeatability and test-retest reliability in healthy subjects and in acute stroke patients were 
examined. The most relevant measurement parameters for subsequent clinical studies were 
PECF of voluntary cough, PECF of capsaicin-induced reflex cough, PEmax and PImax.  
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Instrument repeatability was good, with conservative error estimates of <4% for expiratory flow 
measurements using the cough flow measurement systems; and <2% for pressure 
measurements using the MicroRPM device for maximal mouth pressure measurement. The 
cough flow measurement systems showed adequate linearity and dynamic response.  
 
Test-retest reliability was of approximately equivalent magnitude in healthy subjects and in 
stroke patients, demonstrating that these respiratory assessments can be performed as reliably 
in the clinical population of interest for the present studies as in healthy subjects. Test-retest 
reliability was high for PECF of voluntary cough, PEmax and PImax (ICCs >0.90), and moderate 
for PECF of reflex cough (ICCs 0.60 to 0.70).  
 
The magnitude of test-retest variability in the unit of measurement was described using Bland-
Altman statistics (mean difference, 95% limits of agreement) and the coefficient of variation. 
Accordingly, the minimal detectable difference, taking into account all possible sources of 
measurement variability (instrument, intra-rater and intra-subject) and using the mean 
coefficient of variation observed in stroke patients, is: >7% change in PECF of voluntary cough; 
>26% change in PECF of reflex cough; >8% change in PEmax; and >6% change in PImax.  
 
These data informed the design, analysis and interpretation of the subsequent clinical studies.  
 
 - 118 - 
Chapter 4 Accuracy of portable flow measurement devices for 




Cough flow testing is useful as an outcome measure in research and a monitoring or diagnostic 
tool in clinical practice. Peak expiratory cough flow (PECF) is commonly used as an indicator of 
the strength or effectiveness of cough, particularly in clinical populations with neuromuscular 
impairment (Jones et al. 2012). Cough can be accurately quantified using laboratory 
pneumotachograph based systems as described by Singh et al. (1994), but these can often 
consist of several components, can be expensive, not easily transportable, and require 
significant knowledge by the user for correct operation. Practical devices, which can 
conveniently be applied in clinical settings, patients’ homes or other community locations, may 
be of use to clinicians and researchers. In several clinical studies, standard peak flow meters 
and hand-held spirometers have been used to measure PECF (Table 21). These devices are 
designed to measure peak flow during a forced expiratory manoeuvre, and their accuracy in 
measuring peak flow during cough is uncertain.  
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Table 21. Portable peak flow meters and spirometers used for the measurement of peak cough flow in clinical research.  
Device Study Study population 
Peak flow meters   
AsmaPLAN (Vitalograph, Ennis, Ireland) LoMauro et al. 2014 Duchenne muscular dystrophy 
Sancho et al. 2004  Neuromuscular disease, healthy subjects 
Assess (Philips Respironics, Pittsburgh, 
Pennsylvania) a 
Cleary et al. 2013  Amyotrophic lateral sclerosis 
Bach et al. 2006 Restrictive pulmonary syndrome due to neuromuscular 
disease 
Kang et al. 2006b Cervical spinal cord injury 
Bach et al. 1997 Duchenne muscular dystrophy 
Bach & Saporito 1996 Spinal cord injury, progressive neuromuscular disease 
Bach 1995 Amyotrophic lateral sclerosis 
Astech (Astech, New York, New York) Daftary et al. 2007 Duchenne muscular dystrophy 
MicroPeak (Micro Medical Ltd, Rochester, England) Lee et al. 2013 Traumatic brain injury, healthy subjects 
Mini-Wright (Clement Clarke International, Harlow, 
England) 
Silverman et al. 2014 Healthy subjects, Parkinson’s disease 
Cardoso et al. 2012 Healthy subjects 
Freitas et al. 2010 Healthy elderly subjects 
Brito et al. 2009 Duchenne muscular dystrophy 
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Table 21. continued 
Mini-Wright DIGITAL 
(www.miniwrightpeakflowmeter.com) 
Silverman et al. 2014 Healthy subjects, Parkinson’s disease 
Wright (Wright & McKerrow 1959) Gauld & Boynton, 2005 Duchenne muscular dystrophy 
Leiner et al. 1966 Obstructive and/or restrictive pulmonary disease, healthy 
subjects 
Personal Best (Philips Respironics, Pittsburgh, 
Pennsylvania) 
Suarez et al. 2002 Duchenne muscular dystrophy, amyotrophic lateral sclerosis 
Pocketpeak (Ferraris Medical Ltd, Enfield, England) Dohna-Schwake et al. 2006 Muscular dystrophies 
Spirometers   
Autospiro AS-505 (Minato Medical Science, Osaka, 
Japan) 
Kimura et al. 2013 Stroke 
Micro-S 2000 (C. Schatzman, Madrid, Spain) Sancho et al. 2007 Amyotrophic lateral sclerosis 
Spirobank (Medical International Research, Rome, 
Italy) 
Fiore et al. 2008 Cardiac surgery 
a Formerly manufactured as Access Model 710 peak flow meter (Health Scan Products Inc, Cedar Grove, New Jersey, USA) 
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4.2 Aims and objectives 
 
A series of experiments was conducted to examine the accuracy of two commonly used peak 
flow meters and one hand-held spirometer when measuring PECF. The purpose was to 
investigate whether the pneumotachograph-based measurement system used in subsequent 
clinical studies, which provided physiologically detailed measurements but consisted of an 
elaborate and expensive equipment setup, could potentially be substituted with convenient and 
less expensive hand-held clinical flow measurement devices.  
The specific objectives were to:  
 Describe the accuracy of devices when measuring PECF 




4.3.1 Study design 
 
Three hand-held devices were examined: the Assess peak flow meter (range 60-880 L/min, 
accuracy ±10% or 20 L/min according to manufacturer, Philips Respironics, Pittsburgh, 
Pennsylvania); the Mini-Wright Standard peak flow meter (European Union (EU) Scale, range 
60-800 L/min, accuracy ±10% or 10 L/min according to manufacturer, Clement Clarke 
International, Harlow, England); and the SpiroUSB turbine spirometer, (range 12-900 L/min, 
accuracy ±3% according to manufacturer, CareFusion, San Diego, California). These three test 
devices were selected as they are produced by leading manufacturers and frequently used in 
clinical practice.  
 
Three experiments were conducted to assess the accuracy of PECF measurements, and each 
of these has advantages and limitations. The first approach was to compare PECF 
measurements from healthy subjects’ maximal volitional coughs, which were recorded with each 
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of the test devices in turn. The limitation of this approach is that findings are biased by error due 
to intra-subject variability of repeated maximal volitional cough efforts.  
 
The second approach was to connect each test device in series with a calibrated 
pneumotachograph. Healthy subjects produced cough efforts at different levels of intensity 
through the setup. For each cough manoeuvre, PECF readings from the pneumotachograph 
and the test device were compared. In this approach, the pneumotachograph measurement 
was taken as the gold standard method of measurement. The advantage of this approach is 
that PECF readings from coughs of various intensity can conveniently be compared between 
the pneumotachograph and second device. The limitation of this approach is that the in-series 
connection of pneumotachograph and second device may introduce error due to alteration of 
airflow characteristics and instrument performance.  
 
The third approach was to mechanically generate short duration flow bursts, the flow-time 
traces of which resembled those of human coughs. These simulated ‘coughs’ could be 
reproduced with consistent peak flow and discharged repeatedly into each of the test devices in 
turn. The advantage of this approach is that the peak flow of these simulated ‘coughs’ can be 
conveniently varied across the range of clinically relevant peak flow values. The limitation of this 
approach is that these mechanically generated ‘coughs’ may not represent the entire range of 
relevant physical characteristics of human cough, although key parameters (peak flow, rise 




Healthy adults with no medical history of respiratory disease or conditions affecting the anatomy 
and function of the upper airway who were comfortable coughing repeatedly over a short period 
of time were recruited. The study had ethical approval from the Psychiatry, Nursing and 
Midwifery Research Ethics Committee at King’s College London, UK (study reference 
PNM/12/13-143). All participants gave written informed consent.  
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4.3.3 Data collection 
 
For the first experiment, a bacterial filter (Spiroguard Standard, Air Safety Medical, Morecambe, 
England) was connected to the devices under test. The calibration of the SpiroUSB spirometer 
was verified with a three-litre calibration syringe at the beginning of each testing session as per 
manufacturer’s recommendation Subjects were seated comfortably and gave maximal volitional 
coughs (investigators instruction: ‘Take a deep breath in and give a strong cough’) through the 
open port of the bacterial filter, while maintaining a good lip seal around the port. For each of 
the three test devices, participants made five consecutive maximal cough efforts, and the 
highest PECF measurement was taken for analysis. Test devices were rotated in random order.  
 
For the second experiment, the bacterial filter, a pneumotachograph and one test device were 
connected in series. The pneumotachograph system consisted of a Fleisch-type 
pneumotachograph (ID 4.4 cm, length 6.0 cm, PK Morgan Ltd, Rainham, England). Differential 
pressure was measured using a Validyne differential pressure transducer (MP45, range ± 2 
cmH2O, Validyne Engineering, Northridge, CA) and the signal amplified (CD15, Validyne 
Engineering, Northridge, CA) and acquired on a laptop running LabChart software (LabChart 
Pro, version 7.2.2, ADInstruments Ltd, Oxford, England) with analog-to-digital sampling of 2 kHz 
(PowerLab/16SP, ADInstruments Ltd, Oxford, England). The pneumotachograph system was 
linear in the flow range from zero to 700 L/min (r2 = 0.999845). A two-point calibration was 
performed at the beginning of each testing session, using a rotameter (InFlux OF1”S, 60-600 
L/min flow, Techniquip Ltd, Taunton, England). Participants were instructed to cough through 
the filter so that the peak flow of each cough was measured by the pneumotachograph system 
and the portable device. Participants gave five strong coughs (from total lung capacity), five 
weak coughs (from residual volume) and five coughs of subjectively moderate strength 
(between strong and weak cough efforts). Participants were seated during testing. Altogether, 
300 coughs were measured per test device. Devices were rotated in random order.  
 
For the third experiment, short duration airflow bursts of consistent peak flow were mechanically 
generated using a 50 L pressure vessel (Medical Engineering Department, Royal Brompton 
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Hospital, London, England) connected to a balloon occlusion valve (Medical Engineering 
Department, Royal Brompton Hospital, London, England). The vessel was pressurised with 
compressed air to a predetermined pressure, monitored with a digital manometer (C9553 
Pressure Meter, Comark, Norwich, England), at which point the occlusion valve was opened 
and a burst of short duration airflow released. The consistency of peak flow for these flow bursts 
was confirmed with five consecutive measurements with the pneumotachograph system. Vessel 
pressures of 5, 10, 15, 20, 30 and 40 cmH2O were used, resulting in bursts of airflow with mean 
(SD) peak flows of 138 (0.4), 250 (1.3), 343 (0.8), 422 (0.8), 559 (1.6) and 684 (2.9) L/min, 
respectively. Five flow bursts at each flow level were discharged into each portable test device 
with bacterial filter.  
 
4.3.4 Data analysis 
 
Data were analysed using statistical software (Stata version 12.1, StataCorp LP, College 
Station, Texas; Microsoft Office Excel 2007, Microsoft Corporation, Redmond, WA). To quantify 
intra-subject variability of PECF measurements from maximal volitional coughs, coefficients of 
variation were calculated for each set of five consecutive PECF readings from the first 
experiment (standard deviation of five measurements/mean of five measurements) (Hankinson 
et al. 1998). To describe agreement between devices in the first experiment, data was plotted 
for visual analysis, and ICCs for comparison of individual absolute agreement were calculated 
(StataCorp 2013). Data from the second experiment was analysed using the Bland-Altman 
method (Bland & Altman 1999), comparing peak flow measurements obtained from the devices 
under test against the pneumotachograph. For the purpose of this analysis, the 
pneumotachograph system was taken as the gold standard measurement technique. To 
examine the influence of shorter rise time, a key characteristic distinguishing flow-time traces of 
cough from those of forced expiratory manoeuvres, differences between pneumotachograph 
and test devices were correlated with rise time. Results from the third experiment were plotted 
for visual analysis. Instrument repeatability for the three devices under test was expressed as 
the mean ± SD of five consecutive measurements.  
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4.4 Results 
 
Twenty volunteers, mean (SD) age 45 (16) years, were studied, with at least one female and 
one male participant per age decade. Figure 9 displays each individual’s PECF measurements 
obtained with the Assess, Mini-Wright and SpiroUSB devices. The Assess device was biased 
towards giving the highest PECF readings, and the Mini-Wright was biased towards giving the 
lowest PECF measurements. The ICC (95% CI) was 0.78 (0.47, 0.91) for comparison across all 
three devices; 0.72 (0.07, 0.91) for comparison between the Assess and Mini-Wright devices; 
0.90 (0.77, 0.96) for comparison between the Mini-Wright and SpiroUSB devices; and 0.76 
(0.23, 0.92) for comparison between the SpiroUSB and Assess devices. The median (range) 
coefficient of variation for five consecutive maximal voluntary coughs was 7% (1, 45).  
 
 
Figure 9. Individual peak expiratory cough flow (PECF) measurements from 20 healthy 
volunteers, using three clinical flow measurement devices (Assess peak flow meter, Mini-Wright 
peak flow meter and SpiroUSB spirometer). For each device, the highest PECF value from five 
consecutive maximal volitional cough efforts is shown.  
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The mean differences and 95% limits of agreement for volunteers’ PECF obtained with the 
pneumotachograph and test devices in series are plotted in Figure 10. Bland-Altman analysis 
indicated that the test devices returned on average lower PECF readings than the 
pneumotachograph system. Measurements of PECF were markedly lower using the Mini-Wright 
peak flow meter (mean (95% limits of agreement) bias 56 (-26, 138) L/min), with the difference 
increasing with increasing PECF (Spearman’s rank correlation coefficient rs=0.38, p<0.0001). 
The SpiroUSB also returned PECF readings that were consistently lower than those from the 
pneumotachograph system (mean (95% limits of agreement) bias 50 (-26, 125) L/min). Despite 
a small overall mean (95% limits of agreement) bias of 3 (-76, 82) L/min across the range, 
PECFs measured using the Assess device were lower than the pneumotachograph system at 
low PECF and higher at high PECF (rs=-0.46, p<0.0001). Some coughs with low peak flows 
were not registered by the portable devices and were excluded from the Bland Altman analysis. 
The Mini-Wright and Assess peak flow meters did not register 15 coughs with PECF between 
60 L/min (lowest mark on the devices’ scale) and 118 L/min, as measured by the 
pneumotachograph. Thirty-four coughs with PECF from 89 to 207 L/min were not registered by 
the SpiroUSB spirometer.  
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Figure 10. Bland-Altman plots of the agreement in measuring peak cough flow (L/min) between 
the pneumotachograph measurement system and (a) the Mini-Wright peak flow meter, (b) the 
Assess peak flow meter, and (c) the SpiroUSB spirometer. The difference between two 
measurements (pneumotachograph – second device) is plotted against the mean of two 
measurements. Solid lines indicate the lines of equality (no difference between measurements). 
Three dashed lines indicate the mean difference between measurements (bias) and the upper 
and lower 95% limits of agreement (bias ± 1.96SD).  
 
Correlation analysis to examine the relationship between cough rise time (time from initiation of 
positive flow to peak flow) and the degree of inaccuracy indicated statistically significant weak 
inverse correlations for the Mini-Wright (rs=-0.29, p<0.0001) and the Assess peak flow meter 
(rs=-0.28, p<0.0001); and statistically significant moderate inverse correlations for the SpiroUSB 
spirometer (rs=-0.68, p<0.0001) (Figure 11).  
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Figure 11. Coughs by healthy volunteers: The difference (pneumotachograph – alternative 
device) in measured peak cough flow (L/min) between pneumotachograph and (a) Mini-Wright 
peak flow meter, (b) Assess peak flow meter, and (c) SpiroUSB spirometer is plotted against 




The results for peak flow measurements of mechanically generated flow bursts are presented in 
Table 22 and Figure 12. Example flow-time traces of mechanically generated flow bursts in 
comparison with human cough flow-time traces are given in Figure 13. The Mini-Wright device 
consistently returned the lowest peak flow readings. The Assess and SpiroUSB devices had 
good agreement up to the flow range of about 300 L/min. From 300 L/min upwards, the Assess 
device returned higher measurements than the SpiroUSB device.  
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Table 22. Peak flow measurements of mechanically generated short duration flow bursts 
(simulated ‘coughs’) using three clinical flow measurement devices. 
Test device Flow level (pressure vessel driving pressure, cmH2O) 
1 (5) 2 (10) 3 (15) 4 (20) 5 (30) 6 (40) 
Assess (L/min) 109 ± 2 190 ± 0 253 ± 3 310 ± 0 414 ± 2 554 ± 6 
Mini-Wright (L/min) 80 ± 0 131 ± 2 190 ± 0 232 ± 3 325 ± 0 390 ± 0 
SpiroUSB (L/min) 110 ± 1 192 ± 2 257 ± 1 306 ± 2 384 ± 2 454 ± 3 




Figure 12. Peak flow measurements of mechanically generated short duration flow bursts 
(simulated ‘coughs’) obtained with three clinical flow measurement devices (Assess peak flow 
meter, Mini-Wright peak flow meter and SpiroUSB spirometer) 
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Figure 13. Examples of flow-time plots showing human coughs and mechanically generated 
airflow bursts of corresponding peak flow. (a) Maximally effortful voluntary cough from a healthy 
volunteer (peak cough flow = 666 L/min, rise time = 0.05 sec, volume expelled = 3.5 L). (b) 
Mechanically generated airflow burst (peak flow = 680 L/min, rise time = 0.03 sec, volume 
expelled = 1.6 L). (c) Maximally effortful voluntary cough from a subject with severely weakened 
cough following stroke (peak flow = 120 L/min, rise time = 0.14 sec, volume expelled = 0.4 L). 
(d) Mechanically generated airflow burst (peak flow = 138 L/min, rise time = 0.04 sec, volume 





This study identified potential inaccuracy of considerable magnitude when PECF is measured 
using different clinical flow measurement devices. When compared to a gold standard 
laboratory pneumotachograph based measurement system, the three devices examined were 
inaccurate and returned lower PECF readings. These differences are clinically relevant when 
compared with the magnitude of PECF measurements in clinical populations. In addition, some 
low flow coughs were not registered by these devices, which impacts on their utility in very weak 
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The advantage of a compact, portable and practical clinical flow measurement device over a 
complex pneumotachograph system for the purpose of clinical practice and research is self-
evident. This is particularly true for clinical populations with neuromuscular conditions, where 
mobility and transportation can be problematic. However, it should not be assumed that portable 
peak flow meters and hand-held spirometers are accurate when used for PECF measurement, 
as these devices are designed to measure peak flow during a forced expiratory manoeuvre. In 
measurements of mechanically generated airflow bursts, the portable devices under test 
showed good instrument repeatability, with small standard deviations at each level of flow. It 
could be argued that good instrument repeatability justifies the use of these devices in studies 
with repeated measures designs. However, the accuracy of PECF measurements becomes 
particularly problematic when patients are assessed against absolute thresholds. Clinical 
guidelines cite PECF thresholds of 160 L/min and 270 L/min to direct respiratory care of 
patients with neuromuscular conditions (Hull et al. 2012, Bott et al. 2009, American Thoracic 
Society (ATS) 2004). A scenario can be envisaged whereby the PECF measured for a patient 
could lie on either side of these threshold values, depending on the measurement device used. 
These data highlight the importance of considering which measurement device was used to 
measure PECF when interpreting values.  
 
An added advantage of using a pneumotachograph system for cough flow measurement is that 
the flow-time trace is visualised, and further cough parameters can be derived from the trace, 
i.e. inspired pre-cough lung volume, glottis compression time, rise time and expelled lung 
volume. The latter two are used to compute cough volume acceleration. These parameters may 
provide useful information in addition to PECF. For example, Smith Hammond et al. (2009) 
found that PECF, rise time and cough volume acceleration all correlated with presence of 
aspiration, whereby cough volume acceleration and rise time were stronger predictors than 
PECF. In the study by Pitts et al. (2009), expiratory muscle training in individuals with 
Parkinson’s disease lead to improvements in rise time and cough volume acceleration, but not 
in PECF.  
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The Mini-Wright and Assess peak flow meters have been used previously for PECF 
measurement in clinical studies (Table 21). The Assess peak flow meter (formerly Access 
Model 710, Health Scan Products Inc, Cedar Grove, NJ) was used in the frequently cited clinical 
studies by Bach and collaborators (Bach et al. 1997, Bach & Saporito 1996, Bach 1995), from 
which the current clinical recommendations for PECF thresholds are derived. The SpiroUSB 
spirometer has not previously been used for PECF measurement in any of the clinical studies 
cited here, but a similar turbine-based hand-held spirometer (Spirobank, Medical International 
Research, Rome, Italy) was used in the study by Fiore et al. (2008).  
 
Sancho et al. (2004) and Silverman et al. (2014) have both previously examined the accuracy of 
different portable devices for cough flow testing using repeated maximal cough efforts. This 
method, however, presumes that repeated coughs are sufficiently consistent for intra-subject 
variability to be ignored. Although intra-subject variability may be accounted for by randomising 
the order of devices, and by obtaining repeated measurements within a certain range, for 
example three maximal coughs within 5% PECF as in the study by Sancho et al., intra-subject 
variability due to fatigue, discomfort, motivation, or practice effect remains a limitation of this 
method, especially with increasing number of repetitions. Also, measurements across the mid 
and lower range of potential values may not be assessed conveniently using maximal efforts. In 
the present study, the method was strengthened by connecting devices in series with a 
pneumotachograph and by using mechanically generated ‘coughs’ of consistent peak flow.  
 
Using mechanically generated flow waves, simulating human expiratory flow waves with 
consistent peak flows, has been used previously to test performance characteristics of 
spirometers and peak flow meters (Miller et al. 2005, 2003). Such an approach allows 
comparison of measurement devices without the influence of intra-subject variability or bias due 
to in-series connection of instruments. The mechanical testing system employed in the current 
study produced flow bursts with peak flows and rise times within the range observed in human 
coughs (Sivasothy et al. 2001).  
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In cough, the time to peak flow (rise time) is shorter than during a forced expiratory manoeuvre 
(Miller et al. 2002, Sivasothy et al. 2001). This short rise time may be the critical characteristic 
causing inaccuracies in measurement, as peak flow meters and hand-held spirometers may not 
respond adequately to such a rapid change in signal and ‘miss’ the true peak. Thus, increasing 
inaccuracy could be expected with shorter cough rise time. The data presented here partly 
support this theory. There was a correlation of weak to moderate strength between cough rise 
time and the inaccuracy in PECF in human volunteers. Other factors contributing to differences 
in performance of measurement instruments may be related to the particular geometry of 
devices, and inertia and friction of moving parts. For spirometers, the primary purpose of use is 
the measurement of respiratory volumes (as opposed to flow) for the diagnosis of restrictive or 
obstructive lung disease. Software algorithms correct for inertia of turbine spirometers’ blades to 
achieve optimal accuracy in volume measurements, and this may detract from absolute 
accuracy of peak flow measurements.  
 
In order to advance cough flow measurement in clinical research, recommendations based on a 
consensus statement would be of benefit, similar to those produced for the measurement of 
cough frequency and reflex cough sensitivity (Morice et al. 2007). The frequent use of hand-
held flow measurement devices for PECF assessment in clinical research demonstrates that 
there is a demand for technology that enables scientifically accurate, but also practical and 




In conclusion, the three portable clinical flow measurement devices examined in our study did 
not accurately measure PECF. It was identified that the short rise time in cough contributes to 
some degree to the inaccuracies observed, although other instrument characteristics are likely 
to contribute to differences in instrument performance.  
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It is important to recognise that, depending on the measurement instrument, absolute values of 
PECF reported in the literature may not be directly comparable. Similarly, peak flow meters and 
hand-held spirometers should be used with caution when measuring PECF in clinical practice, 
particularly in the context of using absolute threshold values in clinical decision-making.  
 
Instrument repeatability was shown to be good for the portable devices, which may lead to 
some researchers considering these devices appropriate for studies with repeated measures 
design. However, pneumotachograph systems have the advantage of providing further cough 
parameters in addition to PECF and can therefore be regarded as the preferred measurement 
method.  
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Chapter 5 Randomised controlled trial of respiratory muscle 




Pneumonia is a relevant medical complication in acute stroke patients occurring within the first 
weeks of onset (Hannawi et al. 2013, Teramoto 2009). National Stroke Audit data for England, 
Wales and Northern Ireland, show PSP incidence rates of 16% and 13% in 2008 and 2010, 
respectively (Royal College of Physicians 2011, 2009). PSP patients have a two- to six-fold 
increase in risk of death (Wilson 2012, Finlayson et al. 2011, Koennecke et al. 2011, Tong et al. 
2010, Saposnik et al. 2008, Sellars et al. 2007, Ovbiagele et al. 2006, Hinchey et al. 2005, 
Aslanyan et al. 2004, Heuschmann et al. 2004, Katzan et al. 2003, Vernino et al. 2003) and are 
three to six times more likely to have poor rehabilitation outcomes (Finlayson et al. 2011, 
Koennecke et al. 2011, Hong et al. 2008, Ovbiagele et al. 2006, Aslanyan et al. 2004). Patients 
with PSP are also likely to stay in the acute hospital three times longer than those without 
pneumonia, and require higher levels of care after hospital discharge (Wilson 2012, Finlayson et 
al. 2011, Tong et al. 2010, Christensen et al. 2009, Katzan et al. 2007, Ovbiagele et al. 2006, 
Hinchey et al. 2005).  
 
The risk of PSP increases with increasing level of stroke severity, older age and presence of 
swallowing difficulty (Hoffmann et al. 2012, Shaheen et al. 2012, Finlayson et al. 2011, 
Chumbler et al. 2010, Lakshminarayan et al. 2010, Royal College of Physicians 2009, 
Indredavik et al. 2008, Sellars et al. 2007, Ovbiagele et al. 2006, Hinchey et al. 2005, Martino et 
al. 2005, Aslanyan et al. 2004, Roth et al. 2001, Smithard et al. 1996). Currently, the most 
widely used clinical strategy for preventing PSP is early screening for swallowing difficulties 
coupled with implementation of dysphagia management strategies (Hannawi et al. 2013, 
Ickenstein et al. 2010, Lakshminarayan et al. 2010, Hinchey et al. 2005). Other preventive 
approaches lack evidence and include body positioning, intensive oral hygiene, antibiotic 
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prophylaxis, and ACE inhibitors to improve reflex cough sensitivity (Hannawi et al. 2013, 
Teramoto 2009).  
 
Cough (voluntary and induced) is the most immediate defence mechanism against aspiration 
(Fontana & Lavorini 2006). Cough production requires coordinated activation of respiratory 
muscles (inspiratory and expiratory) and intrinsic laryngeal muscles (Widdicombe et al. 2011) 
and is impaired in acute stroke. Studies comparing acute stroke patients with matched control 
subjects have shown significant reductions in respiratory muscle strength and cough flow for 
both voluntary and reflex cough (Zhou et al. 2012, Yoon et al. 2011, Ward et al. 2010, Harraf et 
al. 2008). It is not known whether respiratory muscle strength or cough flow improve with 
recovery in stroke patients.  
 
RMT aims to improve respiratory performance by loading the respiratory system beyond its 
usual level of functioning, thereby creating a training effect. (Syabbalo 1998, Polkey et al. 1995, 
Reid & Dechman 1995, Goldstein 1993). RMT has been shown to be effective in healthy 
subjects, athletes and patients with cardio-respiratory conditions. A small number of studies 
have investigated RMT in groups with neurological conditions (Pollock et al. 2013) and shown 
that RMT can improve respiratory muscle strength in patients with degenerative neurological 
diseases. The clinical benefit of RMT in stroke patients remains unknown.  
 
5.2 Aims and objectives 
 
The aim of this pilot study was to investigate a respiratory muscle training programme in the first 
weeks after stroke, providing estimates on its magnitude of effect, safety, acceptability and 
feasibility, and informing about the value and design of a large clinical trial. The specific 
objectives were:  
 To determine the magnitude of effect of respiratory muscle training on cough generation, 
respiratory muscle strength, and incidence of pneumonia 
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 To explore the training duration, frequency and intensity required to achieve improvement in 
cough flow rate and inspiratory and expiratory muscle strength 
 To evaluate patient participation, acceptability of study procedures to participants, and 
concordance with training protocol 
 To describe safety parameters and potential adverse effects of respiratory muscle training 
in this patient group 
 To describe characteristics of those patients most likely to gain from the intervention 
 To determine the relevance and feasibility of delivering respiratory muscle training to acute 




5.3.1 Design  
 
This was a single-blind randomised controlled trial with three study groups. Participants were 
randomised to receive inspiratory muscle training, expiratory muscle training, or sham RMT. 
Outcome was assessed at the end of the training period (28 ± 2 days) and at 90 ± 5 days. The 




Patients were recruited at King’s College Hospital, a comprehensive stroke centre in London, 
UK. Participants could be discharged home or transferred to stroke rehabilitation units in local 
hospitals during the study period. Patients received standardised stroke rehabilitation on 
accredited units or from supported discharge teams at home.  
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5.3.3 Participants 
 
Acute haemorrhagic or ischemic stroke patients aged 18 years and above were recruited within 
two weeks of stroke onset. Inclusion criteria were: NIHSS score of 5-25 with motor impairment; 
and ability to give informed consent and follow study procedures. Exclusion criteria were: poorly 
controlled hypertension (blood pressure >180/100 on three or more occasions in 24 hours); 
myocardial infarction, angina or acute heart failure in the preceding three months; pulmonary 
disease including asthma and COPD; neurological conditions other than stroke; and 
orthopaedic conditions adversely affecting the respiratory pump. Written informed consent was 
obtained prior to inclusion and the study was approved by the UK NRES (Wandsworth 
Research Ethics Committee, study reference 10/H0803/32).  
 
5.3.4 Randomisation and treatment allocation 
 
Subjects were randomly allocated after informed consent to the three trial arms on a 1:1:1 
basis. The allocation sequence was concealed in sequentially numbered sealed envelopes, 
which contained the computer-generated randomisation codes. Block randomisation (blocks of 
twelve, containing four participants per study arm) was used to ensure even participant spread 
across the trial groups. Subjects and health care staff were blinded to treatment allocation.  
 
5.3.5 Intervention  
 
The training consisted of respiratory muscle strengthening undertaken daily for four weeks 
using the pressure threshold loading method (Reid & Samrai 1995). Participants were required 
to perform five sets of ten breaths with a one-minute rest in between sets, once daily. 
Participants were breathing in (inspiratory training) or breathing out (expiratory training) against 
resistance through a commercially available hand-held resistance device (Threshold IMT, 
Threshold PEP, Respironics, Parsippany, New Jersey). The training resistance was set at 50% 
of the individual’s maximum inspiratory or expiratory mouth pressure for the inspiratory and 
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expiratory training groups, respectively. Maximal mouth pressures were re-assessed weekly 
and the training resistance re-adjusted to 50% of the measured maximal mouth pressure. 
Participants in the sham training group were also given a training device, with the resistance set 
to an ineffectual 10% of maximal mouth pressure. Participants were instructed in the correct 
training technique during the baseline session. Participants were asked to keep a daily record of 
training and any adverse events. Training technique and completion of the training diary were 
reviewed weekly. 
 
5.3.6 Assessments and outcomes 
 
Baseline assessments included patient demographics and stroke characteristics. Pre-morbid 
functional status was evaluated using the Nottingham Extended Activities of Daily Living 
Questionnaire (NEADL) (Gladman et al. 1993). Swallowing function was described according to 
swallow screens and clinical bedside assessments, which were conducted as part of routine 
acute stroke care (Appendix 2). Respiratory assessments were forced spirometry, maximal 
mouth pressure measurements and cough flow measurements of volitional and capsaicin-
induced reflex cough. These were conducted at baseline, 28 ± 2 days (post-intervention) and 90 
± 5 days (sustainability of training effect). A detailed description of respiratory assessment 
methods is given in chapter 3. Incidence of pneumonia was determined from medically 
documented diagnosis of pneumonia or prescription of antibiotics for pneumonia. Appendix 3 
details the underlying definition of pneumonia adopted for the present study.  
 
The primary outcome measure was PECF of voluntary cough at the end of the intervention 
period (28 ± 2 days). Secondary outcomes were PECF of capsaicin-induced involuntary cough 
and maximal mouth pressures (PEmax, PImax) at 28 ± 2 days.  
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5.3.7 Sample size 
 
Sample size requirements were determined using the nomogram for comparing more than two 
independent samples by Day and Graham (1989). The initial sample size estimate was based 
on an assumed group standard deviation (SD) of 50 L/min for the primary outcome measure 
(voluntary cough PECF), based on a cross-sectional study of acute stroke patients (Ward et al. 
2010). A sample size of 16 subjects per group would give the study 80% power to detect a 50 
L/min difference between groups at the 5% significance level. However, blinded data from the 
first 40 participants not divided by allocation showed PECF standard deviation of 100 L/min. A 
revised sample size calculation revealed that 20 participants per group would be required to 
detect a treatment difference of 90-100 L/min at the 5% significance level and with 80% power. 
Taking into account an attrition rate of 25%, the sample size of the study was increased to 78 
subjects (26 in each group).  
 
5.3.8 Statistical analysis 
 
Descriptive and inferential statistics were used to compare baseline and outcome data between 
the groups. Data are presented as mean (SD), median (IQR), or frequency and percentage (%). 
Baseline characteristics were compared between groups using ANOVA, Kruskal-Wallis, Chi 
squared or Fisher’s exact test as appropriate.  
 
The main inferential analysis strategy was an “intention-to-treat” analysis of the primary and 
secondary outcome measures. An analysis of co-variance (ANCOVA) model was used, 
comparing group means of PECF of voluntary and capsaicin-induced involuntary cough, PEmax 
and PImax at the primary endpoint (day 28 ± 2), and adjusting for sex, age, smoking, stroke 
severity (NIHSS score) and training intensity. Multiple imputation was used to deal with missing 
values (White et al. 2011). In addition, an “on-treatment” analysis was also conducted, which 
included only those participants who remained in the study until the primary endpoint. For this, 
between-group comparisons of group means at the primary endpoint, mean group change 
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scores, and mean change scores expressed as percentage of the baseline value were 
conducted, using ANOVA and Kruskal-Wallis test as appropriate. Within-group comparisons 
from baseline to primary endpoint were conducted using Wilcoxon’s signed ranks test.  
 
Fisher’s exact test was used to compare the incidence of pneumonia from baseline through 
week 4 between the three study groups. Sub-analyses were undertaken, comparing patients 
who completed the study with those who discontinued; and comparing participants with good 
training completion with those with poor training concordance. Training safety data was 
summarised descriptively and compared against pre-set safety parameters (standard safe 
ranges of vital parameters as used in clinical practice).  
 
Data analyses were conducted using Stata statistical software (Stata v12.1, StataCorp, College 




5.4.1 Recruitment and participant flow through the study 
 
1,827 acute stroke patients were screened for eligibility, of whom 191 (10%) were eligible and 
82 (4.5%) consented to participate. For the 1,636 ineligible patients, the main reasons for 
exclusion were NIHSS score <5 on admission (n=725, 44%), unable to give consent or follow 
study procedures (n=342, 21%), transfer to local hospitals in the first 72 hours (n=207, 13%), 
and cardiac problems in the preceding three months or respiratory and neurological conditions 
other than stroke (n=194, 12%). Of the 191 eligible patients, 41 (22%) declined participation in 
the study giving no reason; 37 (19%) thought study procedures were too demanding; 29 (15%) 
were not interested in research participation; and 2 (1%) were concerned about adverse effects. 
Of the 82 consented participants, 63 (77%) completed the primary endpoint (day 28) and 46 
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(56%) completed assessments at 90 days. The Consolidated Standards of Reporting Trials 
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Figure 14. CONSORT flow diagram 
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5.4.2 Baseline characteristics 
 
Participants were comparable across the three study groups. Patient characteristics, stroke 
characteristics and respiratory parameters at baseline showed no differences between the 
groups (Table 23).  
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Table 23. Baseline characteristics according to study group 







Age (years) 65.7 (15.4) 62.5 (14.6) 65.1 (13.9) 0.702 
Males 14 (52%) 17 (65%) 16 (64%) 0.541 
NIHSS score (median, IQR)  7 (5, 12) 8 (6, 11) 8 (6, 12) 0.645 
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Table 23. continued 
Current smoker 6 (22%) 5 (19%) 9 (36%) 0.344 
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Table 23. continued 


















































Figures are mean (SD) and frequency (%), unless stated otherwise 
p-values were calculated using the appropriate parametric (ANOVA) or non-parametric (Kruskal-Wallis test) statistical significance test for continuous data, 
and Chi squared or Fisher’s exact test for categorical data 
BSA, bedside swallowing assessment; CVAC, cough volume acceleration; CVE, cough volume expired; CVI, cough volume inspired; FVC, forced vital 
capacity; FEV1, forced expiratory volume in one second; GCT, glottis compression time; NEADL, Nottingham Extended Activities of Daily Living 
questionnaire; PECF, peak expiratory cough flow; PEF, peak expiratory flow; PEmax, maximal expiratory mouth pressure; PICF, peak inspiratory cough flow; 
PImax, maximal inspiratory mouth pressure 
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5.4.3 Intention-to-treat analysis 
 
Table 24 summarises all available data at the study time points for cough flow and respiratory 
muscle strength outcomes. Figure 15 displays group means over time.  
 
Table 24. Intention-to-treat analysis: cough flow and maximal mouth pressure outcomes at the 
study time points 
 Baseline Primary 





p-values a  
Expiratory training (n=27) 
Voluntary cough PECF (L/min) 























Inspiratory training (n=26) 
Voluntary cough PECF (L/min) 























Sham training (n=25) 
Voluntary cough PECF (L/min) 























Figures are mean (SD) 
a p-values are for within-group comparisons from baseline to primary endpoint and were 
calculated using the Wilcoxon’s signed ranks test with no adjustment for multiple testing 
PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; PImax, 
maximal inspiratory mouth pressure 
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Figure 15. Cough flow and maximal mouth pressure outcomes at the study time points by study 
group. Error bars represent standard error of the mean (SEM).  
 
Intention-to-treat analyses for cough flow and maximal mouth pressure outcomes were 
conducted using an ANCOVA model. Each intervention group was compared against the sham 
training group at the primary endpoint. Missing data were imputed through multiple imputation, 
using predictive model-based imputation (White et al. 2011, StataCorp 2011).  
 
The missing data structure was assessed. Logistic regression was used to assess for potential 
predictors for “missingness”. All predictor variables for “missingness” with p-value <0.1 were 
included in the ANCOVA analysis model, thereby creating missing at random (MAR) conditions.  
 
Multiple imputations were then conducted following the usual step-wise process (imputation and 
analysis). Twenty multiply imputed datasets were generated per outcome (StataCorp 2011). 
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Linear regression was used to generate multiply imputed datasets. All covariates used in the 
eventual ANCOVA model were also included in the generation of imputed values. Summary 
statistics for selected imputations were compared and no obvious abnormalities were noted.  
 
In the analysis step, which combines complete-data analyses and pooling of complete-data 
analyses, ANCOVA was conducted using pre-determined independent variables (baseline level 
of the outcome variable, study group, sex, age, baseline level of peak expiratory flow, stroke 
severity at admission, and training intensity). Outcome variables were transformed using the 
natural logarithm function to meet model assumptions of normal distribution. Results are 
summarized in Table 25, with regression coefficients, standard errors and 95% confidence 
intervals presented at the transformed level of the outcome variables.  
 
ANCOVA analysis showed no statistically significant treatment effect of either expiratory or 
inspiratory training when compared with sham RMT. One single comparison (involuntary PECF 
in the inspiratory training group) showed a statistically significant p-value. However, with 
adjustment for multiple testing this p-value becomes non-significant.  
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Table 25. Intention-to-treat analysis comparing intervention groups to the sham training group, using analysis of co-variance (ANCOVA) and multiple imputation 
through predictive model-based imputation for missing data. To meet model assumptions, data were transformed using the natural logarithm function (ln). 
Regression coefficients, standard errors and confidence intervals are presented at the level of the transformed scale.  
Outcome 
parameter 




Coef.  SE t-statistic p-value 95% CI 
Voluntary cough 
PECF (ln(L/min)) 
n=78 (55 complete, 23 
imputed) 
Imputations: 20 
Average RVI: 0.5183 
Largest FMI: 0.5026 
Complete DF: 69 
DF min: 24.60 
DF avg: 37.33 
DF max: 53.41 




-0.091 0.078 -1.17 0.246 -0.247, 0.064 
Inspiratory 
training 




n=74 (54 complete, 20 
imputed) 
Imputations: 20 
Average RVI: 0.5319 
Largest FMI: 0.5666 
Complete DF: 65 
DF min: 20.10 
DF avg: 34.27 
DF max: 43.99 




-0.113 0.100 -1.14 0.263 -0.316, 0.089 
Inspiratory 
training 
-0.194 0.094 -2.05 0.046 -0.384, -.003 
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Table 25. continued 
PEmax 
(ln(cmH2O)) 
n=78 (61 complete, 17 
imputed) 
Imputations: 20 
Average RVI: 0.4212 
Largest FMI: 0.4108 
Complete DF: 70 
DF min: 31.07 
DF avg: 41.14 
DF max: 48.45 




0.038 0.099 0.38 0.706 -0.162, 0.237 
Inspiratory 
training 
0.085 0.104 0.82 0.419 -0.125, 0.295 
PImax 
(ln(cmH2O)) 
n=78 (61 complete, 17 
imputed) 
Imputations: 20 
Average RVI: 0.4218 
Largest FMI: 0.5518 
Complete DF: 69 
DF min: 21.74 
DF avg: 41.19 
DF max: 56.77 
F (8, 62.5) = 26.87 
Expiratory 
training 
-0.144 0.091 -1.58 0.120 -0.327, 0.039 
Inspiratory 
training 
0.070 0.096 0.73 0.470 -0.123, 0.263 
PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; PImax, maximal inspiratory mouth pressure 
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5.4.4 On-treatment analysis 
 
On-treatment (complete case) analyses were conducted for participants who remained in the 
study from baseline to primary endpoint (day 28 ± 2). Within-group and between-group 
comparisons are shown in Tables 26 and 27, respectively. There were no statistically significant 
differences in between-group comparisons of outcome parameters expressed as group means 
at the primary endpoint, group mean changes from baseline to primary endpoint, and change as 
percentage of the baseline value. Within-group comparison showed statistically significant 
improvements for all outcomes but PECF of involuntary cough. For the entire sample, 
improvements in PECF of voluntary cough, PEmax and PImax were highly significant with p-
values of 0.0002, <0.0001 and <0.0001, respectively.   
 
Table 26. On-treatment analysis: within-group comparison of change (day 28 – baseline) in 
cough flow and respiratory muscle strength from baseline to primary endpoint 
  Group 











Change in voluntary cough 
PECF (L/min) 
74 (150) 49 (121) 91 (184) 84 (146) 
p-value a 0.0002 0.135 0.010 0.016 
Change in involuntary cough 
PECF (L/min) 
14 (95) 17 (83) -4 (121) 32 (76) 
p-value a 0.328 0.469 0.586 0.124 
Change in PEmax (cmH2O) 15 (18) 12 (15) 20 (20) 12 (18) 
p-value a <0.0001 0.003 0.0006 0.0071 
Change in PImax (cmH2O) 14 (16) 10 (12) 18 (20) 14 (15) 
p-value a <0.0001 0.0018 0.0004 0.0002 
Figures are mean (SD) 
a p-values were calculated using the Wilcoxon’s signed ranks test with no adjustment for 
multiple testing 
PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; PImax, 
maximal inspiratory mouth pressure 
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Table 27. On-treatment analysis: between-group comparison of group means at the primary 
endpoint, group mean changes (day 28 – baseline) and group mean changes expressed as 









Voluntary cough     
PECF at day 28 
(L/min) 
556 (274) 552 (366) 656 (321) 0.47 
Change in PECF (day 
28 – baseline, L/min) 
49 (121) 91 (184) 84 (146) 0.46 
Percentage change 
from baseline (%) 
20 (22) 32 (34) 23 (25) 0.37 
Reflex cough     
PECF at day 28 
(L/min) 
317 (129) 301 (182) 310 (104) 0.42 
Change in PECF (day 
28 – baseline, L/min) 
17 (83) -4 (121) 32 (76) 0.41 
Percentage change 
from baseline (%) 
9 (26) -2 (33) 18 (29) 0.14 
PEmax     
PEmax at day 28 
(cmH2O) 
80 (31) 70 (34) 80 (40) 0.59 
Change in PEmax 
(day 28 – baseline, 
cmH2O) 
12 (15) 20 (20) 12 (18) 0.35 
Percentage change 
from baseline (%) 
32 (46) 47 (52) 26 (41) 0.37 
PImax     
PImax at day 28 
(cmH2O) 
55 (33) 60 (34) 65 (30) 0.47 
Change in PImax (day 
28 – baseline, cmH2O) 
10 (12) 18 (20) 14 (15) 0.30 
Percentage change 
from baseline (%) 
38 (50) 55 (56) 34 (42) 0.37 
Figures are mean (SD), a p-values were calculated using ANOVA or Kruskal-Wallis test as 
appropriate; PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; 
PImax, maximal inspiratory mouth pressure 
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5.4.5 Incidence of pneumonia 
 
Table 28 shows the cumulative incidence of pneumonia by day 28 for all participants who 
remained in the study until the primary endpoint, and there was no statistically significant 
difference between the study groups. As participants who discontinued the study were not 
followed up for the incidence of pneumonia, intention-to-treat analysis was conducted through a 
sensitivity analysis of four extreme possible outcomes: (a) none of the participants who dropped 
out developed pneumonia; (b) all participants who dropped out developed pneumonia; (c) none 
of the participants who dropped out in the sham training group developed pneumonia, and all of 
those who dropped out in the intervention groups did (negative effect of the interventions on 
pneumonia rates); and (d) all of the participants who dropped out in the sham training group 
developed pneumonia, and none of those who dropped out in the intervention groups did 
(positive effect of the interventions on pneumonia rates). These scenarios are summarised in 
Table 29. In none of the scenarios the p-value is statistically significant.  
 
 
Table 28. Number of participants developing pneumonia according to study group, only 
including participants who remained in the study until the primary endpoint. Fisher’s exact test 
shows no statistically significant difference between the study groups (p =1.0).  
 No Pneumonia by day 28 Pneumonia by day 28 Total 
Expiratory 
training 
18 (86%) 3 (14%) 21 
Inspiratory 
training 
19 (90%) 2 (10%) 21 
Sham training 18 (86%) 3 (14%) 21 
Total 55 (87%) 8 (13%) 63 
Figures are number of participants (percentage of row total) 
 
Table 29. Sensitivity analysis of cumulative pneumonia incidence by day 28. Four extreme 
scenarios are compared.  
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Scenario (a) none of the participants who dropped out developed pneumonia, p=0.902 
 No Pneumonia by day 28 Pneumonia by day 28 Total 
Expiratory training 26 (90%) 3 (10%) 29 
Inspiratory training 25 (93%) 2 (7%) 27 
Sham training 23 (88%) 3 (12%) 26 
Total 74 (90%) 8 (10%) 82 
    
 
Scenario (b) all participants who dropped out developed pneumonia, p=0.836 
 No Pneumonia by day 28 Pneumonia by day 28 Total 
Expiratory training 18 (62%) 11 (38%) 29 
Inspiratory training 19 (70%) 8 (30%) 27 
Sham training 18 (69%) 8 (31%) 26 
Total 55 (67%) 27 (33%) 82 
    
 
Scenario (c) none of the participants who dropped out from the sham training group developed 
pneumonia, and all participants who dropped out from the intervention groups did, p=0.070 
 No Pneumonia by day 28 Pneumonia by day 28 Total 
Expiratory training 18 (62%) 11 (38%) 29 
Inspiratory training 19 (70%) 8 (30%) 27 
Sham training 23 (88%) 3 (12%) 26 
Total 60 (73%) 22 (27%) 82 
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Table 29. continued 
 
Scenario (d) all participants who dropped out from the sham training group developed 
pneumonia, and none of the participants who dropped out from the intervention groups did, 
p=0.060 
 No Pneumonia by day 28 Pneumonia by day 28 Total 
Expiratory training 26 (90%) 3 (10%) 29 
Inspiratory training 25 (93%) 2 (7%) 27 
Sham training 18 (69%) 8 (31%) 26 
Total 69 (84%) 13 (16%) 82 
    
Figures are number of participants (percentage of row total) 
p-values were calculated using Fisher’s exact test 
 
 
5.4.6 Treatment concordance and impact on outcomes 
 
Table 30 presents details of training frequency by study group. There was wide variation in how 
often participants trained, from those who completed the training as prescribed (28 days, 140 
sets, 1,400 breaths) to those who trained minimally (only when prompted by the investigator 
during follow-up visits). Across the entire sample, the median (IQR) number of training days was 
17 (6, 24), and the median (IQR) number of training breaths was 803 (250, 1,150).  
 
Baseline characteristics were compared for those participants who had high training 
concordance (who trained half or more of the prescribed training breaths, n=42) and low training 
concordance (who trained less than half of the prescribed training breaths, n=21). Participants 
who trained more were generally more able from the start. Although both groups had median 
NIHSS scores of 8, those who trained more were younger (mean age 62 versus 68 years), had 
somewhat better pre-morbid function (median NEADL score 63 versus 53), and better 
respiratory parameters throughout (for example mean PECF of voluntary cough 530 L/min 
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versus 394 L/min). Cough flow and respiratory muscle strength outcomes were compared for 
participants who trained more and participants who trained less (Table 31).  
 
 








Days from onset of stroke 
to baseline assessment 
7 (4, 11) 6 (3, 9) 7 (3, 10) 0.577 
Days trained a 17 (6, 27) 17 (9, 22) 16 (5, 25) 0.871 
Breaths trained b 806 (300, 1,303) 799 (260, 1,050) 800 (230, 1,215) 0.583 
Training completion (mean 
(SD) percentage of 
maximum prescribed) 
56 (36) 48 (32) 52 (37) 0.664 
Figures are median (IQR) unless stated otherwise 
p-values were calculated using ANOVA and Kruskal-Wallis test as appropriate 
a maximum prescribed: 28 days 
b maximum prescribed: 1,400 breaths 
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Table 31. Group means and mean change for cough flow and respiratory muscle strength 
outcomes in participants who trained half or more (700+ breaths) of the prescribed repetitions 
compared with participants who trained less than half (<700) of the prescribed repetitions 






PECF at day 28 (L/min) 
Change in PECF (day 











PECF at day 28 (L/min) 
Change in PECF (day 










Maximal mouth pressures 








Change in PEmax (day 
28 – baseline, cmH2O) 
18 (20) 9 (13) 0.102 
PImax at day 28 
(cmH2O) 
68 (34) 44 (22) 0.006 
Change in PImax (day 
28 – baseline, cmH2O) 
15 (18) 12 (11) 0.732 
Figures are mean (SD) 
PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; PImax, 
maximal inspiratory mouth pressure 
p-values were calculated using the Mann-Whitney U test with no adjustment for multiple testing 
 
 
5.4.7 Training safety and adverse events 
 
Vital parameters before and after respiratory training for the entire study sample are listed in 
Table 32. Sample means of blood pressure, heart rate and oxygen saturation remained stable 
before and after respiratory muscle training, although individual participants did show 
fluctuations in measurements. Measurements were compared with standard safe reference 
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ranges for these parameters, as used in clinical practice (safe range for systolic blood pressure 
110-130 mmHg; diastolic blood pressure <105 mmHg; heart rate 60-120 bpm; oxygen 
saturation >90%). Reports of subjective symptoms were recorded, in particular of headache, 
chest pain, or overall strain.  
 
Altogether, vital parameters were monitored in 254 training session. Where vital parameters 
were outside the safe reference ranges, they were within the individual medically accepted 
range for the person and stable before and after training, and participants did not report any 
training-related subjective adverse symptoms.  
 
In one single case, an increase in blood pressure from 140 mmHg before training to 187 mmHg 
after training (EMT) was observed. This participant also reported subjective strain and 
discomfort in the region of both temples. Blood pressure and subjective symptoms resolved 
within minutes of discontinuing training. This participant was withdrawn from the study, and the 
episode was recorded as a significant adverse event related to the study intervention.  
 
Other observations recorded as minor adverse events and unrelated to study procedures were 
headache and general fatigue. Observations recorded as minor adverse events and related to 
study procedures were: fatigue after training (within acceptable range for an acute exercise 
intervention); and light-headedness after training (resolved by increasing the number of pauses 
between training breaths).  
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Table 32. Vital parameters taken immediately before and after training. Parameters were 
measured at baseline and in weekly investigator visits.  








 Pre Post Pre Post Pre Post Pre Post 
Baseline 
(n=78) 
132 (19) 132 (20) 81 (13) 82 (13) 76 (14) 75 (13) 96 (2) 96 (2) 
Day 7 
(n=66) 
125 (19) 124 (16) 80 (11) 81 (12) 76 (12) 76 (13) 97 (2) 97 (2) 
Day 14 
(n=59) 
126 (17) 124 (15) 79 (13) 78 (12) 74 (13) 76 (13) 96 (2) 97 (2) 
Day 21 
(n=51) 
128 (17) 129 (16) 81 (11) 83 (10) 74 (13) 73 (14) 96 (2) 96 (2) 
Figures are mean (SD) 
 
 
5.4.8 Between-group comparison of area under the curve for respiratory muscle 
strength outcomes 
 
Weekly measurements of maximal mouth pressures were analysed using area under the curve 
(AUC) and time of maximum (Tmax) as summary measures. The rationale was that groups may 
not differ when compared with respect to their change from baseline to primary endpoint (day 
28±2); but that the improvement in maximal mouth pressures seen across all groups may have 
set in earlier in the intervention groups, thereby providing improved respiratory function and 
protection from aspiration earlier than in the control group. Maximal mouth pressure 
measurements were made weekly during the intervention period.  
 
All participants who remained in the study until the primary endpoint were included in this 
analysis (n=63). Forty-five missing observations (all follow-up sessions at weeks one, two or 
three) were imputed by using the lower of the preceding or following available observation, 
thereby giving a conservative method of single imputation. The results are presented in Table 
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33. There were minor differences between the groups in AUC and Tmax, none of which were 
statistically significant.  
 
Table 33. Between-group comparison of area under the curve (AUC) and time to maximum 
(Tmax) for expiratory and inspiratory mouth pressures 









PEmax      
AUC 294 (144) 297 (120) 253 (140) 0.51 0.26 
Tmax (week) 2.3 (1.5) 2.8 (1.5) 2.8 (1.3) 0.38 0.34 
      
PImax      
AUC 229 (114) 199 (126) 206 (125) 0.70 0.53 
Tmax (week) 3.2 (1.2) 3.1 (1.4) 3.0 (1.3) 0.89 0.80 
      
Figures are mean (standard deviation) and number of observations 
ANOVA, analysis of variance; AUC, area under the curve; PEmax, maximal expiratory mouth 
pressure; PImax, maximal inspiratory mouth pressure; Tmax, time of maximum  
 
 
5.4.9 Correlation between training frequency, change in cough flow and change in 
respiratory muscle strength 
 
Correlation analysis (Spearman’s rank correlation coefficient) was conducted to explore in how 
far training frequency (total number of training breaths) was correlated with change in cough 
flow and respiratory muscle strength. Correlation was examined for absolute change in outcome 
and for percentage change from baseline. The findings are summarised in Table 34.  
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The correlations observed are of weak to moderate strength, for both absolute change on 
outcome and percentage change from baseline. The highest correlation is with voluntary cough 
PECF in the sham group (rs=0.42), but this is not statistically significant. The only statistically 
significant correlation is with change in voluntary cough PECF for the entire sample (rs=0.30; 
p=0.021).  
 
 - 163 - 
Table 34. Correlation between training frequency (total number of training breaths) and 
outcomes  
  Group 




Change in voluntary 










Voluntary cough PECF 










     
Change in involuntary 










Involuntary cough PECF 










     
Change in PEmax (day 




















     
Change in PImax (day 




















     
Figures are Spearman’s rank correlation coefficient, number of observations, and p-values (with 
no adjustment for multiple testing) 
PECF, peak expiratory cough flow; PEmax, maximal expiratory mouth pressure; PImax, 
maximal inspiratory mouth pressure 
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5.4.10 Pooled analysis of outcome respiratory muscle strength including previous 
research 
 
In order to increase the power of analysis, data from the present study was pooled with findings 
from two previous randomised controlled trials of RMT in subacute and chronic stroke patients, 
in which maximal mouth pressure outcomes (PImax, PEmax) were reported (Britto et al. 2011, 
Sutbeyaz et al. 2010). These findings were combined in a random effects meta-analysis using 
non-standardised effect sizes. Data were pooled according to two assumptions: (a) assuming 
that both inspiratory (IMT) and expiratory (EMT) muscle training could lead to improvements in 
either PImax, PEmax or both (Figure 16); and (b) assuming that the outcome should correspond 
with the direction of training, combining studies of inspiratory muscle training (IMT) for outcome 
PImax, and studies of expiratory muscle training (EMT) for outcome PEmax (Figure 17).  
 
These pooled analyses increased the overall sample size. An overall trend towards improved 
respiratory muscle strength with RMT is shown, more so for outcome PImax; however, this is 
not statistically significant and the intervention effect can be described as modest in absolute 
terms  
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Figure 16. Random effects meta-analysis, assuming that both inspiratory (IMT) and expiratory 
(EMT) muscle training could lead to improvements in either PImax, PEmax, or both 
 
 
























Sutbeyaz 2010, n (IMT) = 15, n (control) =15
Outcome PImax (cmH2O)
Britto 2011, n (IMT) = 9, n (control) = 9
Kulnik, n (IMT) = 21, n (control) = 21
Kulnik, n (EMT) = 21, n (control) = 21
Outcome PEmax (cmH2O)
Sutbeyaz 2010, n (IMT) = 15, n (control) = 15
Kulnik, n (IMT) = 21, n (control) = 21
Kulnik, n (EMT) = 21, n (control) = 21
Difference in mean change score
non-standardized
Subtotal (I-squared = 64.4%, p = 0.038)
Subtotal (I-squared = 11.8%, p = 0.322)
Overall (I-squared - 69.2%, p = 0.003)
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Difference in mean change score
Sutbeyaz 2010 , n (IMT) = 15, n (control) = 15
Britto 2011, n (IMT) = 9, n (control) = 9
Kulnik, n (IMT) = 21, n (control) = 21
Kulnik, n (EMT) = 21, n (control) = 21
non-standardized
Subtotal (I-squared = 49.8%, p = 0.136)
Subtotal (I-squared = .%, p = .)
Overall (I-squared = 40.5%, p = 0.169)
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Figure 17. Random effects meta-analysis, combining studies of inspiratory muscle training 




This study showed that peak expiratory flow of voluntary cough and maximal inspiratory and 
expiratory mouth pressures improved in the first 4 weeks after acute stroke onset, but there 
were no changes in peak expiratory flow of involuntary cough. A standardised programme of 
inspiratory or expiratory RMT delivered for 4 weeks did not significantly add to the extent or 
speed of recovery of respiratory muscle strength or cough flow. Although RMT was safe in 
acute stroke patients it had low eligibility (10% of patients screened), participation (43% of 
eligible patients consented) and concordance (33% of patients completed less than 50% of 
training).  
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The variability in training concordance may be interpreted as both a limitation and strength of 
the present study. On the one hand, from the point of view of internal validity, it is desirable that 
the intervention under investigation is carried out ‘as prescribed’. Full concordance with the 
training protocol would increase confidence in the conclusion that there was lack of effect (or, 
conversely, confidence in the conclusion that there was a positive treatment effect, if such an 
effect were observed). Additional measures could have been taken in the present study to 
maximise participants’ adherence to the intervention, such as daily visits or reminder phone 
calls by the investigator. On the other hand, from the point of view of external validity and from a 
pragmatic standpoint, concordance with active training and exercise interventions in real-life 
clinical practice is variable; and staff resources to supervise or prompt adherence to prescribed 
exercise are limited. Adherence to prescribed training as observed in the present study is likely 
to represent the clinical reality in NHS settings. Therefore, the findings from the present study 
have greater external validity and generalisability to this clinical environment than if additional 
measures for maximising adherence had been incorporated in the study protocol. 
 
The rate of participant recruitment and attrition observed in this study highlights the challenge of 
conducting this type of research, which is set in the intense and fast-paced clinical care pathway 
of acute stroke; involves active engagement of participants in addition to the often already 
dense schedule of medical, therapy and other clinical activities; and investigates an aspect of 
stroke that may not intuitively seem relevant to potential participants. From a practical viewpoint, 
the three strategies that clearly facilitated participant recruitment and retention were: (i) the 
provision of transportation free of charge for participants to attend study appointments; (ii) the 
option to bring testing equipment to participants, to conduct measurements at their location 
(collaborating hospital site, participants’ homes); and (iii) flexibility of the investigator to carry out 
study procedures during clinical ‘down time’, for example in the evenings or on weekends. 
 
The intervention as applied in this study can be considered safe in acute stroke patients. It is 
recommended that the first training session is conducted under the supervision of an 
appropriately trained health care professional to adjust the appropriate level of resistance, 
advise on correct technique and observe for any adverse effects. The cost of delivering RMT in 
 - 168 - 
the acute phase of stroke may vary. Table 35 lists relevant cost considerations. The assumption 
is that RMT is provided as a routine intervention to all eligible patients with the purpose of 
preventing pneumonia. As one worked example, one could consider the running cost (excluding 
overheads and staff training costs) of RMT for a patient who is provided with one device, 
instructed in its use for 15 minutes by a junior grade nurse, and then asked to continue training 
independently without further staff supervision. The estimated cost would be GBP 9.99- (unit 
cost) plus GBP 2.7- (staff time, based on lowest pay point of the basic Band 5 Agenda for 
Change pay rate, rates as of 1 April 2014) (NHS Careers, no date), totalling an estimated cost 
of GBP 12.69- per patient. As an alternative example, one could consider the running cost of 
RMT for a patient who is provided with one device, instructed in its use by a junior 
physiotherapist for 15 minutes, and is subsequently seen daily for 10 minutes by a healthcare 
assistant for supervised/assisted training over four weeks. The estimated cost would be GBP 
9.99- (unit cost), plus GBP 2.7- (Band 5 physiotherapist time, pay point as above), plus GBP 
45.00- (health care assistant time, based on lowest pay point of the basic Band 4 Agenda for 
Change pay rate, rates as of 1 April 2014), totalling an estimated cost of GBP 57.69- per 
patient.  
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Table 35. Cost considerations for delivering respiratory muscle training (RMT) in the acute 
phase of stroke 
Cost Considerations 
Unit cost of the training 
device 
Unit cost may vary, depending on the particular terms negotiated with 
the manufacturer. For the present study, the individual unit price was 
GBP 9.99- for both the Threshold IMT and the Threshold PEP 
devices, excluding freight and VAT.  
Administrative costs of 
purchasing, storing and 
distributing the devices 
Depending on current systems, the administration of purchase and 
storage of devices may create additional cost, or may be absorbed 
by existing systems.  





Based on the experiences of the investigator, two possible scenarios 
of delivering the RMT training protocol used in this study in the acute 
phase of stroke could be envisaged (applicable to an inpatient 
setting, i.e. stroke unit or bedded rehabilitation unit):  
(a) A staff member issues the device and instructs and supervises 
the patient once in using the device. The patient is then 
encouraged to continue with training daily, but no further staff 
time is afforded to supervise or assist with the intervention. The 
estimated staff time requirement would be between 10-30 
minutes, depending on the needs of the patient.  
(b) In addition to (a), staff members provide daily prompting and 
supervision with the training intervention. Staff time requirements 
could vary between an estimated 5-15 minutes daily in an 
inpatient setting, depending on patient needs.  
The cost of staff time will also depend on the staff grade. As a simple 
intervention, RMT could, for example, be administered by a junior 
grade nurse or physiotherapist; or an appropriately trained health 
care assistant or therapy assistant.  
Cost of staff training Training costs are to be considered, which includes training for all 
staff on a unit for familiarisation with a newly introduced intervention; 
and in-depth training for staff members who distribute RMT devices 
and instruct and supervise patients in its use. Costs will vary, 
depending on the number of staff members involved and staff 
turnover on the unit.  
GBP, Pound Sterling; IMT, inspiratory muscle trainer; PEP, positive expiratory pressure; RMT, 
respiratory muscle training; VAT, value added tax 
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In this exploratory study, PECF was used as a surrogate marker for effective cough, which is an 
important defence against aspiration and PSP (Fontana & Lavorini 2006). Inspiratory muscle 
training was aimed at facilitating effective cough by increasing pre-cough lung volume, thus 
enabling the generation of higher expiratory cough flow. Expiratory muscle training was aimed 
at increasing expiratory driving pressure, resulting in higher expiratory cough flow. In previous 
clinical research, RMT was investigated with respect to various physiological and functional 
outcomes, such as respiratory muscle strength, respiratory muscle endurance, subjective 
perception of dyspnoea, lung function, exercise tolerance, ambulation, functional independence 
in daily living and health-related quality of life. In the present study, the ultimate clinical objective 
of RMT was to reduce PSP in the first few weeks after stroke. This exploratory study was not 
powered to show, and did not show, an effect on PSP incidence after stroke. A randomised 
controlled trial to show a 5% decrease in PSP would require 828 patients to have 80% power at 
the 5% significance level based on data from this study and using pair-wise comparisons (Chow 
et al. 2008) Taking into account an attrition rate of approximately 25% and a participation rate of 
<5%, over 22,000 acute stroke admissions would need to be screened for eligibility, which may 
not be feasible, even as a multicentre study. Given the lack of effectiveness of RMT to alter the 
physiological variables on which the assumption of PSP prevention is based, undertaking such 
a study may be regarded as futile.  
 
The small sample size in the present study is a limitation, but the power of analysis was 
increased by applying strict inclusion criteria, increasing the sample size following interim 
analysis of the observed variations in the primary outcome and undertaking pooled analysis. 
Variable training concordance is a potential source of bias, but neither comparison based on 
training intensity nor sensitivity analysis showed significant differences in outcomes. Correlation 
analysis of training concordance with training effects showed weak correlations. Although the p-
values were largely non-significant, this suggests that the number of training breaths did not 
considerably influence the change in outcomes observed. This lends further support to the 
overall interpretation of the findings that the investigated training intervention did not show any 
effect in improving these outcomes. Missing data, confounding due to non-significant 
differences in baseline prognostic variables and multiple testing are sources of potential 
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statistical bias, but these were minimised by using regression with predictive model-based 




With respect to the study aim, it can be concluded that RMT delivered at the frequency and 
intensity as applied in this study was not effective in increasing peak expiratory flow of voluntary 
and reflex cough or expiratory and inspiratory maximal mouth pressures when compared with 
sham respiratory muscle training. Training concordance varied widely and is acknowledged as a 
limitation to the study. However, it is suggested that this reflects adherence to prescribed 
exercise in real life clinical practice, thereby giving the study greater external validity than if 
additional measures for maximising concordance had been incorporated.  
 
RMT delivered at the frequency and intensity as applied in this study can be considered a safe 
and generally well tolerated intervention in acute stroke patients who do not have raised intra-
cranial pressure or acute cardiac conditions. RMT did not affect participants’ vital parameters, 
except in one case where the participant became hypertensive and experienced subjective 
discomfort after training. Several participants experienced light-headedness during or after 
RMT, which was related to hyperventilation and resolved with increasing number of rests 
between breaths. It is therefore recommended that the first session of RMT is supervised by an 
appropriately trained health professional to observe for potential adverse effects and to adjust 
the training procedure to avoid light-headedness.  
 
Due to the lack of demonstrable intervention effect, it was not possible to identify a specific 
subpopulation of stroke patients who are likely to gain from the intervention as delivered in this 
study. For researchers who are interested in continuing this type of research, we suggest that 
the target population should be those acute stroke patients who (i) are identified as being at risk 
of aspiration (i.e. have an unsafe swallow); and (ii) have low voluntary cough flow values, 
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predisposing them to an increased risk of pneumonia and giving adequate scope for 
physiological improvement in cough flow (From the data observed, we would recommend an 
estimated upper threshold of approximately 500 to 600 L/min). Narrowing the inclusion criteria 
accordingly would impact on the number of eligible participants and therefore the feasibility and 
timescales of any such research project.  
 
RMT, as delivered in this study, was found to be a relatively safe and low-cost intervention, and 
therefore, from a practicality standpoint, its implementation within the NHS stroke care pathway 
would be feasible. At this time, based on the evidence available from this and other studies, 
RMT is not considered a relevant treatment intervention in the acute care of stroke patients. 
Further research of RMT in stroke might be warranted.  
 
To conclude, this study shows that although RMT is safe in acute stroke patients, only a small 
number of incident stroke patients are eligible, will participate and be concordant with 
respiratory muscle training protocols. As these have no significant effect on increasing muscle 
strength or cough effectiveness, RMT is unlikely to make a clinically meaningful difference in 
reducing PSP in acute stroke patients. Hence, further trials of RMT with the clinical endpoint of 
PSP prevention may not be warranted.  
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Chapter 6 Relationship between cough flow and incidence of 




The association between impaired swallow and increased risk of pneumonia in stroke patients 
is well established (Ickenstein et al. 2010, Lakshminarayan et al. 2010, Hinchey et al. 2005, 
Martino et al. 2005), and studies show a five- to eleven-fold increase in risk of PSP with 
dysphagia and aspiration (Martino et al. 2005).  
 
The occurrence of PSP depends not only on aspiration but also on the integrity of mechanical 
and immunological defense mechanisms (Hannawi et al. 2013; Teramoto 2009). Of these, 
cough is the most immediate and important defense against the development of PSP in stroke 
patients with aspiration (Widdicombe et al. 2011). Studies show that voluntary and reflex cough 
are both significantly impaired in acute stroke patients (Zhou et al. 2012, Yoon et al. 2011, Ward 
et al. 2010, Harraf et al. 2008). Reduced or absent reflex cough sensitivity has been shown to 
be associated with higher incidence of PSP (Masiero 2008, Addington et al. 2005, 1999a, Holas 
1994). Expiratory cough flow, however, has not been examined as a risk factor for PSP in acute 
stroke. Figure 18 gives a schematic of the current available evidence on the interactions 
between swallow, pneumonia and cough in stroke, including studies demonstrating an 
association between degree of swallowing impairment and reduction in cough flow (Kimura et 
al. 2013, Smith Hammond et al. 2009, 2001).  
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Figure 18. Inter-relationships between swallow, cough and pneumonia and studies examining 
the respective two-way interactions in stroke populations.  
 
 
The aim of the present study was to explore the relevance of PECF as a predictor/mediator in 
the relationship between swallowing impairment and pneumonia in acute stroke. The hypothesis 
was that higher PECF would be protective against the risk of PSP in acute stroke patients with 
swallowing problems. The specific objectives were:  
 To investigate the association between PECF of voluntary and induced reflex cough, and 
the development of PSP in stroke patients stratified by swallowing status.  
 To quantify the interaction between PECF, aspiration risk and pneumonia risk.  
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6.2 Methods 
 
6.2.1 Design  
 
This was an exploratory study of PECF as a predictor variable for pneumonia incidence in 
stroke. A secondary analysis was conducted, using data from a randomised controlled trial of 
RMT in stroke (study reference ISRCTN40298220) (chapter 5). For the purpose of this study, 
the data structure assumed was that of a prospective longitudinal observational study for 




Participants were recruited at King’s College Hospital, a comprehensive stroke centre in 
London, UK. Participants could be discharged home or transferred to stroke rehabilitation units 
in local hospitals during the study period. Patients received standardised stroke rehabilitation on 
accredited units or from supported discharge teams at home.  
 
6.2.3 Participants  
 
Acute haemorrhagic or ischemic stroke patients aged 18 years and above were recruited within 
two weeks of stroke onset. Inclusion criteria were: NIHSS score of 5-25 with motor impairment; 
and ability to give informed consent and follow study procedures. Exclusion criteria were: poorly 
controlled hypertension (blood pressure >180/100 on three or more occasions in 24 hours); 
myocardial infarction, angina or acute heart failure in the preceding three months; pulmonary 
disease including asthma and COPD; neurological conditions other than stroke; and 
orthopaedic conditions adversely affecting the respiratory pump. Written informed consent was 
obtained prior to inclusion and the study was approved by the UK NRES (Wandsworth 
Research Ethics Committee, study reference 10/H0803/32).  
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6.2.4 Baseline assessments  
 
Baseline assessments were conducted within 2 weeks of stroke onset and included patient 
demographics, stroke characteristics and respiratory parameters. Swallowing function was 
described according to swallow screens and clinical bedside assessments, which were 
conducted as part of routine acute stroke care (Appendix 2). Respiratory assessments at 
baseline were forced spirometry, maximal mouth pressure measurements and cough flow 
measurements of volitional and capsaicin-induced reflex cough. A detailed description of 
respiratory assessment methods is given in chapter 3.  
 
6.2.5 Outcome assessment 
 
The outcome of interest was incidence of pneumonia, which was observed for four weeks 
following baseline assessment and determined from medically documented diagnosis of 
pneumonia or prescription of antibiotics for pneumonia.  
 
6.2.6 Sample size 
 
The study was a secondary analysis of available clinical trial data. No prospective sample size 
calculation was conducted with respect to the statistical analyses presented here.  
 
6.2.7 Statistical analysis 
 
The statistical analysis approach was hypothesis-driven, examining only the predictor PECF of 
voluntary and reflex cough according to aspiration risk. First, the sample was stratified 
according to aspiration risk, into those with safe swallow (low risk of aspiration) and those with 
unsafe swallow (high risk of aspiration). Predictor (PECF) and outcome variables (pneumonia 
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incidence) between the two groups were compared using the appropriate test for comparison of 
independent samples.  
 
Second, statistical methods for diagnostic accuracy (receiver-operated characteristics (ROC) 
curve, sensitivity, specificity, positive predictive value, negative predictive value, false-positive 
rate, false-negative rate, accuracy, likelihood ratio, and pre- and post-test odds) were applied to 
assess predictor characteristics of PECF with respect to outcome PSP (Altman 1991, pp 409-
419). Statistics for diagnostic accuracy were calculated from logistic regression models, where 
the independent variable was expressed as an interaction between swallow safety and PECF, 
i.e. the model included two different models of association between cough flow and pneumonia, 
depending on swallow safety (as opposed to confounding, where one single model is generated 
for the association between two variables in the presence of a confounder variable). Model 
goodness of fit was assessed using Pearson chi-squared and Hosmer-Lemeshow tests 
(StataCorp 2013, pp. 958-961).  
 
Third, exact logistic regression (StataCorp 2013, pp. 507-528, Mehta & Patel 1995) was 
conducted to quantify how baseline PECF in interaction with swallow safety modifies four-week 
risk of PSP. Exact logistic regression is an alternative to the standard maximum likelihood 
based logistic regression estimator, and yields greater statistical precision in small samples and 
in scenarios where outcomes are rare (StataCorp 2013, pp. 507-508). All data analyses were 




6.3.1 Baseline characteristics 
 
The sample consisted of 72 participants. Baseline characteristics are given in Table 36. When 
the sample was stratified by aspiration risk, patients with unsafe swallow (n=33) were older 
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(mean (SD) age 70.2 vs 59.9 years, p=0.0022) and had more severe stroke impairment (median 
(IQR) NIHSS score 9 (7, 14) vs 6 (5, 10), p=0.0002) than patients with safe swallow. Patients 
with unsafe swallow also performed worse on a number of variables of forced spirometry (FVC, 
FEV1, PEF), voluntary cough (PECF, CVI, CVE, CVAC), reflex cough (PICF, CVI), and 
respiratory muscle strength (PEmax, PImax) (Table 36).  
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Table 36. Baseline characteristics of the sample 
  Stratification by aspiration risk  
 Total sample (n=72) Safe swallow (n=39) Unsafe swallow (n=33) p-value 
Age (years) 64.6 (14.4) 59.9 (14.0) 70.2 (13.1) 0.0022 
Males 42 (58%) 23 (59%) 19 (59%) 0.905 
NIHSS score (median, IQR)  8 (5, 12) 6 (5, 10) 9 (7, 14) 0.0002 
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Current smoker 18 (25%) 10 (26%) 8 (24%) 0.891 
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Table 36. continued 


















































Figures are mean (SD) and frequency (%), unless stated otherwise 
p-values are for between-group comparison of patients with safe and unsafe swallow and were calculated using the appropriate parametric (independent samples t-
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test) or non-parametric (Mann-Whitney U test) statistical significance test for continuous data, and Chi squared or Fisher’s exact test for categorical data (5% 
significance level alpha, 80% power) 
CVAC, cough volume acceleration; CVE, cough volume expired; CVI, cough volume inspired; FVC, forced vital capacity; FEV1, forced expiratory volume in one 
second; GCT, glottis compression time; NEADL, Nottingham Extended Activities of Daily Living questionnaire; PECF, peak expiratory cough flow; PEF, peak 
expiratory flow; PEmax, maximal expiratory mouth pressure; PICF, peak inspiratory cough flow; PImax, maximal inspiratory mouth pressure 
 
 - 184 - 
6.3.2 Predictor and outcome variables according to aspiration risk 
 
Out of 72 participants, 13 (18%) developed pneumonia within four weeks from baseline 
assessment. In the safe swallow group, two (5%) out of 39 patients developed pneumonia. 
There was no statistically significant difference between PECF of either voluntary or involuntary 
cough in the safe swallow group between patients who developed pneumonia and those who 
did not (Table 37). In the unsafe swallow group, eleven (33%) out of 33 patients developed 
pneumonia. In patients who developed pneumonia, mean PECF of voluntary cough was lower 
by 196 L/min (p=0.0053). Mean PECF of involuntary cough was also lower by 45 L/min in 
patients who developed pneumonia, although this was not statistically significant (p=0.277) 
(Table 37).  
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Table 37. Peak expiratory cough flow (PECF) according to four-week incidence of pneumonia in patients with low aspiration risk (safe swallow) and 
high aspiration risk (unsafe swallow) 
 Low risk of aspiration (safe swallow)  High risk of aspiration (unsafe swallow) 









Voluntary cough PECF (L/min) 535 (264) 546 (307) 0.917  448 (244) 252 (130) 0.0053 
Capsaicin-induced involuntary cough 
PECF (L/min) 
301 (110) 324 (168) 0.945  276 (124) 231 (100) 0.277 
Figures are mean (SD) 
p-values were calculated using independent samples t-test with unequal variance 
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6.3.3 Diagnostic accuracy of peak cough flow in interaction with aspiration risk for 
outcome pneumonia 
 
The ability to predict the outcome pneumonia with a probability of >0.5 from the interaction 
between PECF and aspiration risk was modelled for both voluntary and reflex cough. Appendix 
4 gives full details of Stata commands and outputs. Model goodness-of-fit tests were 
satisfactory, with p-values >0.05.  
 
For voluntary cough PECF, the model yielded 46.15% sensitivity and 93.22% specificity. 
Positive and negative predictive values were 60.0% and 88.71%, respectively. The false 
positive rate was 6.78% in all patients who did not develop the outcome; and 40% in all patients 
for whom pneumonia had been predicted. The false negative rate was 53.85% in all patients 
who did develop pneumonia; and 11.29% in all patients who had been predicted not to develop 
pneumonia. The overall accuracy (all cases correctly classified) was 84.72%. The area under 
the ROC curve was 0.836 (Figure 19). Sensitivity and specificity according to probability cut-off 
are shown in Figure 20.  
 
The positive likelihood ratio for this model was 6.8, and the negative likelihood ratio was 0.58. 
Assuming a PSP incidence over four weeks of 15%, the pre-test odds of developing PSP are 
0.18 (two to eleven, in favour of not developing pneumonia). A positive model prediction 
therefore resulted in post-test odds of 1.22 for developing PSP (approximately ten to eight, in 
favour of developing pneumonia); and a negative model prediction almost halved the odds of 
developing pneumonia to 0.10 (one to ten, in favour of not developing pneumonia).  
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Figure 19. Receiver operating characteristic (ROC) curve for logistic regression model 
predicting outcome pneumonia from interaction between voluntary peak cough flow and 
aspiration risk 
 




































Figure 20. Sensitivity and specificity according to probability cut-off for logistic regression model 




For capsaicin-induced involuntary cough PECF, the model failed to predict any of the 
pneumonia cases; although the model correctly identified 82.61% of cases who did not develop 
pneumonia, and the area under the ROC curve was 0.768.  
 
A third model was explored, adjusting the interaction between voluntary cough PECF and 
aspiration risk with the confounders age, sex and stroke severity. In addition to swallowing 
impairment, these three risk factors for PSP are the most frequently identified in the literature. 
This model also showed satisfactory goodness-of-fit and yielded 53.85% sensitivity and 93.22% 
specificity. Positive and negative predictive values were 63.64% and 90.16%, respectively. The 
false positive rate was 6.78% in all patients who did not develop the outcome; and 36.36% in all 
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patients for whom pneumonia had been predicted. The false negative rate was 46.15% in all 
patients who did develop pneumonia; and 9.84% in all patients who had been predicted not to 
develop pneumonia. The overall accuracy (all cases correctly classified) was 86.11%. The area 
under the ROC curve was 0.855 (Figure 21). Sensitivity and specificity according to probability 
cut-off are shown in Figure 22.  
 
The positive likelihood ratio for this model was 7.9, and the negative likelihood ratio was 0.50. 
Based on a PSP incidence of 15% and pre-test odds of developing PSP of 0.18 (two to eleven, 
in favour of not developing pneumonia), a positive model prediction therefore resulted in post-
test odds of 1.42 for developing PSP (approximately ten to seven, in favour of developing 
pneumonia); and a negative model prediction reduced the odds of developing pneumonia to 
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Figure 21. Receiver operating characteristic (ROC) curve for logistic regression model 
predicting outcome pneumonia from interaction between voluntary peak cough flow and 
aspiration risk, and adjusted for age, sex and stroke severity 




































Figure 22. Sensitivity and specificity according to probability cut-off for logistic regression model 
predicting outcome pneumonia from interaction between voluntary peak cough flow and 
aspiration risk, and adjusted for age, sex and stroke severity 
 
 
6.3.4 Modification of pneumonia risk according to cough flow 
 
Exact logistic regression was used to model how PSP risk changes according to magnitude of 
cough flow. To fit the model, the continuous variable peak cough flow had to be categorised. 
Increments of 50 L/min were selected for categorisation, which lies just above the average test-
retest variability to be expected in the absence of change (chapter 3). Stata commands and 
outputs for the applied exact logistic regression models are given in Appendix 5.  
 
Analysis showed that for patients at high risk of aspiration (unsafe swallow), each increase in 
voluntary cough PECF by 50 L/Min was associated with a statistically significant decrease in 
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pneumonia risk (OR 0.73, 95%CI 0.51-0.95, p=0.012). For involuntary cough PECF, each 
increase by 50 L/min was also associated with a reduction in pneumonia risk, although this was 
not statistically significant (OR 0.87, 95%CI 0.60-1.20, p=0.45). For patients at low risk of 
aspiration (safe swallow), there was no association between PECF of either voluntary (OR 1.01, 
95%CI 0.74-1.33, p=0.89) or involuntary cough (OR 1.11, 95%CI 0.55-2.23, p=0.84) and 
pneumonia. In Figures 23 and 24 the probability of developing pneumonia is plotted according 
to PECF. For patients who were at high risk of aspiration and who had voluntary cough flow of 
>600 L/min, the probability of pneumonia was equivalent to patients who were at low risk of 
aspiration. The shapes of the 95% confidence intervals in Figures 23 and 24 are explained by 
the distribution of data points across the PECF range, which was denser where confidence 
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Figure 23. Probability of pneumonia, according to swallow safety and peak expiratory flow of 
voluntary cough at baseline 
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Figure 24. Probability of pneumonia, according to swallow safety and peak expiratory flow of 





This exploratory study demonstrated that PECF of voluntary cough, measured within two weeks 
of stroke onset, was associated with the four-week risk of developing PSP in patients with high 
aspiration risk. It was shown that the interaction between aspiration risk and voluntary cough 
PECF can be used to refine the odds of developing PSP. The model performed stronger in 
predicting negative outcome (no development of PSP) than positive outcome. The association 
between the magnitude of voluntary cough PECF and the probability of outcome PSP was also 
demonstrated. PECF had minimal influence on PSP probability in patients with safe swallow; 
however, in patients with unsafe swallow, the model showed decreasing PSP probability with 
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increasing peak cough flow. From a PECF of approximately 600 L/min upwards, PSP probability 
was reduced to that equivalent in patients with safe swallow. Overall, these data support the 
hypothesis and logic model that stronger cough, as measured by expiratory cough flow, is 
protective of PSP in patients who are at risk of aspiration.  
 
A number of limitations to this study are acknowledged. First, this was an exploratory, 
secondary analysis of clinical trial data. Investigations of diagnostic predictors are generally 
addressed in observational study designs. While these data were collected prospectively, which 
can be regarded as a strength in comparison with a retrospective observational design, the 
study sample is selective due to the trial eligibility criteria. The incidence of PSP (18%) within 
this sample is in the higher range of reported pneumonia incidence rates in non-ICU settings 
(median (IQR) 10% (6.4, 16.2) (Hannawi et al. 2013). This influences the performance of the 
predictor models, which depends on the baseline incidence. Post-estimation odds according to 
varying baseline incidence are given in Table 38. These post-estimation odds demonstrate that 
the predictor models are more informative in identifying patients who are unlikely to develop 
PSP (halving the pre-estimation odds), but less informative in predicting who will develop PSP.  
 
 - 194 - 
Table 38. Post-estimation odds for developing post-stroke pneumonia (PSP) as predicted from 








Voluntary cough PECF and 
aspiration risk 
 Voluntary cough PECF, 





Odds of not 
developing PSP 
 Odds of 
developing PSP 
Odds of not 
developing 
PSP 
5% 0.05 0.34 0.029  0.40 0.025 
10% 0.11 0.75 0.064  0.87 0.055 
15% 0.18 1.22 0.10  1.42 0.09 
20% 0.25 1.50 0.14  1.98 0.12 
25% 0.33 2.24 0.19  2.61 0.16 
30% 0.43 2.92 0.25  3.40 0.22 
 
 
Second, the use of trial data for this secondary analysis was considered appropriate, since the 
trial intervention (respiratory muscle strengthening to improve PECF) did not show an effect. It is 
possible, however, that participation in the experimental and sham groups introduced unknown 
bias. Third, the study sample was small, and the outcome PSP occurred in only two patients in 
the safe swallow group. Statistical precision was maximised by examining only one association 
of interest, which was defined a priori; and by using exact logistic regression. Commonly, 
models are developed using stepwise regression approaches to statistically identify the most 
relevant predictors from a number of potential candidate variables. The validity of these 
approaches depends on the sample size, which needs to be larger the more candidate 
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variables are added to the analysis. From the baseline variables of the present sample, other 
potential predictor variables for PSP may be considered relevant, e.g. FVC, FEV1, PEF, PEmax 
and PImax. These respiratory parameters all link with cough function and all showed statistically 
significant differences when the sample was stratified according to swallow safety. However, the 
small sample precluded a valid exploration of these parameters in comparison with PECF, and 
PECF was selected a priori as the most immediate parameter of cough effectiveness.  
 
Despite these limitations, the present analysis provides valuable information in a little 
researched field. The importance of cough is frequently discussed in the context of swallowing 
impairment and aspiration pneumonia. However, to our knowledge there is no published 
evidence demonstrating the association between cough intensity and pneumonia risk after 
stroke. The notion that strong cough protects from aspiration pneumonia is a generally held 
clinical belief, probably because of its intuitive plausibility. Some evidence is available from 
patients with degenerative neuromuscular conditions, which shows that weaker cough is 
associated with increased risk of failed weaning from mechanical ventilation and with increased 
risk of hospitalisation due to pulmonary complications (Bach et al. 1997, Bach & Saporito 1996). 
Cough intensity is not routinely measured in clinical practice and may therefore not be 
conveniently studied as a risk factor for PSP. The data presented here therefore provided an 
opportunity to explore the role of cough intensity in interaction with swallowing function and 
pneumonia risk in the acute phase of stroke, and the hypothesis and logic model were indeed 
supported by the data. In view of the study limitations, it would be desirable to replicate the 
findings in an observational study design, with a larger sample that is representative of the 
majority of patients with incident stroke.  
 
Overall, these data demonstrate that measurements of peak expiratory flow during cough could 
find clinical utility in quantifying PSP risk, in particular for categorising patients to high or low 
risk, according to a certain PECF threshold. With respect to the absolute value of such a PECF 
threshold, the potential for considerable inaccuracy between different flow measurement 
devices has to be taken into account (chapter 3). The threshold value of 600 L/min suggested 
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by the present study therefore needs to be used with reference to the particular measurement 




These data show that the risk of PSP decreases in proportion with increasing PECF of voluntary 
cough in stroke patients who are at risk of aspiration, but not in patients with safe swallow. This 
association is more pronounced and statistically significant for voluntary PECF, compared with 
PECF of involuntary cough. These data confirm that stronger cough protects from aspiration-
related pneumonia after stroke. A threshold value for voluntary cough PECF may be useful in 
clinical practice to categorise patients according to PSP risk; however, routine clinical 
application is dependent on the availability of portable devices that can measure peak cough 
flow accurately in clinical settings.  
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Chapter 7 Longitudinal observation of cough frequency in the 




Cough frequency is a parameter of interest in cough research, in particular in studies of 
excessive coughing and cough suppressants, or where cough is examined as a positive clinical 
sign of respiratory disease (Sunger et al. 2013, Decalmer et al. 2012, Birring 2011, Morice et al. 
2007, Raj & Birring 2007, Birring et al. 2006). Few studies have examined cough frequency in 
the context of impaired swallowing and pneumonia risk, an interaction that is relevant in patients 
with neurogenic swallowing dysfunction. As one example, the occurrence of coughing bouts and 
choking episodes was investigated in one study of patients with motor neuron disease 
(Hadjikoutis et al. 2000). Using a self-report diary over a three day period, it was found that 27 
out of 37 patients with motor neuron disease experienced between one and 50 coughing and 
choking episodes, while ten patients did not report any coughing or choking. This was 
compared with a group of 23 healthy control subjects, out of whom two subjects reported one to 
two episodes of coughing or choking and 21 reported none. Coughing and choking in patients 
with motor neuron disease coincided partly with meal times, but occurred equally often outside 
meal times. Higher frequency of coughing and choking was associated with poorer performance 
in volitional respiratory and cough function tests (forced spirometry, peak flow and sound level 
during maximal volitional cough). Out of 37 patients, only two had developed a chest infection 
since disease onset, and both these patients had reported coughing and choking episodes. 
None of the ten patients who did not report any coughing or choking episodes had developed 
chest infections since the onset of the condition.  
 
As in the study by Hadjikoutis and colleagues, cough frequency assessments can complement 
investigations of swallowing function and pneumonia risk in neurological patient groups. 
Aspiration of food and drink during the act of swallowing may trigger protective coughs. 
Increased cough frequency, for example during mealtimes, may therefore be interpreted as a 
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warning sign that the person is dysphagic and at increased risk of aspiration and aspiration 
pneumonia (Miller & Britton 2011, pp. 23-42, Singh & Hamdy 2006, Ramsey et al. 2003). 
Relating this scenario to the acute stroke population, it may be hypothesised that increased 
cough frequency will correlate with presence of dysphagia, risk of aspiration and risk of 
pneumonia.  
 
An alternative hypothesis may postulate that reduced cough frequency will identify lack of 
reflexive protection from aspiration in dysphagic patients, therefore indicating greater risk of 
aspiration and aspiration pneumonia. Other than in motor neuron disease, where the sensory 
afferents are generally not affected by the disease process, stroke can lead to an impairment of 
the sensory afferents and central nervous pathways processing cough as well as the efferent 
pathways effecting cough. The potential for stroke to reduce reflex cough sensitivity has been 
demonstrated (Addington et al. 2005, 1999a). As a result, cough frequency may be diminished 
in a portion of acute stroke patients.  
 
To date, cough frequency has not been described in acute stroke. Longitudinal observation of 
cough frequency is of interest, to allow comparison with normative values and describe trends 
of recovery.  
 
7.2 Aims and objectives 
 
The aim of the present study was to explore cough frequency in a cohort of acute stroke 
survivors. Specific study objectives were:  
 To validate the Leicester Cough Monitor (LCM) as a method of cough frequency 
measurement in acute stroke 
 To describe 24-hour cough frequency longitudinally over twelve weeks 
 To compare the cough frequency in stroke survivors with normative values 
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 To explore relationships between cough frequency and other parameters, e.g. swallowing 






Acute haemorrhagic or ischemic stroke patients aged 18 years and above were recruited within 
two weeks of stroke onset. Patients were recruited consecutively from the hyper-acute stroke 
unit at one tertiary stroke centre in London, UK. Inclusion criteria were: NIHSS score of 5-25 
with motor impairment; and ability to give informed consent and follow study procedures. 
Exclusion criteria were: poorly controlled hypertension (blood pressure >180/100 on three or 
more occasions in 24 hours); myocardial infarction, angina or acute heart failure in the 
preceding three months; pulmonary disease including asthma and COPD; neurological 
conditions other than stroke; and orthopaedic conditions adversely affecting the respiratory 
pump. Written informed consent was obtained prior to inclusion and the study was approved by 
the UK NRES (Wandsworth Research Ethics Committee, study reference 10/H0803/32).  
 
7.3.2 Cough frequency measurements 
 
Cough frequency measurements were made using the LCM, a semi-automated cough 
frequency measurement system (Birring et al. 2008, Matos et al. 2007, Matos et al. 2006). This 
device consists of a portable sound recording device (Digital Voice Tracer LFH0662, Philips 
Electronics UK Ltd, Guildford, England), which is worn in a pouch or pocket. A small 
microphone is clipped onto the patient’s collar or lapel, as close as possible to the anterior neck. 
A continuous sound recording is made, generally over an entire 24-hour period. The digital 
recording is then processed through accompanying computer software (Leicester Cough 
Monitor, Version 2.0, October 2012, lcmonitor@gmail.com), which automatically registers sound 
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patterns typical for cough. During data processing, a human operator listens back to examples 
of identified sound patterns and confirms whether or not the identified sound is in fact a cough 
sound. Sounds sometimes misidentified by the software as cough sounds are, for example, 
short sharp sounds such as the closing of doors or dropping of objects. The automated cough 
count is refined through the feedback provided by the human operator. The software output lists 
the total number of cough events over the entire time period of recording; the average number 
of cough events per hour; the total number of cough bouts; the average number of cough bouts 
per hour; the average number of cough events per bout; and the day time and night time values 
for each of these statistics.  
 
7.3.3 Study design 
 
7.3.3.1 Validation of the Leicester Cough Monitor in acute stroke 
 
To validate the LCM for acute stroke patients, a validation study was conducted with a group of 
five participants. Participants were inpatients on the acute stroke unit at the time and shared an 
open hospital bay with up to three other patients. Potential concerns regarding the validity of the 
sound-based LCM system in this environment were that coughs from patients sharing the room, 
members of staff or visitors could contaminate the patient cough count and result in higher 
measurements; or that for patients with severely weakened or atypical sounding cough (e.g. 
‘bovine’ cough sound in bulbar involvement) the LCM software would not recognise coughs, 
resulting in lower measurement. Participants wore the LCM for 15 minutes, while a researcher 
observed the participant from close proximity ‘live’ for the entire duration of the recording. The 
researcher conducted a ‘live’ count of coughs by the participant (patient coughs), and of all 
other coughs which could be heard by the researcher, including coughs from other patients, 
staff and visitors within the area (ambient coughs). To ensure that there were cough events to 
be recorded, the participant and other people in the room were prompted to cough several times 
during the 15 minutes recording.  
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LCM recordings were processed using the accompanying computer software. When giving 
operator input to cough sound recognition, the researcher consciously assessed for each sound 
sample presented by the programme: (a) whether the sound was a cough sound (designating 
sounds that did not resemble cough sounds as ‘non-cough’); (b) if the sound was a cough 
sound, whether it sounded distant or near on the recording (designating distant sounding 
coughs as ‘non cough’); (c) if the sound was a cough sound, whether it sounded as if it 
generated from a person of the opposite sex to the test subject (designating coughs from 
persons of the opposite sex as ‘non-cough’); and (d) whether the test subject had a particularly 
characteristic sounding cough, such as a bovine or wheezing cough quality, which could assist 
in distinguishing the test subject’s coughs from coughs generated by other persons.  
 
7.3.3.2 Longitudinal cough frequency measurements 
 
Baseline assessments were conducted within 2 weeks of stroke onset and included patient 
demographics, stroke characteristics and respiratory parameters. Swallowing function was 
described according to swallow screens and clinical bedside assessments, which were 
conducted as part of routine acute stroke care (Appendix 2). The swallow was deemed ‘unsafe’ 
if any swallowing precautions or specific dysphagia management strategies had been specified 
for the person, which could include nil by mouth (NBM), modified texture diet and thickened 
fluids, or specific swallowing strategies (body positioning, head turn swallow, supervision by 
staff when swallowing, etc.). The swallow was deemed ‘safe’ if the patient was allowed to eat 
and drink normally without any precautions or instructions. Respiratory assessments at baseline 
were forced spirometry, maximal mouth pressure measurements and cough flow measurements 
of volitional and capsaicin-induced reflex cough. A detailed description of respiratory 
assessment methods is given in chapter 3.  
 
LCM devices were fitted to patients at baseline; and at one week, four weeks and twelve weeks 
thereafter. 24-hour cough frequency counts were obtained at each of these time points. Patients 
were either inpatients on the acute stroke unit, or had already been discharged home at the 
time of recording. Patients were asked to wear the device during the entire 24-hour period, 
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except for when having a bath or shower. Patients were instructed that, when asleep, they 
should either continue wearing the device on their person, or place it close by, for example on a 
bedside table. These instructions and the researcher’s contact details were provided to 
participants with an information leaflet. LCM devices were collected after the recording period, 
and recordings were processed by the researcher. Summary reports generated by the LCM 
software were printed, and data transferred to a Microsoft Office Excel spreadsheet.  
 
7.3.4 Data analysis 
 
Data pertaining to the validation of the LCM in this sample was analysed through assessment of 
the raw data and descriptive statistics; and by calculation of the ICC for absolute agreement 
(Streiner & Norman 2008), using Stata statistical software (Stata v12.1, StatCorp, College 
Station, TX) and a two-way mixed effects model for individual agreement (StataCorp 2013).  
 
Data from longitudinal cough frequency measurements was collected on a Microsoft Office 
Excel spreadsheet. To allow for convenient assessment of the distribution of cough events over 
a 24-hour period, hourly cough counts were re-arranged so that for each participant the 24-hour 
period started at 00:00 hours midnight (e.g., if the LCM recording had started at 10:00am and 
ended at 10:00am the following day, cough counts recorded from 00:00 to 10:00am the 
following day were cut and pasted to the beginning of the time period, thereby resulting in a 
00:00 to 24:00 hours period). Descriptive statistics were used to describe hourly and total cough 
counts, calculating arithmetic mean, median and geometric mean. The diurnal distribution of 
hourly cough frequency was illustrated graphically. Repeated measures ANOVA was used to 
assess for within-group differences at study time points. For this analysis, square root 
transformation of data was conducted to obtain approximately normally distributed data. Original 
and square root transformed data were also used to compute 95% confidence intervals as an 
inferential estimate of cough frequency for the study population. To compare the stroke cohort 
with norm values, logarithmic transformation of data was conducted, as in the literature cough 
frequency data is commonly reported as geometric mean and logSD. Statistical significance test 
for the mean difference between two independent samples with unequal variance was used to 
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compare the stroke cohort with norm values from healthy subjects and subjects with respiratory 
disease. Relationships between cough frequency and participant characteristics were explored 
using Spearman’s rank correlation coefficient and independent samples comparison tests. This 
basic approach was selected due to the small sample size and the exploratory nature of the 
analysis. Also, no adjustment for multiple testing was made, and this needs to be considered 
when interpreting the reported p-values. Analyses were conducted using Microsoft Office Excel 




7.4.1 Description of the sample 
 
Data were collected from 21 acute stroke patients between September 2012 and November 
2013. Sample characteristics are summarised in Table 39. The cohort consisted of 7 women 
and 14 men with mean (SD) age of 60 (15) years. The majority had a moderate level of stroke 
impairment on admission, with a median (IQR) NIHSS score of 8 (5, 11). The aetiology of stroke 
was ischemic in 86% and hemorrhagic in 14%. The majority of patients had cortical (43%) or 
subcortical (43%) stroke lesion sites. Two patients (10%) had brainstem strokes and one (5%) 
had a cerebellar stroke. Approximately two thirds of patients (62%) were considered to have 
safe swallow function according to the routine bedside swallow assessment, and approximately 
one third (38%) had unsafe swallow. Seven patients (33%) had pre-existing prescriptions for 
ACE inhibitors, which were continued for the duration of the study. Eleven patients (52%) were 
non-smokers, seven (33%) were current smokers, and three (14%) had quit smoking more than 
five years prior to the study. During the study period, chest radiographs were taken for 13 
patients (62%), no abnormalities were detected on any radiographs. The remaining eight 
patients did not have chest radiographs due to lack of clinical indication. Pneumonia incidence 
was observed for the first four weeks following baseline assessment for the entire sample, and 
from week four to week twelve for those patients who remained in the study. There was one 
participant (5%) who developed pneumonia.  
 - 204 - 
Table 39. Sample characteristics at baseline 
Sample characteristics at baseline n=21 
Age 60 (15) 
Sex  
Female 7 (33%) 
Male 14 (67%) 
Stroke type  
Ischemic 18 (86%) 
Hemorrhagic 3 (14%) 
Stroke side  
Left-sided 12 (57%) 
Right-sided 8 (38%) 
Bilateral 1 (5%) 
Stroke site  
Cortical 9 (43%) 
Subcortical 9 (43%) 
Brainstem 2 (10%) 
Cerebellar 1 (5%) 
Stroke severity (median (IQR) NIHSS score) 8 (5, 11) 
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Table 39. continued 
Smoking 
Never smoked 11 (52%) 
Quit >5 years ago 3 (14%) 
Current smoker 7 (33%) 
Swallowing status 
Safe 13 (62%) 
Unsafe 8 (38%) 
ACE-inhibitor use 
Yes 7 (33%) 
No 14 (67%) 
Chest radiograph 
Normal 13 (62%) 
Abnormal 0 
Not taken 8 (38%) 
Pneumonia from baseline to week four 
Yes 1 (5%) 
No 20 (95%) 
Figures are mean (SD) and frequency (%), unless stated 
otherwise; ACE, angiotensin-converting enzyme; NIHSS, National 
Institutes of Health Stroke Scale 
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Baseline respiratory parameters for the sample are presented in Table 40. Lung function (forced 
spirometry) showed that average forced vital capacity, forced expiratory volume in one second, 
and peak expiratory flow was approximately 70% of the respective predicted values. Mean (SD) 
expiratory and inspiratory mouth pressures were 69 (40) and 48 (33) cmH2O, respectively. 
Mean (SD) peak expiratory flow of voluntary and involuntary cough were 500 (255) and 259 
(113) L/min, respectively.  
 
Table 40. Summary of baseline respiratory parameters for the sample 
Parameter (n=21) 
Forced spirometry  
FVC (L) 2.6 (1.2) 
% of predicted FVC 70 (23) 
FEV1 (L) 2.1 (1.0) 
% of predicted FEV1 71 (24) 
PEF (L/min) 315 (156) 
% of predicted PEF 70 (29) 
Respiratory muscle strength  
PEmax (cmH2O) 69 (40) 
PImax (cmH2O) 48 (33) 
Cough intensity  
Voluntary cough PECF (L/min) 500 (255) 
Involuntary cough PECF (L/min) 259 (113) 
Figures are mean (SD) 
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FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PECF, 
peak expiratory cough flow; PEF, peak expiratory flow; PEmax; maximal 
expiratory mouth pressure; PImax, maximal inspiratory mouth pressure 
 
 
7.4.2 Validation of the Leicester Cough Monitor in acute stroke 
 
Potential concerns regarding the validity of the sound-based LCM system in this patient group 
were that, for patients who are inpatients at the time of recording, coughs from patients sharing 
the room, members of staff or visitors may contaminate the patient cough count and result in 
higher measurement; or that for patients with severely weakened or atypical sounding cough 
(e.g. ‘bovine’ cough sound in a patient with bulbar involvement) the LCM software would not 
recognise coughs and result in lower measurement. Table 41 shows the cough counts obtained 
during a 15-minutes period from ‘live’ observation by a researcher compared with cough counts 
obtained from the LCM device.  
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Table 41. Cough counts obtained during a 15-minutes period from five test subjects in a four-
bedded acute hospital bay. Subjects’ coughs and ambient coughs were observed and counted 
‘live’ by a researcher who was present for the duration of the recording.  
Subject Direct observation Automated cough 
count (LCM) 
 
Total number of 
coughs in the 
environment (subject’s 
coughs plus ambient 
coughs) Subject’s coughs  
1 24 11 12 
2 17 5 5 
3 21 9 9 
4 51 27 28 
5 35 15 14 
Total 148 67 68 
Arithmetic mean 30 13 14 
Median 24 11 12 
Geometric mean 27 12 12 
LCM, Leicester Cough Monitor 
 
 
From an assessment of the raw data and the group totals, means and medians presented in 
Table 41, it is evident that there was good agreement between subjects’ coughs as counted by 
the observing researcher and as determined from the LCM system. Based on the assumption 
 - 209 - 
that the observing researcher’s ‘live’ cough count (group total of 67) is taken as the ‘true’ cough 
count, the LCM system accurately measured subjects’ cough frequency to within one cough 
(group total of 68). Although during the observation period a considerable number of cough 
sounds had been counted by the observing researcher, which had not generated from the test 
subject but from other persons in the environment (group total of 81), these ambient coughs did 
not contaminate the LCM cough frequency measurement. The particular strategy of giving 
operator input when processing LCM sound recordings and refining the cough counts is likely to 
be crucial in this context. The high level of agreement is reflected in the ICC (95% CI) of 0.996 
(0.967, >0.999).  
 
7.4.3 Longitudinal observation of cough frequency in a cohort of acute stroke patients 
 
7.4.3.1 Description of cough frequency in the sample 
 
Subjects’ 24-hour cough frequency and average hourly cough frequency over 24 hours for each 
study time point are summarised in Table 42. Arithmetic mean, median and geometric mean are 
presented. Since the data shows a skewed distribution, median is more appropriate than 
arithmetic mean. The geometric mean is commonly used and reported in the literature, as data 
are generally transformed logarithmically for inferential statistical analysis.  
 
The summary of cough frequency measurements shows that there was higher cough frequency 
at baseline (median (range) 24-hour cough frequency 118 (4, 375)), which dropped during the 
course of the study to 56 (1, 186) at four weeks and 34 (6, 108) at twelve weeks; although 
participant attrition between four and twelve weeks was high, and data from the twelve week 
time point is therefore less representative. Also, the wide range of observed cough counts 
amongst individuals is notable, from very low 24-hour cough frequency (below ten coughs) to 
higher counts (>300 coughs). There was a diurnal pattern, whereby cough frequency was 
consistently higher during day time than during night time. Figures 25 to 28 show averages and 
ranges for hourly cough frequency at each of the study time points. Figure 29 shows median 
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hourly cough frequency at baseline, week one and week four, illustrating the decrease of cough 
frequency with time.  
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Table 42. Summary of cough frequency at each time point 
Cough frequency summary measure Baseline (n=21) Week 1 (n=20) 
Arithmetic mean 
(SD) 




Median (range) Geometric mean 
(logSD) 
Cough frequency over 24 hours 130 (102) 118 (4, 375) 84 (1.2) 80 (69) 60 (6, 217) 52 (1.0) 
Average hourly cough frequency for 24 
hour period 
5 (4) 5 (0, 16) 4 (1.2) 3 (3) 2 (0, 9) 2 (1.0) 
Number of day time coughs a 95 (74) 86 (4, 282) 63 (1.1) 57 (53) 30 (6, 159) 37 (1.0) 
Average hourly cough frequency at day 
time 
7 (5) 6 (0, 20) 4 (1.2) 4 (4) 2 (0, 11) 3 (1.0) 
Number of night time coughs a 34 (36) 21 (0, 112) 20 (1.3) 23 (19) 18 (0, 58) 17 (1.1) 
Average hourly cough frequency at 
night time 
3 (4) 2 (0, 11) 2 (1.3) 2 (2) 2 (0, 6) 2 (1.1) 
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Table 42. continued 
Cough frequency summary measure Week 4 (n=17) Week 12 (n=5) 
Arithmetic mean 
(SD) 




Median (range) Geometric mean 
(logSD) 
Cough frequency over 24 hours 66 (59) 56 (1, 186) 36 (1.5) 54 (44) 34 (6, 108) 35 (1.1) 
Average hourly cough frequency for 24 
hour period 
3 (2) 2 (0, 8) 2 (1.2) 2 (2) 1 (0, 4) 2 (1.0) 
Number of day time coughs a 48 (36) 41 (1, 108) 29 (1.4) 41 (33) 26 (5, 84) 27 (1.1) 
Average hourly cough frequency at day 
time 
4 (3) 3 (0, 8) 2 (1.4) 3 (2) 2 (0, 6) 2 (1.0) 
Number of night time coughs a 18 (26) 9 (0, 90) 12 (1.2) 13 (14) 8 (0, 42) 9 (1.3) 
Average hourly cough frequency at 
night time 
2 (3) 1 (0, 9) 1 (1.2) 1 (1) 1 (0, 4) 0 (1.2) 
a Daytime: 06:00 to 22:00; night time: 22:00 to 06:00 
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Figure 25. Hourly cough frequency at baseline. The line indicating the minimum hourly cough frequency corresponds with the x-axis, as minimum hourly cough 
frequencies across the entire 24 hour time period were zero.  
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Figure 26. Hourly cough frequency at week 1. The line indicating the minimum hourly cough frequency corresponds with the x-axis, as minimum hourly cough 
frequencies across the entire 24 hour time period were zero. The median line overlaps with the x-axis between 01:00 and 06:00 hours.  
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Figure 27. Hourly cough frequency at week 4. The line indicating the minimum hourly cough frequency corresponds with the x-axis, as minimum hourly cough 
frequencies across the entire 24 hour time period were zero. The median line overlaps with the x-axis between 00:00 and 08:00 hours.  
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Figure 28. Hourly cough frequency at week 12. The line indicating the minimum hourly cough frequency corresponds with the x-axis, as minimum hourly cough 
frequencies across the entire 24 hour time period were zero. The mean line overlaps with the x-axis between 00:00 and 02:00 hours, and the median line overlaps 
with the x-axis between 00:00 and 08:00 hours.  







Hourly cough frequency (median) at baseline (n=21), 
week 1 (n=20) and week 4 (n=17)
Baseline Week 1 Week 4
 
Figure 29. Hourly cough frequency (median) at baseline (n=21), week 1 (n=20) and week 4 (n=17). The graph illustrates a trend of decreasing cough frequency over 
time. Area under the curve (AUC) at baseline, week 1 and week 4 is 64.7, 33.3 and 20.1, respectively (p=0.0003).  
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7.4.3.2 Within-group comparison of cough frequency at the study time points 
 
Within-group comparisons of 24-hour cough frequency and average hourly cough frequency 
confirmed that the observed decrease in cough frequency over time is statistically significant. 
Arithmetic mean 24-hour cough frequency at the four study time points decreased from 130 at 
baseline to 80 at week one, 66 at week four, and 54 at week twelve. Arithmetic mean hourly 
cough frequency at the study time points decreased from 5 at baseline to 3 at week one, 3 at 
week four, and 2 at week twelve. The respective p-values (using square root transformed data 
to meet normality assumptions in a repeated-measures ANOVA) were 0.0142 and 0.0153.  
 
7.4.3.3 Estimation of cough frequency in the population from which the study sample 
was selected 
 
The observed cough frequency data showed a skewed distribution, and were most successfully 
transformed to normally distributed data using the square root transformation. The 95% 
confidence intervals were calculated for 24-hour cough frequency at baseline and for average 
hourly cough frequency at baseline (Table 43). The 95% confidence intervals for the root 
transformed data have greater validity, since the normality assumption is met, but these cannot 
be meaningfully back-transformed to the original unit of measurement. Confidence intervals 
were therefore also computed for the data in original unit of measurement; however, due to the 
skewed distribution of the original data these estimates are likely to lack the statistical precision 
that could be achieved with normally distributed data. Bearing this limitation in mind, it can be 
concluded that in the population from which the sample came, average 24-hour cough 
frequency is likely to lie within the range from 83 to 176 coughs with 95% probability; and 
average hourly cough count is likely to lie within the range from 4 to 7 coughs with 95% 
probability.  
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Table 43. Sample mean (95% confidence intervals) for 24-hour cough frequency and average 
hourly cough count at baseline (n=21). 95% confidence intervals are given for the data in the 
original unit of measurement (counts) and for the square root transformed data.  
 Original unit of measurement Square root transformed data 
24-hour cough frequency 130 (83, 176) 10 (8, 13) 
Average hourly cough 
count 
5.4 (3.5, 7.4) 2.1 (1.7, 2.6) 
 
 
7.4.3.4 Comparison of cough frequency in acute stroke with healthy subjects and 
subjects with respiratory disease 
 
Reference values for 24-hour cough frequency are reported by Yousaf et al. (2013). The 
geometric mean (logSD) 24-hour cough frequency was 18.6 (0.5) in a sample of 44 healthy 
non-smokers, and 33 (0.6) in a group of 6 healthy smokers. The stroke sample in the present 
study had geometric mean (logSD) 24-hour cough counts of 84 (1.2) at baseline, 52 (1.0) at 
week one, 36 (1.5) at week four, and 35 (1.1) at week twelve. Compared with healthy non-
smokers, the stroke cohort had significantly higher 24-hour cough frequency at baseline and 
week one with p-values of <0.0001 and 0.0002, respectively. At weeks four and twelve, the 
differences were no longer statistically significant with p-values of 0.093 and 0.27, respectively. 
Baseline 24-hour cough frequency was also significantly higher in the stroke group compared 
with healthy smokers (p=0.018), but not at the later time points. Reported 24-hour cough 
frequency in groups with respiratory disease ranges from geometric mean (logSD) of 106 (0.7) 
in bronchitis (n=5) to 477 (0.3) in patients with unexplained chronic cough (n=34) (Yousaf et al. 
2013). Cough frequency in the present stroke sample was therefore lower than in groups with 
respiratory pathologies, and higher than in healthy non-smokers and smokers within the first 
three weeks of stroke onset, with a trend towards normal values thereafter.  
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Of note, there was a difference in 24-hour cough frequency between stroke patients who were 
using ACE inhibitors (baseline geometric mean (logSD) 119 (0.7), n=7) and stroke patients who 
were not (baseline geometric mean (logSD) 70 (1.3), n=14), although this difference was not 
statistically significant (p=0.25). The cough frequency of stroke patients taking ACE inhibitors in 
was similar to the geometric mean (logSD) cough frequency of 128 (0.2) reported for a group of 
4 healthy subjects using ACE inhibitors (Yousaf et al. 2013).  
 
7.4.3.5 Relationship between cough frequency and other parameters in acute stroke 
 
Baseline 24-hour cough frequency and average hourly cough count at baseline were examined 
in relation to patient characteristics (sex, age, stroke site, stroke severity and swallowing safety) 
and respiratory parameters at baseline (lung function, respiratory muscle strength, cough flow).  
 
There was no statistically significant difference in baseline cough frequency between male and 
female participants (Table 44). There was no correlation between age and cough frequency 
(rs=0.08) or between stroke severity (NIHSS score on admission) and cough frequency (rs 
=0.09), and correlation coefficients were not statistically significant with p-values of 0.72 and 
0.69, respectively.  
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Table 44. Baseline cough frequency according to sex 
  Male (n=14) Female (n=7) p-value a 
24-hour cough 
frequency 
Arithmetic mean (SD) 121 (96) 147 (120)  
Median (range) 109 (8, 357) 119 (4, 375)  
Geometric mean (logSD) 82 (1.1) 87 (1.1) 0.92 
Average hourly 
cough frequency b 
Arithmetic mean (SD) 5 (4) 6 (5)  
Median (range) 6 (<1, 15) 5 (<1, 16)  
Geometric mean (logSD) 3 (1.5) 4 (1.4) 0.86 
a Mann-Whitney test using log-transformed data 
b Average hourly cough frequency during 24 hours 
 
 
Baseline cough frequency varied according to stroke lesion site (Table 45) with statistically 
significant differences, although these data need to be interpreted with caution due to low 
numbers of subjects with brainstem (n=2) and cerebellar stroke (n=1). The highest cough 
frequency was observed in the two patients with brainstem strokes, with 24-hour cough counts 
of 225 and 357, followed by patients with cortical stroke (median (range) 24-hour cough 
frequency of 123 (4, 375)). The lowest cough frequency was seen in patients with subcortical 
stroke lesions (median (range) 24-hour cough frequency of 72 (8, 141)).  
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Table 45. Baseline cough frequency according to stroke lesion site 
  Cortical (n=9) Subcortical 
(n=9) 





Arithmetic mean (SD) 155 (108) 69 (44) 291 (93) 127 c  
Median (range) 123 (4, 375) 72 (8, 141) 291 (225, 357)   
Geometric mean (logSD) 102 (1.3) 50 (1.0) 283 (0.3)  0.0496 
Average hourly 
cough frequency b 
Arithmetic mean (SD) 6 (4) 3 (2) 12 (4) 5 c  
Median (range) 5 (<1, 16) 3 (<1, 6) 12 (9, 15)   
Geometric mean (logSD) 4 (1.2) 2 (1.0) 12 (0.3)  0.0496 
a Kruskal-Wallis test using log-transformed data 
b Average hourly cough frequency during 24 hours 
c One observation only 
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There was no difference in 24-hour cough frequency or average hourly cough count between 
patients with safe and unsafe swallow (Table 46). There were weak to moderate inverse 
correlations between baseline respiratory parameters and cough frequency. Spearman’s rank 
correlation coefficients for the correlations between FVC, FEV1, PEF, PEmax, PImax, voluntary 
cough PECF and involuntary cough PECF were -0.26 (p=0.25), -0.30 (p=0.18), -0.16 (p=0.49), -
0.13 (p=0.57), -0.41 (p=0.065), -0.02 (0.94) and -0.13 (p=0.56), respectively.  
 
Table 46. Baseline cough frequency according to swallow safety 








Arithmetic mean (SD) 136 (104) 118 (106)  
Median (range) 119 (4, 375) 112 (8, 357)  
Geometric mean (logSD) 87 (1.2) 79 (1.2) 0.85 
Average hourly 
cough frequency 
Arithmetic mean (SD) 6 (4) 5 (4)  
Median (range) 5 (<1, 16) 5 (<1, 15)  
Geometric mean (logSD) 4 (1.2) 3 (1.2) 0.81 





The present study was the first to explore cough frequency in a sample of acute stroke patients. 
For this purpose, the LCM cough frequency measurement system was validated for use on an 
acute stroke unit. A high ICC of 0.996 was observed. When interpreting the magnitude of ICC 
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values, a distinction is made with respect to the use of a measurement. When a measurement 
is made for the purpose of individual clinical judgement, discrepancies between individual 
measurements have greater influence and reliability should therefore be very high (e.g. ICC of 
≥0.90). When a measurement is made for the assessment of group averages, as is the case in 
the present research, the sample size serves to reduce the error of measurement and lower 
reliability coefficients are acceptable (e.g. ICC ≥0.70) (Streiner & Norman 2008, pp. 194-5). 
Accordingly, the present data suggests that cough counts using the LCM system are accurate 
for the purpose of individual and group average measurement in acute stroke unit 
environments. A limitation of the validation method used was that it relied on accurate ‘live’ 
cough counts by the observing researcher, which were taken as the ‘true’ cough counts for 
analysis and could not be verified at a later time. An alternative would have been to video-
record the participant during the entire time of cough monitoring, which would have allowed for 
retrospective verification of subjects’ actual cough frequency. From the validation study it was 
also noted that, for the application of the LCM in neurological populations where cough sounds 
can be atypical (e.g. ‘bovine’ cough sounds in patients with bulbar involvement), it may be 
useful to provide the software operator with a sound sample of the individual subject’s cough as 
a reference example; and/or to refine the LCM system’s cough sound library according to these 
atypical cough sounds.  
 
For the cohort study, a convenience sample of 21 acute stroke patients was recruited. In this 
sample, average cough frequency within two weeks of stroke was approximately four times 
higher than in healthy non-smokers, and reduced over the following twelve weeks to 
approximately twice the level of healthy non-smokers. There was great variation in individual 
cough frequency, from values in the low range of normal cough frequency to values seen in the 
higher range of individuals with respiratory pathology. Cough frequency was approximately 
twice as high in cortical stroke patients as it was in patients with subcortical stroke lesion. 
Cough frequency in patients with brainstem and cerebellar stroke was also high, but these 
measurements are limited due to the small number of patients (n=3). There were no 
associations between cough frequency and sex, age, stroke severity or respiratory parameters. 
There was no difference in cough frequency between patients who were assessed to have safe 
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swallow, and patients whose swallow was assessed to be unsafe. One participant developed 
pneumonia during the study period.  
 
The present study is limited due to the small sample size. The data have been submitted to 
multiple exploratory statistical analyses, which were unadjusted for multiple comparison and 
lacked adequate statistical power. These results, in particular regarding relationships between 
cough frequency and patient characteristics, therefore need to be interpreted with caution. Two 
observations appear reasonably valid and merit further discussion: high cough frequency soon 
after stroke, which gradually decreases with time; and few instances of very low cough 
frequency.  
 
First, if the presence of cough and increased cough frequency are interpreted as potential signs 
of dysphagia (as is the case in clinical swallowing assessment), the observed reduction of 
cough frequency with time corresponds with the good potential for spontaneous improvement of 
dysphagia in the short term following stroke (Smithard et al. 2007, Singh & Hamdy 2006). There 
was no difference in cough frequency between patients with safe and unsafe swallow; although 
this may be confounded due to the small sample, potential subclinical levels of dysphagia 
undetected by BSA, and the use of ACE inhibitors by one third of participants. ACE inhibitors 
are known to sensitise the cough reflex and increase cough frequency. Participants who used 
ACE inhibitors had increased cough frequency similar to healthy subjects who use ACE 
inhibitors. ACE inhibitors in these patients were clinically indicated, and ethically it was not 
possible to alter these prescriptions. However, those participants who did not use ACE inhibitors 
still exhibited cough frequencies that were over three times higher than normal values for 
healthy subjects. Cough frequency may also be increased due to respiratory pathology. This 
study excluded patients with pre-existing respiratory disease, and chest radiographs were 
conducted in two thirds of patients during the study period to exclude respiratory disease (chest 
radiographs were not clinically indicated in the remaining patients during the study period). It 
may therefore be assumed that the high cough frequency observed was not related to the 
presence of respiratory disease.  
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Second, the majority of patients showed no dampening of the cough reflex, as most participants 
had normal or increased cough frequencies. Only three participants (14%) exhibited very low 
cough frequencies of less than one hourly coughs. Cough frequency in this study sample may 
be interpreted as an indicator of reflex cough sensitivity, based on the assumption that coughs 
are triggered mechanically to protect from potential aspiration of saliva, food or drink; and based 
on the exclusion of patients with respiratory pathology, which could otherwise cause increased 
cough frequency. If very low cough counts are taken as an indication of dampened cough reflex, 
the incidence observed in the present study (14%) corresponds with the findings from 
Addington et al. (2005, 1999a), who tested reflex cough through inhaled L-tartaric acid and 
reported a diminished or absent cough reflex in 11% (112 out of 979) of acute stroke patient.  
 
Only one participant developed pneumonia during the study period, which does not provide 
statistically useful data. This patient was a 78 years old male with a subcortical stroke and 
admission NIHSS score of 12. This patient’s cough frequency was at the lower range of normal, 
with 24-hour cough counts around 30 and hourly cough frequencies of one to two. In future 
studies, it may be of interest to examine cough frequency as a predictor of pneumonia incidence 
after stroke. Addington et al. (2005, 1999a) have shown that diminished or absent reflex cough 
is associated with increased risk of post-stroke pneumonia. However, their method of assessing 
the cough reflex through inhaled L-tartaric acid requires the patient to perform an adequate 
volitional inhalation, to ensure appropriate delivery of the irritant to the broncho-laryngeal 
receptor sites. This can be difficult to achieve in patients with cognitive impairment or limited co-
operation. The LCM, as a non-invasive tool that requires minimal patient effort, may offer a 
convenient alternative to inform about reflex cough in this patient group.  
 
The distribution of cough frequency over the day, in particular in relation to ingestion of food and 
drink, may identify an interesting area for future research. The diurnal distribution of cough 
frequency in the present study (i.e. higher cough counts during waking hours, lower cough 
counts during night time) corresponds with data from healthy subjects (Yousaf et al. 2013). In 
the present study, the times at which participants had food or drink were not captured. It was 
therefore not possible to compare cough frequency at times of ingesting food or drink with 
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cough frequency in between the ingestion of food or drink. In the context of neurogenic 
dysphagia and cough as protection from aspiration, a study of this interaction may inform about 
the relative importance of aspiration risk during ingestion of food and drink (hypothesising that 
high cough frequency will coincide with mealtimes) versus ongoing micro-aspiration of saliva 
(hypothesising that cough frequency in between mealtimes will be similar to when food and 




The present study explored longitudinal cough frequency measurements in a cohort of 21 acute 
stroke patients. For this purpose, the LCM was validated for cough frequency measurement in 
an acute stroke unit environment. The device showed a high level of accuracy for both 
individual and group level cough counts.  
 
24-hour cough frequency within the first two weeks of stroke was found to be four times higher 
than in healthy non-smokers. Cough frequency steadily reduced with time to a level twice as 
high as in healthy non-smokers at twelve weeks post baseline. There was wide individual 
variation in cough frequency from normal values, as seen in healthy subjects, to very high 
values, as seen in patients with respiratory disease. Only three patients had cough frequencies 
lower than those in healthy non-smokers.  
 
The study is limited due to the small sample size, and findings therefore need to be interpreted 
with caution. Use of ACE inhibitors by some patients may have introduced bias towards higher 
cough frequency; but exclusion of patients with pre-existing respiratory disease eliminated 
respiratory causes for increased cough counts. This exploratory study is the first study to 
describe cough frequency in acute stroke. These data provide a basis for hypothesis-generation 
and may serve further study of cough frequency in the context of neurogenic dysphagia and 
aspiration pneumonia.  
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Chapter 8 Discussion 
 
The course of studies described in this thesis aimed to investigate RMT as an intervention for 
improving respiratory muscle strength and cough effectiveness in acute stroke, in the context of 
preventing pneumonia. Previous research has provided evidence for the problem of aspiration-
related pneumonia in the first weeks after stroke, and for the impairment of cough in acute 
stroke. The rationale for the present research was that RMT might improve cough effectiveness 
and lead to increased protection from aspiration, thus lowering incidence of pneumonia in acute 
stroke patients.  
 
The present study applied maximal mouth pressure measurements as markers of respiratory 
muscle strength; and cough flow measurements as parameters of cough effectiveness. 
Depending on study settings, accuracy and reproducibility of these volitional respiratory 
assessments can be limited. For the present research, methodological aspects of these 
assessment procedures were therefore investigated in-depth. PECF was the primary outcome 
of interest. The accuracy of different instruments when measuring PECF was assessed to 
inform the selection of the most appropriate measurement device (chapter 4). Good instrument 
performance of the study mouth pressure meter and cough flow measurement system was 
demonstrated in a series of laboratory bench tests. It was shown that test-retest reliability in 
humans was good and of equivalent magnitude in healthy volunteers and in stroke patients, 
demonstrating that these respiratory assessments could be performed as reliably in the patients 
enrolled in the research as in healthy subjects (chapter 3).  
 
These measurement techniques were used to investigate the effectiveness of RMT for 
improving cough flow in a single-blind randomised placebo-controlled trial, which included 82 
patients in three study arms (expiratory muscle training, inspiratory muscle training and sham 
respiratory training; chapter 5). The trial was novel in that it investigated RMT in the acute 
phase of stroke and with the aim of improving cough flow. RMT was shown to be safe, well 
tolerated and a low-cost intervention in this patient group. However, training at the frequency 
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and intensity as applied in this study was not effective in increasing cough flow or maximal 
mouth pressures when compared with sham training. In a secondary analysis of trial data, 
cough flow was examined as a predictor of four-week pneumonia incidence (chapter 6). 
Although the incidence of PSP was not different in study groups, the risk of PSP decreased in 
proportion with increasing PECF in stroke patients who were at risk of aspiration, but not in 
patients with safe swallow. This confirms that stronger cough protects from aspiration-related 
pneumonia after stroke. PECF of volitional cough was a stronger predictor than PECF of reflex 
cough, and it may be useful to assess voluntary PECF in clinical practice to categorise patients 
according to PSP risk.  
 
Lastly, cough frequency was studied longitudinally in a cohort of 21 acute stroke patients. This 
was the first study of cough frequency in acute stroke. For this purpose, an automated cough 
frequency measurement system was validated for use in an acute stroke unit environment. 24-
hour cough frequency within the first two weeks of stroke was found to be four times higher than 
in healthy non-smokers. Twelve weeks later, cough frequency had reduced to a level twice as 
high as in healthy non-smokers. Individual variability in cough frequency was wide, and cough 
frequency did not correlate with sex, age, stroke severity, respiratory function, cough intensity, 
or swallow safety. These data provide a basis for hypothesis-generation and may serve further 
study of cough frequency in the context of neurogenic dysphagia and aspiration pneumonia.  
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8.1 Potential sources of bias and limitations 
 
8.1.1 Internal validity 
 
8.1.1.1 Passage of time 
 
The work presented in this thesis was conducted over the period of several years. History can 
present a threat to the internal validity of studies which run over an extended period of time 
(Domholdt 2005, pp. 86-88); although this would potentially have more impact on the 
observational study of cough frequency (chapter 7) than on the randomised controlled trial of 
RMT (chapter 5). There was no significant historical event, such as a major change in stroke 
care provision at the study site, during the data collection period. The most significant recent 
innovation in UK stroke care has been the introduction of hyper-acute stroke units with routine 
provision of thrombolysis for ischemic stroke. This was introduced at the study site in 2008, well 
before the present research took place. Rehabilitation provision can change over time to adapt 
to local requirements, but there was no re-structuring of inpatient or community stroke 
rehabilitation services at the study site during the study period.  
 
Another potential threat to internal validity related to the passage of time is that study 
instruments may be affected through wear and tear, or that instruments may be switched during 
the course of research, which may lead to skewed findings (Domholdt 2005, p. 91). For the 
present studies, the same instruments were used throughout the data collection period, and 
regular calibration checks were conducted to ensure stable instrument performance (chapter 3).  
 
8.1.1.2 Repeated testing 
 
Repeated testing, and in particular repeated performance of volitional tests, may impact on 
internal validity (Domholdt 2005, pp. 89-91). It is possible for a measured change to occur due 
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to familiarisation with the testing procedure, rather than the intervention stimulus. This point has 
been raised in the context of using maximal mouth pressure measurements as outcomes in 
studies of RMT (Polkey & Moxham 2004). One method of controlling for this threat to validity is 
the inclusion of a control group, which completes all assessment procedures in the same way 
the intervention group does, and this method was applied in the randomised trial of RMT 
(chapter 5). The overall improvement that was observed in all study groups may therefore be 
attributed to spontaneous post-stroke recovery, familiarisation with the volitional tests (i.e. 
participants became better at performing test procedures), or a combination of both. To inform 
the potential for measurement change due to repeat testing, the volitional respiratory 
assessment methods applied in the present study were examined for test-retest reliability in the 
absence of ‘true’ change (chapter 3). Healthy volunteers and stroke patients repeated the tests 
in the space of two hours. These data were important to inform about the expected magnitude 
of measurement variability in the absence of change; and to interpret the magnitude of 
differences in pre- and post-intervention tests.  
 
Alternative methods to control for the effect of repeated testing have been described (Domholdt 
2005, pp. 89-91). In a controlled study design, it is possible to conduct a post-intervention test 
only; although this eliminates the possibility of comparing study groups at baseline for relevant 
differences in the outcome parameter. A familiarisation period can be planned at the study start, 
with the aim to achieve stable repeat test performances by participants before the intervention is 
introduced. This method is more suitable for study populations which are stable within their 
condition and where timeliness is not a factor. This approach was not possible in the present 
study, which relied on recruitment of participants and implementation of the intervention as early 
as possible after stroke, in order to meet the clinical aim. Lastly, measurement of physiological 
or biological markers through non-volitional tests may offer alternatives or correlates to volitional 
repeat tests. In the field of respiratory muscle assessment, the diaphragm and abdominal 
muscles can be stimulated involuntarily through trans-cutaneous magnetic or electric 
stimulation. Pressure measurements from gastric and oesophageal balloon catheters during 
stimulation can inform about the function of respiratory muscles. The obvious disadvantages of 
these specialist methods are patient discomfort from the invasive balloon catheter, equipment 
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requirements and investigator expertise (American Thoracic Society (ATS) & European 
Respiratory Society (ERS) 2002, pp. 528-547).  
 
8.1.1.3 Peak cough flow as a surrogate endpoint 
 
In the present trial of RMT, the primary outcome peak cough flow was used as a physiological 
surrogate endpoint in lieu of the actual clinical outcome of interest, pneumonia. This allowed for 
adequate statistical power with a smaller sample size than if the study would have been 
powered for outcome pneumonia (section 5.5). Peak cough flow was selected based on a 
reasoned assumption and on evidence from a mechanical model (section 1.3.3). A retrospective 
secondary analysis of trial data contributed to validating the association between peak cough 
flow and PSP risk (chapter 6). Nevertheless, it is acknowledged that the use of surrogate 
outcomes can be problematic; and that findings based on surrogate outcomes should be 
interpreted with caution when drawing conclusions with respect to clinical endpoints (Joffe & 
Greene 2009, Goetzsche et al. 1996). Although surrogate endpoints may be selected based on 
sound logic and theory and on established statistical association (for example statistical 
evidence of a predictor-outcome association), past research provides examples where 
improvement in surrogate measures did not correspond with beneficial clinical outcomes 
(Goetzsche et al. 1996, D’Agostino 2000).  
 
The parameter PECF relates closely to the mechanics of cough and protection from aspiration, 
and on this basis it was selected as the surrogate measure for the present research. However, 
other physiological surrogate measures relating to cough function and cough effectiveness may 
be considered. Inspiratory and expiratory maximal mouth pressures, forced vital capacity and 
peak expiratory flow have been examined as indicators of cough strength in a small number of 
studies (Boitano 2006). These measurements, as well as a number of other standardised 
respiratory function assessments, may potentially correlate well with cough effectiveness; and 
may potentially pose fewer challenges with respect to measurement instruments and 
standardised measurement techniques than the assessment of peak cough flow. However, 
there has been insufficient investigation of this.  
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Further, cough aspects other than peak cough flow may warrant consideration. For example, in 
the present study PECF of maximal volitional cough was measured, which is comparable to a 
‘personal best’ performance. This, however, may not be the functionally relevant aspect in the 
context of protection from continuous aspiration threat. It may be that the capacity to 
consistently and repeatedly produce a certain minimum level of expiratory cough flow may 
constitute a more relevant measure. Non-volitional measures of cough strength over an 
extended period of time, as opposed to volitional ‘one-off’ measurements, may be more 
appropriate in this context. Long-term cough sound recordings with evaluation of sound 
pressure levels may offer an alternative measurement method, although the relevant technology 
requires further development and validation at this time.  
 
8.1.1.4 Interpreting the lack of response to RMT 
 
In the randomised controlled trial of RMT, no intervention effect was observed in comparison 
with sham training, and all groups improved with time. As discussed above, this improvement 
with time could be related to the effect of repeated testing. Alternatively, it could also be 
interpreted as spontaneous recovery, which usually occurs to some degree in the first weeks 
following stroke (Cramer 2008). Lack of response to RMT could also be related to poor training 
completion in the intervention groups. However, while training concordance was variable across 
the entire sample, it was also balanced in all study groups. Training completion was 
incorporated as a co-variate in the intention-to-treat analysis of the trial (section 5.3.3); and 
correlation analysis of change in outcome according to training completion provided evidence of 
weak correlations only (section 5.3.9). Overall, this supports the interpretation that the lack of 
demonstrated intervention effect was due to lack of response to training, as opposed to 
confounding through inadequate training completion.  
 
A further possibility for the lack of response to RMT is that RMT may have been delivered with 
an inadequate ‘active ingredient’. In the present trial, the ‘active ingredient’ in the intervention 
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was the training intensity (i.e. the resistance threshold), which was 50% of maximal mouth 
pressure in the training groups, and 10% of maximal mouth pressure in the control group. 
Training frequency and duration were the same in all study groups. The training parameters 
selected for the present study lie within the range of parameters applied in previous studies of 
RMT in neurological populations; although training duration was one of the shortest and 
intensity and frequency of training were among the highest (section 1.5.3.2). This mirrored the 
aim of training (i.e. improving cough, which occurs in short bouts of high intensity; as opposed 
to, for example, improving cardio-respiratory endurance, which requires capacity at lower 
intensity over a longer period of time). While, based on training protocols applied in previous 
research, the RMT protocol in the present study could reasonably have been expected to 
produce an intervention effect, it may be necessary to deliver RMT at even higher frequency 
and/or intensity to achieve improvements in respiratory muscle strength and cough flow in acute 
stroke; although this would likely have implications on the feasibility and completion rate of such 
a training protocol.  
 
Another possibility to account for the lack of response to RMT is that the observed improvement 
with time in the present trial could also be related to improvement due to focussed breathing 
through a device. This was conducted by participants in all groups, including the sham training 
group. In other words, it is possible that daily focussed breathing through the device, 
irrespective of the threshold level, may have induced improvement. One week of daily volitional 
breathing exercise (diaphragmatic breathing with bio-feedback) in healthy subjects has been 
shown to induce plasticity of cortico-spinal diaphragm control, leading to larger cortical 
representation of the diaphragm (Demoule et al. 2008). A similar mechanism may have 
contributed to the findings of the present trial. To investigate this aspect, a factorial study design 
could have been considered (Domholdt 2005, pp. 128-134), whereby different treatment 
conditions and interactions between factors could have been compared against each other. 
Such a study design could have included a ‘no respiratory training’ control group, as well as a 
sham training group, and several intervention groups with differing training protocols to compare 
different proposed ‘active ingredients’ of training.  
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Lastly, the lack of response to RMT in the present trial may be considered in the context of the 
physiology of cough. As has been discussed in the introduction to this thesis (section 1.3.4), the 
rationale for trialling inspiratory muscle training was to improve pre-cough inspiratory volume. 
Higher pre-cough inspiratory volume increases the potential for high expiratory cough flow, by 
generating volume in the lungs that can then be expelled. In addition, greater inspired volume 
optimises the length-tension relationship of expiratory muscles and allows for higher intra-
thoracic pressure to be built up during the compression phase of cough (American Thoracic 
Society (ATS) & European Respiratory Society (ERS) 2002, p. 535). The rationale for expiratory 
muscle training was to maximise intra-thoracic pressure during the compression phase of 
cough. Glottis function was not addressed in the present study. Intrinsic laryngeal muscle 
function is important in cough, as glottis closure and opening need to function effectively and in 
co-ordination with in- and expiratory muscle action. The rationale for not targeting glottis 
function in the present trial was that in previous physiological studies, glottis function in acute 
stroke patients did not seem to differ from matched healthy control subjects (section 1.3.4). This 
judgement was based on visual analysis of cough time-flow traces, whereby the presence of a 
glottis compression phase (trace levels at zero flow between inspiratory and expulsive phase of 
cough) and its duration were assessed. It is possible that not incorporating glottis function in the 
training intervention may account for the lack of effect on cough flow, and further work may be 
warranted to explore the function and co-ordination of intrinsic laryngeal muscles during cough 
in stroke patients in more depth. Also, an alternative training intervention that involves glottis 
function, either in isolation or in combination with other training components, may be 
considered, such as coughing with bio-feedback or similar.  
 
8.1.2 External validity 
 
External validity, or generalisability, of the present research can be considered with respect to 
the study sample, setting and time (Domholdt 2005, pp. 99-101).  
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8.1.2.1 Sample selection 
 
The sample selection criteria for the present studies were shaped by two main considerations. 
First, participants had to be able to perform volitional respiratory manoeuvres, which excluded 
patients unable to follow instructions. From the point of view of implementing the RMT 
intervention, this first condition was necessary, as respiratory training requires the patient to 
perform co-ordinated volitional respiratory manoeuvres. This criterion therefore in the widest 
sense defined the potential target population for RMT in acute stroke. The second consideration 
in selecting the study sample was to exclude patients with pulmonary co-morbidities and acute 
cardiac events. The rationale for this was mainly related to patient safety, as repeated forceful 
respiratory manoeuvres and intra-thoracic pressure changes may aggravate airway obstruction 
or acute cardiac conditions. In addition, patients with asthma and chronic obstructive pulmonary 
disease can experience expiratory flow limitations due to airway obstruction (Loudon & Shaw 
1967). In these patients, it can be difficult to judge the relative contributions of airway 
obstruction versus respiratory muscle weakness to reduction or improvement in cough flow. Had 
the RMT intervention shown promise, findings could not have been generalised to these patient 
sub-groups. For the data on cough frequency, the exclusion of patients with pulmonary co-
morbidities strengthened the findings, as the risk of confounding due to known increased cough 
frequency in respiratory conditions was minimised.  
 
Systematic differences between participating and non-participating eligible patients can 
potentially introduce bias and limit study generalisability. Although non-participation amongst 
eligible patients in the present research was high (57%), implications on generalisability of 
findings are likely negligible. From the eligibility screening criteria, there were no systematic 
differences between eligible patients who decided to take part and those who declined. High 
rates of non-participation would potentially present a greater threat to external validity if study 
results were in favour of the training intervention, as research volunteers may be more 
motivated to participate in training, particularly if there is an element of self-completed exercise 
(Domholdt 2005, p. 100).  
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Two key sample characteristics were a wide range of stroke severities (median NIHSS score 8, 
range 5-25) and a PSP incidence of 13%, which corresponds with PSP rates on NHS stroke 
units (16% in 2008 and 13% in 2010) (Royal College of Physicians 2011, 2009). In this respect, 
the study sample constituted a good representation of the potential target population with 
respect to the clinical aim of the research, which was to implement RMT as a routine preventive 
intervention early after stroke.  
 
8.1.2.2 Study setting 
 
The present trial of RMT was designed for the hyper-acute and acute stroke care pathway in UK 
NHS settings. Delivery of the RMT intervention was designed taking a pragmatic and feasible 
approach for this setting (section 5.5). Acute stroke care delivered through private sector 
healthcare providers or in other countries may differ in terms of patient characteristics, 
organisation of care (e.g. availability and duration of sub-acute inpatient rehabilitation provision 
as opposed to early supported discharge services), and availability of resources and staff time. 
As one example, some delivery models in continental Europe and in the USA favour early 
stroke rehabilitation in inpatient settings. Patients are admitted to specialised inpatient 
rehabilitation units once they are able to tolerate participation in three hours of daily 
rehabilitative therapies. Compared to an early supported discharge model, an inpatient 
rehabilitation setting may allow for higher levels of staff supervision during RMT and thereby 
promote optimal training completion (and potentially achieve better training concordance than in 
the present trial). At the same time, admission criteria to such an inpatient unit screen out the 
less ‘rehab-ready’ patients, who are also more vulnerable to PSP, which might impact on the 
clinical relevance of PSP and the use of RMT as a preventive intervention. Overall, the present 
research has good generalisability to other NHS hyper-acute and acute stroke care settings; 
however, its relevance (with respect to both the clinical rationale and the study design) to other 
settings will likely depend on the particular local context.  
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8.1.2.3 Time 
 
The time period of the present research may be considered with respect to external validity, in 
particular regarding the rationale for the research. Cough as a treatment target for PSP 
prevention strategies has a place in the context of current knowledge and evidence; however, 
currently ongoing investigations of different novel approaches to PSP prevention (section 1.2.4) 
may lead to successful alternative clinical strategies in the future, which may render the 
approach pursued in the present work redundant.  
 
8.2 Practical considerations 
 
Recruitment and retention of research participants in the acute phase of stroke can be 
challenging, due to the nature of the condition and due to a dynamic, at times intense clinical 
service pathway. An appreciation of these challenges is helpful in the planning and conduct of 
clinical research (Bell et al. 2008, Blanton et al. 2006). Rates of recruitment and attrition in 
stroke rehabilitation research can vary widely. Investigators have reported recruitment rates 
(proportion of patients screened) of 6% (Blanton et al. 2006), 18% (Bernhardt et al. 2008), and 
51% (Lloyd et al. 2010), and attrition rates of 2% (Lloyd et al. 2010), 27% (Bernhardt et al. 
2008), and 39% (Blanton et al. 2006). These variations are likely due to multi-factorial reasons, 
including the time from stroke onset and the length of the trial. In comparison, the present trial of 
RMT (chapter 5) had the lowest recruitment rate at 4.5%. Attrition was fair at the first re-
assessment at four weeks (23%), and high at the second re-assessment at twelve weeks 
(54%).  
 
In the present trial of RMT, time afforded for study procedures was given as one of the most 
frequent reasons to decline participation (19% of eligible patients). The nature of study 
procedures may have contributed to the perceived and actual additional burden for study 
participants. While study activities relating to usual clinical procedures (e.g. trial of very early 
versus standard mobilisation post stroke; Bernhardt et al. 2008) may cause little additional 
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burden for study participants, studies of respiratory aspects, which are not routinely evaluated in 
acute stroke, can add considerable additional burden. Also, respiratory aspects of stroke 
impairment may be perceived as less obvious and therefore less relevant to the individual, 
which may impact on motivation to participate in this type of research. This may partly account 
for those patients who had no interest in the study (15% of eligible patients).  
 
In the present study, a large proportion of eligible patients who decided not to take part did not 
provide a reason for declining. For ethical reasons, patients were not asked to give reasons for 
declining participation. Equally, participants who discontinued the study were not asked to 
provide a reason for discontinuing. However, understanding patients’ motivations for (non-) 
participation and discontinuing gives valuable information for research design and management. 
Incorporating formalised procedures for exploring reasons for non-participation and 
discontinuation, for example through short qualitative interviews, may have provided further 
insights into barriers and facilitators of participant recruitment and retention, which could 
ultimately have been used to maximise recruitment and retention. This ‘researching the 
research process’ also ties in with initiatives for patient and public involvement in research, 
which have been shown to contribute to increased recruitment and improved trial designs 
(INVOLVE 2013, Brett et al. 2010, pp. 49-59, Staley 2009, pp. 30-49).  
 
In the absence of formalised patient and public involvement in the present studies, sensitivity of 
the investigator towards barriers to research procedures identified two main facilitators to 
participant recruitment and retention: provision of transportation, and the option to conduct 
study visits at the participant’s location. Mobility restrictions are a frequently mentioned problem 
in rehabilitation research, and adequate provisions are essential for the success of a study (Bell 
et al. 2008, Blanton et al. 2006). With no financial incentives for study participants, strategies to 
minimise the burden of travelling to and from research visits appeared to make a substantial 
difference to participants. Further, an appreciation of the local stroke service pathways and the 
investigator’s flexibility around the clinical service (i.e. making use of clinical ‘down time’, such 
as weekday evenings and weekends) proved useful in maximising opportunities for study 
activities.  
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8.3 The present research in context 
 
The present studies relate to four wider areas of research: respiratory function and impairment 
following stroke; strategies for reducing pneumonia incidence after stroke; strategies for 
improving neurologically impaired cough; and the application of RMT in stroke rehabilitation.  
 
8.3.1 Respiratory function and impairment following stroke 
 
There is comparatively little research into how stroke affects respiratory function, as opposed to 
the other possible sequelae of stroke. Historically, this may be due to the understanding that 
central neural control of automatic respiration is located at the level of the brainstem; and that 
the most dramatic potential effect of localised stroke on respiratory drive, i.e. acute respiratory 
failure, is seen in brainstem stroke and not in localised stroke lesions elsewhere in the brain (not 
including the effect of raised intracranial pressure and coning in severe malignant stroke) 
(Howard et al. 2001, Bogousslavsky et al. 1990, Patterson & Grabois 1986, Levin & Margolis 
1977, Devereaux et al. 1973). Also, the human cardio-respiratory system adapts well to loss of 
respiratory capacity to a certain extent; and stroke survivors may not experience respiratory 
limitation, such as shortness of breath on exertion, within the often limited cardio-respiratory 
demands of post-stroke rehabilitation and the more sedentary lifestyle of many stroke survivors 
(English et al. 2014, Field et al. 2013). In this respect, respiratory limitations following stroke 
may not be as clinically evident as other stroke-related impairments, leading to lower awareness 
and priority for research. Nevertheless, there is some evidence available to demonstrate various 
aspects of respiratory impairment in stroke.  
 
While insult to the brainstem respiratory centres can result in acute respiratory failure and 
death, a number of studies have reported more subtle disturbances in respiratory patterns, 
which have been described as Cheyne-Stokes or sleep-apnoea type respiration. These 
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breathing patterns have been observed in both sub- and supra-tentorial stroke, with no evident 
links to particular stroke lesion sites (Siccoli et al. 2008, Howard et al. 2001, Bassetti et al. 1997, 
Nachtman et al. 1995, Askenasy et al. 1988, Lee et al. 1971). Previously it was thought that 
these pathological respiratory patterns may be caused by stroke (Cherkassky et al. 2003). More 
recent evidence suggests that pre-existing obstructive sleep apnoea is an independent risk 
factor for stroke (Culebras 2014); and abnormal respiratory patterns detected post stroke may 
partly be accounted for by previously undiagnosed obstructive sleep apnoea.  
 
An aspect of stroke-related respiratory impairment that has been investigated relatively 
frequently is diaphragm function. In several studies diaphragm excursions in stroke survivors 
were compared with healthy control subjects. Some authors found that hemi-diaphragm 
excursions on the contra-lesion side can be significantly reduced in severely impaired stroke 
patients (de Almeida et al. 2011, Lanini et al. 2003, Khedr et al. 2000, Cohen et al. 1994, 
Santamaria & Ruiz 1988, Fluck 1966, Korzcyn 1969, Smith 1962), while others reported 
bilaterally reduced diaphragm excursion following stroke regardless of lesion laterality (Houston 
et al. 1995), or minimal abnormality only (de Almeida et al. 2011, Freeman et al. 2006, Laghi 
and Tobin 2003, McMahon & Heyman 1974, Lee et al. 1971). More recent work (Voyvoda et al. 
2012) identified varying patterns of hemi-diaphragm excursions after stroke, suggesting 
differences according to individual variation in neuromuscular pathways and stroke lesion sites. 
Reduced electro-myographic activity of the diaphragm and intercostal muscles on the stroke-
affected side has also been reported (Przedborski et al. 1988, DeTroyer et al. 1981). Several 
studies have used trans-cranial magnetic stimulation to show the disruption stroke can cause to 
cortico-respiratory projections, with unelicitable or abnormal (longer latency, lower amplitude) 
motor evoked potentials compared to healthy control subjects (Harraf et al. 2008, Urban et al. 
2002, Khedr et al. 2000, Similowski et al. 1996).  
 
Volitional functional respiratory tests, such as spirometry, maximal mouth pressure 
measurements and maximal voluntary ventilation, have been conducted in stroke survivors in a 
number of studies (Pollock et al. 2012, Voyvoda et al. 2012, Zhou et al. 2012, de Almeida 2011, 
Jandt et al. 2011, Yoon et al. 2011, Ward et al. 2010, Harraff et al. 2008, Teixeira-Salmela et al. 
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2005, Lanini et al. 2003, Khedr et al. 2000, Nuzzo et al. 1999). Cough function following stroke 
has also been investigated in several studies, and these have been summarised in the 
introduction to this thesis (section 1.3.4). Overall, there is good evidence to show that stroke 
patients can exhibit considerable reductions in these aspects of respiratory function when 
compared with healthy control subjects. At the same time, there is wide variation in these 
parameters within the stroke population, which mirrors variations in severity of stroke 
impairment as well as natural variation observed in the healthy population.  
 
In relation to this body of evidence, two points can be made from the findings of the present 
studies. First, with respect to exploring respiratory function and impairment after stroke, the 
present work adds the first description of cough frequency to the literature. Although these 
findings are derived from a small and selective convenience sample, it was possible to validate 
an automated cough frequency measurement system and capture longitudinal cough frequency 
data during the first three months following stroke. These data indicate some differences to 
normal cough frequency in humans and may serve hypothesis generation and further research. 
Second, with respect to the observed range in the various respiratory parameters measured, 
the data from the present studies mirror the variation seen in cross-sectional physiological 
studies. This may indicate that, in order to provide clinically useful information and lead to 
clinically meaningful intervention, assessments of respiratory function after stroke need to be 
conducted on individual basis and interpreted in the context of the individual patient. In this 
respect, respiratory impairment after stroke may require very much the same principal approach 
as stroke impairments of other body functions and systems, i.e. individualised assessment and 
intervention, as opposed to standardised treatments which are delivered routinely.  
 
8.3.2 Reducing pneumonia incidence after stroke 
 
Pneumonia following stroke presents a multi-factorial clinical picture. Accordingly, various 
avenues for reducing PSP incidence have been and are currently being pursued. An overview 
of different approaches has been given in the introduction to this thesis (section 1.2.4), and 
further to this three brief points shall be made here. First, compared to past and current studies, 
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the present research was novel in that it targeted cough effectiveness as a strategy to reduce 
PSP incidence. The research was based on a reasoned assumption, which was that stronger 
cough (i.e. higher expiratory cough flow) protects from aspiration-related pneumonia following 
stroke. This assumption had previously not been supported by data, likely because cough flow 
is not routinely captured in clinical practice and therefore not conveniently studied as a risk 
factor for PSP. However, there was some experimental evidence from a mechanical model 
(King et al. 1985). During the course of the present studies, it was possible to support this 
assumption through the retrospective analysis of cough flow as a predictor/mediator of PSP 
incidence (chapter 6); and while it would be desirable to replicate these findings in a dedicated 
study, these findings are original and add new information to the understanding of how cough 
mediates pneumonia risk after stroke. Second, it is noteworthy that the intention of the 
intervention was to achieve a restorative effect (as opposed to a supportive effect, such as is 
provided through manual thoraco-abdominal compression or the use of mechanical cough 
assist devices for the improvement of expiratory cough flow). And third, the intervention required 
active engagement from the participant, which contributed to defining the target population. It is 
acknowledged that this requirement for active engagement in the intervention largely defined 
and also narrowed the eligible patient pool. More severely affected individuals, who may 
present with fluctuating levels of consciousness and inability to follow instructions, are also 
among the higher risk groups for PSP. In future studies, passively administered treatments for 
the improvement of cough effectiveness may therefore be considered in order to allow inclusion 
of this more severely affected group of stroke survivors; whereby these treatments may exert a 
restorative or a supportive effect.  
 
8.3.3 Improving neurologically impaired cough 
 
Although various strategies for improving neurologically impaired cough have been researched 
in the past, the current evidence base is thin and there remains scope for further research and 
development (Jones et al. 2012, Boitano 2006). Among approaches to improving cough, 
supportive and restorative strategies may be distinguished. Supportive strategies aim to 
maximise cough effectiveness or secretion clearance by use of non-invasive cough-
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augmentation techniques and devices. These techniques have mostly been investigated in 
populations with neurodegenerative conditions or spinal cord injury, to offer temporary support 
during acute episodes of respiratory care, or as long-term measures to prevent respiratory 
complications (Jones et al. 2012, Boitano 2006). Restorative strategies aim to achieve lasting 
improvement in cough function by delivering a training stimulus and achieving a training effect, 
which was the approach taken in the present research.  
 
A supportive cough-augmentation technique that has long been in use clinically is manually 
assisted coughing. The patient’s cough effort is supported by abdominal or thoracic 
compression performed by another person, resulting in higher peak cough flow (Boitano 2006, 
Kang et al. 2006a, Trebbia et al. 2005, Sivasothy et al. 2001, Braun et al. 1984, Kirby et al. 
1966). Cough can also be augmented through hyperinflation manoeuvres. Passive increase in 
pre-cough inspiratory volume is achieved by manual hyperinflation or non-invasive ventilation 
devices such as intermittent positive pressure breathing (IPPB). The resulting increase in peak 
cough flow is attributed to both the increase in lung volume, providing more volume to be 
expelled, and elastic recoil energy tapped with increased lung and chest wall expansion 
(Boitano 2006, Kang et al. 2006a, Sivasothy et al. 2001, Bach 1993). A small number of studies 
investigated functional electrical and magnetic stimulation of the expiratory muscles for cough 
augmentation. These techniques appear viable, but require further research and development 
(Boitano 2006, Taylor et al. 2002, Lin et al. 1998, Jaeger et al. 1993). Lastly, mechanical in-
exsufflation for cough augmentation was first described in the 1950s, but has recently gained 
support from a growing evidence base (Boitano 2006, Barach & Beck 1954, Beck & Barach 
1954, Barach et al. 1953). This non-invasive device supports pre-cough inspiration through 
positive pressure, and the expulsive phase of cough through negative pressure (vacuum) 
applied to the airways. Several studies have demonstrated the effect of mechanical in-
exsufflation on increasing peak cough flow (Chatwin et al. 2003, Mustafa et al. 2003, Bach 
1993) and the clinical utility of the device (Vianello et al. 2005, Miske et al. 2004, Sancho et al. 
2003, Marchant & Fox 2002, Garstang et al. 2000, Hanayama et al. 1997).  
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Restorative therapeutic modalities that have been investigated are respiratory muscle training 
and ‘exercise’ in the sense of whole body exercise or pulmonary rehabilitation-type exercise 
(Jones et al. 2012). In populations with neurodegenerative conditions these interventions have 
been researched to address respiratory problems in general; however, cough outcome 
parameters have rarely been measured. The small number of studies that included cough 
outcomes presents a mixed picture. Gosselink et al. (2000) investigated three months of 
expiratory muscle training in a randomised controlled trial in non-ambulatory multiple-sclerosis 
patients. Cough function was assessed using the Pulmonary Index, a composite score of 
objectively and subjectively rated cough effectiveness. This showed a small but statistically 
significant improvement in the intervention group compared to the control group, although it is 
difficult to judge the clinical relevance of this improvement. Chiara et al. (2006) studied the 
effect of eight weeks of expiratory muscle training in a cohort of patients with multiple sclerosis. 
Cough was assessed using cough flow measurements, and showed statistically significant 
improvement only in patients with moderate disease severity, but not with mild disease severity. 
Pitts et al. (2009) investigated four weeks of expiratory muscle training in a cohort of patients 
with Parkinson’s disease. Cough flow measurements showed no statistically significant increase 
in PECF from baseline to post training; but glottis compression time and rise time to PECF 
reduced post training, which also resulted in a statistically significant increase in cough volume 
acceleration post training. The authors offer a discussion of the relative importance of PECF in 
comparison with other parameters that can be derived from a cough-flow trace (i.e. glottis 
compression time, rise time to PECF and cough volume acceleration); but at present it remains 
difficult to interpret how change in parameters other than PECF relates to cough effectiveness 
or protection from aspiration. Lastly, Kim et al. (2009, Kim & Sapienza 2005) investigated four 
weeks of expiratory muscle training in a group of healthy sedentary elderly subjects. Cough was 
evaluated through cough flow traces of capsaicin-induced reflex coughs. At the post-training 
time point, there was a statistically significant improvement in PECF as well as expiratory cough 
volume, and a significant reduction in glottis compression time.  
 
Overall, these studies illustrate that research of restorative treatments for cough in clinical 
populations is in its beginning stages, with heterogeneity in study methodologies (in particular 
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regarding methods of assessing cough effectiveness) and interesting but overall inconclusive 
findings.  
 
8.3.4 Respiratory muscle training in stroke rehabilitation 
 
To date, most research of RMT has been conducted in healthy and athletic populations. 
Although the number of clinical studies is growing, the application of RMT in clinical practice 
remains an emerging area of investigation. As might be expected in such a case, investigators’ 
approaches vary as the potential applications and benefits of RMT are explored, which is 
reflected in different study rationales and selection of outcome measures. Previous studies of 
RMT in stroke (section 1.5) and in other neurological conditions (Pollock et al. 2012) have 
generally focussed on physiological outcomes, whereby the most consistently included outcome 
parameters have been inspiratory and expiratory maximal mouth pressures. Various other 
physiological measures relating to lung function (e.g. spirometry) and cardio-respiratory 
endurance (e.g. peak oxygen consumption) have also been applied.  
 
At the level of physiological impairment, controlled studies generally demonstrate some 
treatment effect of RMT. Arguably, improvement in physiological parameters alone does not 
warrant implementation of an investigational intervention, but there needs to be evidence of 
clinically meaningful patient benefit. For the application of RMT in stroke, this has not been 
convincingly established to date. In the two previous controlled trials of RMT in stroke with 
acceptable study quality (Britto et al. 2011, Sutbeyaz et al. 2010), those outcome measures that 
related directly to everyday life and general wellbeing, i.e. measures of activity, participation and 
quality of life, showed little treatment effect.  
 
As for any clinical research, studies of RMT should be based on a considered rationale; and 
once patient safety and physiological effect have been demonstrated, the inclusion of clinically 
meaningful endpoints becomes increasingly relevant. To date, the accumulated evidence does 
indeed demonstrate that RMT is a generally safe, well tolerated and also inexpensive treatment 
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intervention in clinical populations. Because of that, RMT may lend itself to being researched or 
even prescribed in clinical practice ‘because we can’. Acute and sub-acute stroke rehabilitation 
is time sensitive, and there is the need to focus treatment on the most time-effective and 
meaningful interventions. It may therefore be recommended that in the rationale for future 
studies of RMT in stroke the following points find particular consideration: How likely is it that the 
expected physiological effects of RMT will translate into meaningful patient benefit? And will the 
time spent on RMT be proportionate to other demands on the patient and the loss of opportunity 
to participate in other therapeutic activities? Most likely, these considerations will lead to 
different conclusions for the acute, sub-acute or chronic portion of the post-stroke pathway.  
 
8.4 Suggestions for further studies 
 
During the course of research presented in this thesis, potential areas for further studies have 
become apparent. These are given here in three topic summaries, which offer brief descriptions 
rather than fully developed specific research questions.  
 
8.4.1 Methods of measuring cough effectiveness 
 
The work investigating accuracy of devices for measuring peak cough flow (chapter 4) has 
shown that this area may warrant further research and development. The clinical usefulness of 
cough measurement could potentially be improved by re-examining current concepts of ‘cough 
strength’ and ‘cough effectiveness’; and the methods by which these are measured. The 
measurement of peak cough flow clearly presents considerable challenges, and alternative 
measures of cough effectiveness could be explored, such as cough sound pressure level or 
mouth pressure during cough. The field may also benefit from a guideline or consensus 
statement on the measurement of cough effectiveness, to summarise current knowledge and 
provide guidance to clinicians and researchers. This work could best be addressed in an inter-
disciplinary collaboration between physicists, respiratory physiologists and clinicians with an 
interest in cough effectiveness.  
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8.4.2 Features of cough following stroke 
 
There is scope to further explore features of cough following stroke, both on a physiological 
level and in a clinical context. Physiological work could further investigate the role of glottis and 
intrinsic laryngeal muscle function. These may be more relevant for cough impairment after 
stroke than it was thought in the rationale for the present trial of RMT (section 1.3.4). Methods 
such as electro-myography or ultra-sonography may be able to give a better understanding of 
glottis function during cough, and findings may be useful in the design of novel treatment 
approaches for optimising cough after stroke.  
 
The present studies have contributed somewhat towards the current understanding of the inter-
relationship between swallowing impairment, pneumonia and cough after stroke. Stronger 
cough was shown to be protective from PSP in patients with unsafe swallow, but not in patients 
with safe swallow (chapter 6). Cough frequency after stroke was shown to be significantly 
higher than in healthy non-smokers, but there was no difference between patients with safe and 
unsafe swallow (chapter 7). These findings may warrant replicating in a dedicated observational 
study, which could also incorporate further measures of cough function (e.g. reflex cough 
sensitivity) and more detailed assessment of swallowing impairment (i.e. instrumental 
swallowing assessment). Such a study could add to the current understanding of how aspects 
of cough modify PSP risk after stroke, and contribute to the identification of targets for 
preventive therapies.  
 
8.4.3 Strategies for improving cough effectiveness in acute stroke 
 
Maximising cough effectiveness remains a viable target for PSP prevention strategies. The 
present trial showed that an intervention that requires active engagement from participants 
limits the eligible patient pool, which impacts on the feasibility of conducting this type of 
research. However, it may be warranted to explore treatment options which do not require 
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active patient engagement. The advantage of this could be twofold. First, patients with more 
severe stroke impairment who are inconsistent in following instructions could potentially be 
included for such a treatment. These patients are often also at higher risk of PSP, for example 
due to fluctuating levels of consciousness. Second, an intervention that is delivered passively is 
potentially less likely to detract from patients’ capacity to participate in active rehabilitation 
activities, as it may draw less on patients’ mental and physical resources.  
 
Devising novel investigational treatment approaches provides an opportunity for innovation and 
may draw on previous research of cough-strengthening interventions as well as other work in 
the field of cough or stroke care. Suggestions may include: treatment modalities using electrical 
current stimulation of respiratory muscles; face masks with integrated valves for the delivery of 
added airway resistance; stimulated coughing using nebulised or aerosolised cough stimulants; 
or non-invasive stimulation of the central nervous system, such as TMS or trans-cranial direct 
current stimulation (tDCS).  
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Studies reporting the incidence of pneumonia in stroke survivors 
Author, year and 
country 









Incidence of pneumonia Comments 
n % 





Intensive care 176 a Hospital 
admission 
100 56.8% - 





Intensive care 236 a Intensive care 
admission 
51 21.6% Ischemic stroke only 





Intensive care 55 a Hospital 
admission 
26 47.3% - 
Hilker et al. Prospective Intensive care 124 a Intensive care 
admission 
26 21.0% - 












268 a 30 days 47 16.4% Included 31 
mechanically ventilated 
patients, of whom 24 
had pneumonia 





Acute 60,420 a Hospital 
admission 
- 7.6% Ischemic stroke only 





Acute 25 a 2 weeks from 
stroke 






Acute 18,3976 c Hospital 
admission 
- 8.1% - 





Acute 8,251 a 30 days from 
stroke 
587 7.1% Ischemic stroke only 




Acute 11,757 a Hospital 
admission 
- 8.8% - 
 - 271 - 
Denmark 





Acute 16,518 a Hospital 
admission 
1,269 7.7% - 






Acute 11,353 d Hospital 
admission 
- 13% Audit data from 
England, Wales and 
Northern Ireland 





Acute 1,363 b Hospital 
admission 







Acute 18,017 b Hospital 
admission 
711 3.9% Excluding patients with 
contraindications for 
dysphagia screening 
and patients remaining 
nil by mouth 





Acute 1,150,336 c Hospital 
admission 
- 3.0% Ischemic stroke only 




Acute 11,369 d Hospital 
admission 
- 16% Audit data from 
England, Wales and 
Northern Ireland 
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2009 
United Kingdom 





Acute 1,254 a Hospital 
admission 
151 12.0% Ischemic stroke only 





Acute 489 a 7 days from 
stroke 
55 11.2% Subgroup of 244 
patients observed for 3 
months from stroke, 
with pneumonia 
incidence of 17.2% 





Acute 67 a 6 months from 
stroke 
9 13.4% Stroke patients with 
new oropharyngeal 
dysphagia 





































(a) and suspected 
pneumonia (b) 
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Acute 660 d Hospital 
admission 
66 10.0% Ischemic stroke only 





Acute 579 a Hospital 
admission 
- 10.7% Ischemic stroke only 






Acute 2532 a Hospital 
admission 
- 4.5% Ischemic stroke only 







Acute 1,455 d 3 months from 
stroke 
198 13.6% Previously 
independent acute 
stroke patients; data 
from a randomised 
controlled trial 





Acute 100 a Hospital 
admission 
44 44.0% Acute stroke patients 
with naso-gastric tube 







Acute 13,440 a Hospital 
admission 
- 6.0% Ischemic stroke only 
 - 274 - 
Germany 





Acute 14,293 c Hospital 
admission 
986 6.9% - 





Acute 3,866 a 7 days from 
stroke 
- 7.4% Ischemic stroke only 





Acute 119 a Hospital 
admission 
12 10.1% - 





Acute 128 a 6 months from 
stroke 
26 20.0% Excluding unconscious 









Acute 4,757 c Hospital 
admission 
- 7.1% Ischemic stroke only 




Acute 607 a Hospital 
admission 
70 12.0% - 
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United Kingdom 







818 a Acute and 
rehabilitation 
admission 
35 4.3% - 







311 a 30 months from 
stroke 
- 22% from 
hospital 
admission to 2 
months 
13% from 
discharge to 6 
months 
23% from 6 
months to 18 
months 
29% from 18 
months to 30 
months 
- 





Rehabilitation 1,099 b Rehabilitation 
admission 
36 3.3% - 





Rehabilitation 1,029 d Rehabilitation 
admission 
42 4.0% - 
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Rehabilitation 441 a Acute and 
rehabilitation 
admission 
12 2.7% Patients admitted for 
rehabilitation within 4 
months of stroke 





Rehabilitation 245 a Rehabilitation 
admission 




a stroke unit 






8% of patients 
receiving 
rehabilitation on 
a stroke unit 













Rehabilitation 100 b Rehabilitation 
admission 
7 7.0% - 





Rehabilitation 114 a Rehabilitation 
admission 
9 7.9% Stroke patients with 
dysphagia confirmed 
on videofluoroscopy 
Dobkin Retrospective Rehabilitation 200 d Rehabilitation 
admission 
4 2.0% - 




a, diagnosis of pneumonia made based on clinical criteria, e.g. according to Mann (Mann et al. 1999) or the US Centres for Disease Control (Garner et al. 1988) 
b, diagnosis of pneumonia as per documented clinical diagnosis 
c, diagnosis of pneumonia as per diagnostic codes (International Classification of Diseases, ICD) 
d, criteria for diagnosis of pneumonia not given 
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Appendix 2 
Clinical algorithm for routine swallow screen 
 





The diagnostic criteria for pneumonia and operational procedures for detecting pneumonia in 
the present studies are given below. The diagnostic criteria, although aligned with previous 
criteria applied in clinical research, can be regarded as ‘ad hoc’ criteria (Kishore et al. 2015). 
For data collection purposes, presence of pneumonia was determined either from the treating 
physician’s diagnosis or from participants’ self-report. The methodological limitations to this 
approach are acknowledged, although there is currently no recommended standard method for 
diagnosing pneumonia in clinical stroke research (Kishore et al. 2015).  
 
Diagnostic criteria Operational procedure 
Raised temperature (>37.5 °C on two 
consecutive measurements or a single 
measurement of >38 °C) 
and 
Chest symptoms (dyspnoea, tachypnoea, 
productive cough, reduced oxygen saturation, 
inspiratory crackles, bronchial breathing) 
and ≥1 of the following: 
 White cell count >11,000/mL 
 Pulmonary infiltrate on chest radiograph 
 Positive microbiology cultures 
Yes to any one of the following:  
 Documented medical diagnosis of 
pneumonia / chest infection 
 Prescription of antibiotics for pneumonia / 
chest infection 
 Hospital admission for pneumonia / chest 
infection 
 Self-reported pneumonia / chest infection 
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Appendix 4 
Stata outputs for diagnostic statistics (chapter 6) 
 
1) Model for interaction between swallow safety and voluntary cough PECF 
                                                                                
         _cons     .0493108   .0828928    -1.79   0.073     .0018283    1.329952
 _ISwaXVCPEF_2     .9934487   .0040945    -1.59   0.111     .9854559    1.001506
VCPEFRbaseline      1.00017   .0027795     0.06   0.951     .9947371    1.005632
 _ISwallowsa_2     83.37231   161.9995     2.28   0.023     1.849546    3758.189
                                                                                
 RegPneu4Weeks   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                
Log likelihood = -25.273272                       Pseudo R2       =     0.2567
                                                  Prob > chi2     =     0.0006
                                                  LR chi2(3)      =      17.46
Logistic regression                               Number of obs   =         72
i.Swal~e*VCPE~e   _ISwaXVCPEF_#       (coded as above)
i.Swallowsafe~e   _ISwallowsa_1-2     (naturally coded; _ISwallowsa_1 omitted)
. xi: logistic RegPneu4Weeks i.Swallowsafety1safe2unsafe*VCPEFRbaseline
 
                  Prob > chi2 =         0.7454
      Hosmer-Lemeshow chi2(8) =         5.11
             number of groups =        10
       number of observations =        72
  (Table collapsed on quantiles of estimated probabilities)
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof, group(10)
                  Prob > chi2 =         0.4585
             Pearson chi2(68) =        68.55
 number of covariate patterns =        72
       number of observations =        72
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof
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Correctly classified                        84.72%
                                                  
False - rate for classified -   Pr( D| -)   11.29%
False + rate for classified +   Pr(~D| +)   40.00%
False - rate for true D         Pr( -| D)   53.85%
False + rate for true ~D        Pr( +|~D)    6.78%
                                                  
Negative predictive value       Pr(~D| -)   88.71%
Positive predictive value       Pr( D| +)   60.00%
Specificity                     Pr( -|~D)   93.22%
Sensitivity                     Pr( +| D)   46.15%
                                                  
True D defined as RegPneu4Weeks != 0
Classified + if predicted Pr(D) >= .5
   Total            13            59            72
                                                  
     -               7            55            62
     +               6             4            10
                                                  
Classified           D            ~D         Total
                       True         
Logistic model for RegPneu4Weeks
. lstat
 
area under ROC curve   =   0.8357
number of observations =       72
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2) Model for interaction between swallow safety and reflex cough PECF 
                                                                                
         _cons     .0311995   .0709666    -1.52   0.127     .0003614    2.693388
 _ISwaXRCPEF_2     .9943651   .0075345    -0.75   0.456     .9797069    1.009243
RCPEFRbaseline     1.001937   .0066848     0.29   0.772     .9889199    1.015125
 _ISwallowsa_2     42.85813   105.7364     1.52   0.128     .3404177    5395.781
                                                                                
 RegPneu4Weeks   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                
Log likelihood = -27.747566                       Pseudo R2       =     0.1690
                                                  Prob > chi2     =     0.0103
                                                  LR chi2(3)      =      11.28
Logistic regression                               Number of obs   =         69
i.Swal~e*RCPE~e   _ISwaXRCPEF_#       (coded as above)
i.Swallowsafe~e   _ISwallowsa_1-2     (naturally coded; _ISwallowsa_1 omitted)
. xi: logistic RegPneu4Weeks i.Swallowsafety1safe2unsafe*RCPEFRbaseline
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                  Prob > chi2 =         0.8574
      Hosmer-Lemeshow chi2(8) =         4.00
             number of groups =        10
       number of observations =        69
  (Table collapsed on quantiles of estimated probabilities)
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof, group(10)
                  Prob > chi2 =         0.3452
             Pearson chi2(65) =        68.96
 number of covariate patterns =        69
       number of observations =        69
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof
 
                                                  
Correctly classified                        82.61%
                                                  
False - rate for classified -   Pr( D| -)   17.39%
False + rate for classified +   Pr(~D| +)       .%
False - rate for true D         Pr( -| D)  100.00%
False + rate for true ~D        Pr( +|~D)    0.00%
                                                  
Negative predictive value       Pr(~D| -)   82.61%
Positive predictive value       Pr( D| +)       .%
Specificity                     Pr( -|~D)  100.00%
Sensitivity                     Pr( +| D)    0.00%
                                                  
True D defined as RegPneu4Weeks != 0
Classified + if predicted Pr(D) >= .5
   Total            12            57            69
                                                  
     -              12            57            69
     +               0             0             0
                                                  
Classified           D            ~D         Total
                       True         
Logistic model for RegPneu4Weeks
. lstat
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area under ROC curve   =   0.7679
number of observations =       69
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3) Model for interaction between swallow safety and voluntary cough PECF, adjusted for age, 
sex and stroke severity (admission NIHSS score) 
                                                                                
         _cons     .0017554   .0054221    -2.05   0.040     4.12e-06    .7475254
NIHStrokeScore     1.041476   .0818154     0.52   0.605     .8928558    1.214835
       _ISex_2     1.289419   .9987285     0.33   0.743     .2825462    5.884347
           Age     1.036968    .031596     1.19   0.234     .9768539    1.100782
 _ISwaXVCPEF_2     .9938132   .0039866    -1.55   0.122     .9860304    1.001658
VCPEFRbaseline     1.001362   .0027475     0.50   0.620     .9959912    1.006761
 _ISwallowsa_2      56.2039   105.2511     2.15   0.031     1.431367    2206.896
                                                                                
 RegPneu4Weeks   Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval]
                                                                                
Log likelihood = -24.406782                       Pseudo R2       =     0.2822
                                                  Prob > chi2     =     0.0039
                                                  LR chi2(6)      =      19.19
Logistic regression                               Number of obs   =         72
i.Sex             _ISex_1-2           (naturally coded; _ISex_1 omitted)
i.Swal~e*VCPE~e   _ISwaXVCPEF_#       (coded as above)
i.Swallowsafe~e   _ISwallowsa_1-2     (naturally coded; _ISwallowsa_1 omitted)
. xi: logistic RegPneu4Weeks i.Swallowsafety1safe2unsafe*VCPEFRbaseline Age i.Sex NIHStrokeScore
 
                  Prob > chi2 =         0.7928
      Hosmer-Lemeshow chi2(8) =         4.66
             number of groups =        10
       number of observations =        72
  (Table collapsed on quantiles of estimated probabilities)
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof, group(10)
                  Prob > chi2 =         0.5029
             Pearson chi2(65) =        64.25
 number of covariate patterns =        72
       number of observations =        72
Logistic model for RegPneu4Weeks, goodness-of-fit test
. estat gof
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Correctly classified                        86.11%
                                                  
False - rate for classified -   Pr( D| -)    9.84%
False + rate for classified +   Pr(~D| +)   36.36%
False - rate for true D         Pr( -| D)   46.15%
False + rate for true ~D        Pr( +|~D)    6.78%
                                                  
Negative predictive value       Pr(~D| -)   90.16%
Positive predictive value       Pr( D| +)   63.64%
Specificity                     Pr( -|~D)   93.22%
Sensitivity                     Pr( +| D)   53.85%
                                                  
True D defined as RegPneu4Weeks != 0
Classified + if predicted Pr(D) >= .5
   Total            13            59            72
                                                  
     -               6            55            61
     +               7             4            11
                                                  
Classified           D            ~D         Total
                       True         
Logistic model for RegPneu4Weeks
. lstat
 
area under ROC curve   =   0.8553
number of observations =       72
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Appendix 5 
Stata outputs for exact logistic regression model (chapter 6) 
 
1) Pneumonia risk according to voluntary cough PECF in patients with low aspiration risk 
                                                                           
Cat24_VCPEFR     1.014311          23      0.8907      .7441706    1.326914
                                                                           
RegPneu4We~s   Odds Ratio       Suff.  2*Pr(Suff.)     [95% Conf. Interval]
                                                                           
                                                 Pr >= score   =     0.9487
                                                 Model score   =   .0107891
Exact logistic regression                        Number of obs =         39
. xi: exlogistic RegPneu4Weeks Cat24_VCPEFR if Swallowsafety==1, nolog
 
 
2) Pneumonia risk according to voluntary cough PECF in patients with high aspiration risk 
                                                                           
Cat24_VCPEFR     .7290848          62      0.0122      .5097866    .9487404
                                                                           
RegPneu4We~s   Odds Ratio       Suff.  2*Pr(Suff.)     [95% Conf. Interval]
                                                                           
                                                 Pr >= score   =     0.0186
                                                 Model score   =   5.295465
Exact logistic regression                        Number of obs =         33
. xi: exlogistic RegPneu4Weeks Cat24_VCPEFR if Swallowsafety==2, nolog
 
 
3) Pneumonia risk according to reflex cough PECF in patients with low aspiration risk 
                                                                           
Cat24_RCPEFR      1.10734          14      0.8378      .5522977    2.234083
                                                                           
RegPneu4We~s   Odds Ratio       Suff.  2*Pr(Suff.)     [95% Conf. Interval]
                                                                           
                                                 Pr >= score   =     0.8589
                                                 Model score   =   .1004997
Exact logistic regression                        Number of obs =         37
. xi: exlogistic RegPneu4Weeks Cat24_RCPEFR if Swallowsafety==1, nolog
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4) Pneumonia risk according to reflex cough PECF in patients with high aspiration risk 
                                                                           
Cat24_RCPEFR      .869611          57      0.4481      .6047247    1.202335
                                                                           
RegPneu4We~s   Odds Ratio       Suff.  2*Pr(Suff.)     [95% Conf. Interval]
                                                                           
                                                 Pr >= score   =     0.4083
                                                 Model score   =   .7346174
Exact logistic regression                        Number of obs =         32
. xi: exlogistic RegPneu4Weeks Cat24_RCPEFR if Swallowsafety==2, nolog
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Appendix 6 
Letters from the Research Ethics Committees 
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Appendix 7 
Participant information sheets and informed consent forms 
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Appendix 8 
Data collection forms 
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